10-Q

0000920465-15-000077.txt : 20151110 0000920465-15-000077.hdr.sgml : 20151110 20151105190409 ACCESSION NUMBER: 0000920465-15-000077 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151106 DATE AS OF CHANGE: 20151105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36282 FILM NUMBER: 151202101 BUSINESS ADDRESS: STREET 1: 10182 TELESIS COURT, 6TH FLOOR CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-207-4264 MAIL ADDRESS: STREET 1: 10182 TELESIS COURT, 6TH FLOOR CITY: SAN DIEGO STATE: CA ZIP: 92121 10-Q 1 ljpc-2015930x10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q



x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2015



o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 1-36282

LA JOLLA PHARMACEUTICAL COMPANY

(Exact name of registrant as specified in its charter)



California		33-0361285
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

10182 Telesis Court, 6th Floor San Diego, CA		92121
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 207-4264

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one)



Large accelerated filer	o	Accelerated filer	x
Non-accelerated filer	o	Smaller reporting company	o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of October 31, 2015, La Jolla Pharmaceutical Company had 18,241,509 shares of common stock, $0.0001 par value per share, outstanding.

LA JOLLA PHARMACEUTICAL COMPANY

FORM 10-Q

QUARTERLY REPORT

TABLE OF CONTENTS



PART I — FINANCIAL INFORMATION

ITEM 1. Condensed Consolidated Financial Statements

Condensed Consolidated Balance Sheets as of September 30, 2015 (Unaudited) and December 31, 2014	1

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2015 and 2014	2

Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2015 and 2014	3

Notes to Condensed Consolidated Financial Statements	4

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	14

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk	19

ITEM 4. Controls and Procedures	19

PART II — OTHER INFORMATION

ITEM 1. Legal Proceedings	20

ITEM 1A. Risk Factors	20

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds	20

ITEM 3. Defaults Upon Senior Securities	20

ITEM 4. Mine Safety Disclosures	20

ITEM 5. Other Information	20

ITEM 6. Exhibits	20

SIGNATURES	21

PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

LA JOLLA PHARMACEUTICAL COMPANY

Condensed Consolidated Balance Sheets

(in thousands, except share and par value amounts)



	September 30, 2015			December 31, 2014
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	135,055		$	48,555
Restricted cash	237			37
Prepaid clinical expenses	360			1,528
Prepaid expenses and other current assets	484			137
Total current assets	136,136			50,257
Property and equipment, net	1,751			279
Other assets	57			—
Total assets	$	137,944		$	50,536

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	2,567		$	730
Accrued expenses	1,145			926
Accrued payroll and related expenses	629			424
Total current liabilities	4,341			2,080
Shareholders’ equity:
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 18,241,509 and 15,225,980 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	2			2
Series C-1² Convertible Preferred Stock, $0.0001 par value; 11,000 shares authorized, 3,906 and 3,917 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	3,906			3,917
Series F Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized, 2,737 and 2,798 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	2,737			2,798
Additional paid-in capital	643,651			528,353
Accumulated deficit	(516,693		)	(486,614		)
Total shareholders’ equity	133,603			48,456
Total liabilities and shareholders' equity	$	137,944		$	50,536

See accompanying notes to the condensed consolidated financial statements.

LA JOLLA PHARMACEUTICAL COMPANY

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except per share amounts)



	Three Months Ended September 30,						Nine Months Ended September 30,
	2015			2014			2015			2014
Revenue
Contract revenue - related party	$	647		$	—		$	647		$	—
Total revenue	647			—			647			—
Expenses
Research and development	7,781			2,625			19,637			6,218
General and administrative	3,353			2,436			11,122			8,259
Total expenses	11,134			5,061			30,759			14,477
Loss from operations	(10,487		)	(5,061		)	(30,112		)	(14,477		)
Other income, net	13			9			33			13
Net loss and comprehensive loss	$	(10,474	)	$	(5,052	)	$	(30,079	)	$	(14,464	)
Basic and diluted net loss per share	$	(0.70	)	$	(0.37	)	$	(1.99	)	$	(1.58	)
Shares used in computing basic and diluted net loss per share	14,899			13,646			15,129			9,131

See accompanying notes to the condensed consolidated financial statements.

LA JOLLA PHARMACEUTICAL COMPANY

Unaudited Condensed Consolidated Statements of Cash Flows

(in thousands)



	Nine Months Ended September 30,
	2015			2014
Operating activities
Net loss	$	(30,079	)	$	(14,464	)
Adjustments to reconcile net loss to net cash used for operating activities:
Share-based compensation expense	9,330			6,595
Third party share-based compensation expense	1,013			—
Depreciation expense	209			10
Changes in operating assets and liabilities:
Restricted Cash	(200		)	—
Prepaid clinical expenses	1,168			—
Prepaid expenses and other current assets	(347		)	(110		)
Other assets	(57		)	—
Accounts payable	1,837			(151		)
Accrued expenses	219			713
Accrued payroll and related expenses	205			(68		)
Net cash used for operating activities	(16,702		)	(7,475		)

Investing activities
Purchase of property and equipment	(1,681		)	(86		)
Net cash used for investing activities	(1,681		)	(86		)

Financing activities
Net proceeds from the issuance of common stock	104,596			53,063
Net proceeds from the exercise of stock options for common stock	287			—
Net cash provided by financing activities	104,883			53,063

Net increase in cash and cash equivalents	86,500			45,502
Cash and cash equivalents at beginning of period	48,555			8,629
Cash and cash equivalents at end of period	$	135,055		$	54,131

Supplemental disclosure of cash flow information
Non-cash investing and financing activity:
Conversion of Series C-1² Convertible Preferred Stock into common stock	$	11		$	—
Conversion of Series F Convertible Preferred Stock into common stock	$	61		$	452
Conversion of Series C-1² and D-1² Convertible Preferred Stock into common stock	$	—		$	3,099

See accompanying notes to the condensed consolidated financial statements.

LA JOLLA PHARMACEUTICAL COMPANY

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2015

1. Business

La Jolla Pharmaceutical Company (collectively with its subsidiaries, the "Company") is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is the Company's proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is the Company's novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia and sickle cell disease. LJPC-30Sa and LJPC-30Sb are the Company's next-generation gentamicin derivatives for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. The Company was incorporated in 1989 as a Delaware corporation and reincorporated in California in 2012.

In September 2015, the Company completed a common stock offering and received approximately $104.6 million, net of issuance costs (see Note 4).

The Company has a history of incurring significant operating losses and negative cash flows from operations. Since January 2012, when the Company was effectively restarted with new assets and a new management team, through September 30, 2015, the Company's cash used in operating activities was $36.5 million. The Company had available cash and cash equivalents of $135.1 million at September 30, 2015. Based on current operating plans and projections, management believes that the available cash and cash equivalents will be sufficient to fund operations into 2018.

2. Summary of Significant Accounting Policies

Basis of Presentation and Use of Estimates

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission ("SEC") Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2014, included in the Company's Annual Report on Form 10-K filed with the SEC on March 16, 2015. The unaudited condensed consolidated financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the condensed consolidated balance sheet of the Company at September 30, 2015, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2015, and the condensed consolidated statement of cash flows for the nine months ended September 30, 2015. Estimates were made relating to useful lives of fixed assets, valuation allowances, impairment of assets, share-based compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ materially from those estimates. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the full year or any future interim periods.

Effective January 14, 2014, the Company effected a 1-for-50 reverse split (the "2014 Reverse Stock Split") of its outstanding common stock (See Note 4). All common stock share and per share information in the accompanying unaudited condensed consolidated financial statements have been restated to reflect retrospective application of the 2014 Reverse Stock Split for all periods presented, except for par value per share and the number of authorized share amounts, which were not affected. All stock options and the shares of common stock underlying outstanding convertible preferred stock were ratably adjusted to give effect to the 2014 Reverse Stock Split.

Certain amounts previously reported in the financial statements have been reclassified to conform to the current year presentation. Such reclassifications did not affect net loss, shareholders' equity or cash flows.

Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of La Jolla Pharmaceutical Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity from the date of purchase of less than three months to be cash equivalents. The carrying value of the Company's money market funds is included in cash equivalents and approximates the fair value.

Restricted Cash

Under the terms of the Company's credit card arrangements, there is a requirement to maintain a collateral cash account pledged as security for such credit cards. Under the terms of the leases of certain of the Company's facilities, there is a requirement to maintain a certificate of deposit as security during the terms of such leases. As of September 30, 2015 and December 31, 2014, restricted cash of $237,000 and $37,000, respectively, was pledged as collateral for the credit cards and leases.

Property and Equipment

Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from two to seven years. As of September 30, 2015 and December 31, 2014, the carrying value of property and equipment, net was $1,751,000 and $279,000, respectively, which was comprised of lab equipment, furniture, computer equipment, software and leasehold improvements. Depreciation expense was $114,000 and $209,000 for the three and nine months ended September 30, 2015, respectively, and $5,000 and $10,000 for the three and nine months ended September 30, 2014, respectively.

Revenue Recognition

In accordance with GAAP, the Company recognizes revenue when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the seller’s price to the buyer is fixed or determinable; and (4) collectibility is reasonably assured. The Company currently recognizes revenue from payments received under a services agreement with a related party. Under the terms of this services agreement, the Company receives payments from this related party for research and development services that the Company provides at a negotiated, arms-length rate.

Clinical Trial Expenses

Payments in connection with the Company's clinical trials are often made under contracts with multiple contract research organizations that conduct and manage clinical trials on the Company's behalf. The financial terms of these contracts are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Generally, these contracts set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. Payments under these contracts depend on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. As of September 30, 2015 and December 31, 2014, the prepaid clinical expenses of $360,000 and $1,528,000 on the condensed consolidated balance sheets represent the initial upfront payments to clinical research organizations for two clinical trials that commenced in 2015. The Company amortizes prepaid clinical trial costs to expense based on estimates regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials.

Expenses related to clinical trials are accrued based on estimates regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the contracted amounts are modified, the accruals are modified accordingly on a prospective basis. Revisions in the scope of a contract are charged to expense in the period in which the facts that give rise to the revision occur.

Research and Development Expenses

Research and development expenses include salaries and benefits, facilities and other overhead expenses, research-related manufacturing expenses, contract services and clinical and preclinical-related services performed by clinical research organizations, research institutions and other outside service providers. Research and development expenses are charged to operations as incurred when these expenditures relate to the Company's research and development efforts and have no alternative future uses.

In accordance with certain research and development agreements, the Company is obligated to make certain upfront payments upon execution of the agreement. Advance payments, including nonrefundable amounts, for materials or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed.

Acquisition or milestone payments that the Company makes in connection with in-licensed technology are expensed as incurred when there is uncertainty in receiving future economic benefits from the licensed technology. The Company considers the future economic benefits from the licensed technology to be uncertain until such licensed technology is incorporated into products that are approved for marketing by the U.S. Food and Drug Administration (the "FDA") or when other significant risk factors are abated. For accounting purposes, management has viewed future economic benefits for all of the Company's licensed technology to be uncertain.

Share-Based Compensation

The Company accounts for share-based payment arrangements in accordance with Accounting Standards Codification ("ASC") 718, Compensation - Stock Compensation and ASC 505-50, Equity - Equity Based Payments to Non-Employees, which requires the recognition of compensation expense, using a fair-value based method, for all costs related to share-based payments, including stock options and restricted stock awards. These standards require companies to estimate the fair value of share-based payment awards on the date of the grant using an option-pricing model. See Note 4 for further discussion of the Company's share-based compensation plans.

Net Loss Per Share

Basic net loss per share is calculated based on the weighted-average number of common shares outstanding. Diluted net loss per share is calculated using the weighted-average number of common shares outstanding plus common stock equivalents outstanding. Outstanding convertible preferred stock, stock options and unvested restricted stock awards are considered common stock equivalents and are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Common stock equivalents are not included in the computation of diluted net loss per share if the inclusion of these securities is anti-dilutive. As of September 30, 2015 and September 30, 2014, there were common stock equivalents of 9.1 million shares and 8.1 million shares, respectively, which were excluded from the calculation of diluted net loss per share because they were anti-dilutive.

Comprehensive Loss

Comprehensive loss for the periods reported was comprised solely of the Company's net loss. The comprehensive loss for the three and nine months ended September 30, 2015 was $10.5 million and $30.1 million, respectively, and for the three and nine months ended September 30, 2014 was $5.1 million and $14.5 million, respectively. There were no other changes in equity that were excluded from net loss for all periods presented.

Recent Accounting Pronouncements

In August 2014, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This update is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable) and to provide related footnote disclosures. The ASU provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. The ASU is effective for annual periods ending after December 15, 2016, which for the Company is the annual period ending on December 31, 2016, and interim periods within annual periods beginning after December 15, 2016, which for the Company is the annual period ending December 31, 2017. Early adoption is permitted. The Company does not intend to early adopt this standard. The adoption of this standard will not have a material impact on the Company's financial position or results of operations.

In June 2014, the FASB issued ASU No. 2014-12, Compensation - Stock Compensation (Topic 781): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period. This update requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. This update is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2015, which for the Company is the annual period ending on December 31, 2016. Early adoption is permitted. The Company does not intend to early adopt this standard. Entities may apply the amendments in this update either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of this standard will not have a material impact on the Company's financial position or results of operations.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). This update outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. This guidance was originally effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016, which for the Company is the annual period ending on December 31, 2017. Early adoption was not originally permitted. In July 2015, the FASB approved the deferral of the effective date of the new standard by one year, but to permit companies to adopt one year earlier if they choose. The Company does not intend to early adopt this standard. The standard may be adopted using a full retrospective or a modified retrospective (cumulative effect) method. The adoption of this update will not have a material impact on its financial position or results of operations.

3. Contract Revenue - Related Party

During the three months ended September 2015, the Company entered into a services agreement with a private company that is a related party. Pursuant to the services agreement, the Company provides certain services to this related party, including, but not limited to, research and development and clinical trial design and management. In exchange for providing such services pursuant to the services agreement, the Company receives payments at a negotiated, arms-length rate. As a result, the consideration received by the Company for its services under the services agreement is considered to be no less favorable to the Company than comparable terms that the Company could obtain from an unaffiliated third party in an arms-length transaction. The services agreement may be canceled by either party upon 60-days' written notice to the other party. Additionally, the Company anticipates receiving a non-voting profits interest in the related party, providing the Company with the potential to receive a portion of the future distributions of profits, if any.

During the three and nine months ended September 30, 2015, the Company recognized approximately $647,000 of contract revenue for services and costs provided under the services agreement.

4. Shareholders’ Equity

Common Stock

2015 Common Stock Offering

In September 2015, the Company offered and sold an aggregate of 2,932,500 shares of common stock in an underwritten offering at a public offering price of $38.00 per share, with gross proceeds of approximately $111.4 million. The Company received net proceeds of approximately $104.6 million, net of approximately $6.8 million in underwriting commissions, discounts and other issuance costs.

2014 Common Stock Offering

In July 2014, the Company offered and sold an aggregate of 5,395,000 shares of common stock in an underwritten offering at a public offering price of $10.50 per share, with gross proceeds of approximately $56.6 million. The Company received net proceeds of approximately $53.1 million, net of approximately $3.5 million in underwriting commissions, discounts and other issuance costs.

2014 Reverse Stock Split

In January 2014, the Company enacted the 2014 Reverse Stock Split. The 2014 Reverse Stock Split was approved by the Company's shareholders in June 2013 and resulted in every 50 shares of the Company’s issued and outstanding common stock to be automatically combined into one share of the Company’s common stock. No fractional shares were issued in connection with the 2014 Reverse Stock Split. Shareholders who were entitled to fractional shares instead became entitled to receive a cash payment in lieu of receiving fractional shares equal to the fractional share interest. The 2014 Reverse Stock Split affected all of the holders of the Company’s common stock uniformly. Shares of the Company’s common stock underlying outstanding stock options were proportionately reduced, and the exercise prices of outstanding stock options were proportionately increased in accordance with the terms of the agreements governing such securities. Shares of the Company’s common stock underlying outstanding convertible preferred stock were proportionately reduced, and the conversion rates were proportionately decreased in accordance with the terms of the agreements governing such securities.

Amendment to Articles of Incorporation

In August 2014, at the Company's annual meeting of shareholders, the Company's shareholders approved an amendment to the Company's articles of incorporation to reduce the number of authorized common shares available for issuance to 100,000,000 shares from 12,000,000,000 shares.

Preferred Stock

As of September 30, 2015, the Company is authorized to issue 8,000,000 shares of preferred stock, with a par value of $0.0001 per share, in one or more series, of which 11,000 are designated as Series C-1² Convertible Preferred Stock (the "Series C-1²Preferred") and 10,000 are designated as Series F Convertible Preferred Stock (the "Series F Preferred"). During the nine months ended September 30, 2015, the Company issued 19,134 and 17,360 shares of common stock upon the conversion of Series C-1²Preferred and Series F Preferred, respectively. During the year ended December 31, 2014, the Company issued 5,341,670 shares of common stock upon the conversion of Series C-1² Preferred and 129,105 shares of common stock upon the conversion of Series F Preferred. The Series C-1² Preferred is convertible into common stock at a rate of approximately 1,724 shares of common stock for each share of Series C-1² Preferred, and the Series F Preferred is convertible into common stock at a rate of approximately 286 shares of common stock for each share of Series F Preferred. As of September 30, 2015, there were 3,906 shares of Series C-1² Preferred and 2,737 shares of Series F Preferred issued and outstanding. As such, as of September 30, 2015, the issued and outstanding Series C-1² Preferred and Series F Preferred were convertible into 6,735,378 and 782,032 shares of common stock, respectively.

The holders of preferred stock do not have voting rights, other than for general protective rights required by the California General Corporation Law. The Series C-1² Preferred and the Series F Preferred do not have dividends.

The Series C-1² Preferred and the Series F Preferred have a liquidation preference in an amount equal to $1,000 per share. As of September 30, 2015, the aggregate liquidation preference was approximately $3,906,000 and $2,737,000 on the Series C-1² Preferred and Series F Preferred, respectively.

Share-Based Compensation

Stock Options

2013 Equity Incentive Plan

In September 2013, the Company adopted an equity compensation plan entitled the 2013 Equity Incentive Plan (the “2013 Equity Plan”). The 2013 Equity Plan is an omnibus equity compensation plan that permits the issuance of various types of equity-based compensation awards, including stock options, restricted stock awards, stock appreciation rights and restricted stock units, as well as cash awards, to employees, directors and eligible consultants of the Company. The 2013 Equity Plan has a ten-year term and permits the issuance of incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended. The administrator under the plan has broad discretion to establish the terms of awards, including the size, term, exercise price and vesting conditions. Generally, grants to employees vest over four years, with 25% vesting on the one-year anniversary, and the remainder vesting either quarterly or monthly thereafter; grants to non-employee directors generally vest over three years, with 33% vesting on the one-year anniversary, and the remainder vesting either quarterly or monthly thereafter.

The 2013 Equity Plan previously allowed for automatic annual increases to the number of shares of common stock authorized for issuance under the 2013 Equity Plan on the first day of each year, with such increases based on 10% of the outstanding shares of the Company’s common stock as of the last day of the previous year. On January 1, 2014, the total shares available for grant under the 2013 Equity Plan increased to 440,441. At the 2014 annual meeting of shareholders, the Company's shareholders approved and adopted an amendment to the 2013 Equity Plan to increase the number of shares of common stock authorized for issuance up to a total of 1,100,000 shares and eliminated the automatic annual increase on the first day of each year. At the 2015 annual meeting of shareholders, the Company's shareholders approved and adopted an amendment to the 2013 Equity Plan to increase the number of shares of common stock authorized for issuance up to a total of 3,100,000 shares.

As of September 30, 2015, there were 1,613,525 shares available for future grants under the 2013 Equity Plan.

Share-Based Award Activity

The Company’s stock option and 2013 Equity Plan restricted stock award activity for the nine months ended September 30, 2015 and the year ended December 31, 2014 was comprised of the following:



	Outstanding Stock Options and 2013 Equity Plan Restricted Stock Awards
	Shares Underlying Stock Options and Restricted Stock Awards		Weighted-Average Exercise Price per Share	Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at December 31, 2013	54,000		$6.00
Granted	567,876		$9.88
Restricted stock awards vested	(2,976	)	$0.00
Outstanding at December 31, 2014	618,900		$9.54
Granted	942,285		$23.83
Exercised	(42,535	)	$9.74
Forfeited	(24,465	)	$10.19
Outstanding at September 30, 2015	1,494,185		$18.54	9.21 years	$	15,765,631
Vested and expected to vest at September 30, 2015	1,494,185		$18.54	9.21 years	$	15,765,631
Exercisable at September 30, 2015	211,408		$10.60	8.67 years	$	3,643,505

In April 2015, the Company made a stock option grant to the Company's recently appointed Chief Financial Officer to purchase 60,000 shares of common stock at an exercise price equal to the fair market value of the Company's common stock on the grant date. This grant was awarded as an Inducement Grant outside of the 2013 Equity Plan. The stock option will vest and become exercisable with respect to 25% of the underlying shares on the first anniversary of the grant date, and then with respect to the remaining shares, on a quarterly basis over the next three years, subject to continued service during that time.

As of September 30, 2015, the Company has reserved 3,047,710 shares of common stock for future issuance upon exercise of all outstanding stock options granted or to be granted under the 2013 Equity Plan, which excludes the 60,000 shares underlying the stock option discussed above that was issued in April 2015.

The weighted-average grant date fair values of the stock options granted during the three and nine months ended September 30, 2015 was $21.49 and $21.13 per underlying share, respectively. The weighted-average grant date fair values of stock options granted during the three and nine months ended September 30, 2014 was $8.38 and $9.49 per underlying share, respectively. As of September 30, 2015, approximately $19,856,000 of total unrecognized share-based compensation expense related to non-vested stock options remains and is expected to be recognized over a weighted-average period of approximately 3.0 years. During the three and nine months ended September 30, 2015, stock options to purchase 35,035 and 42,535 shares of common stock, respectively, were exercised with an intrinsic value of $641,000 and $752,000, respectively. No stock option exercises occurred during the year ended December 31, 2014.

Third Party Share-Based Compensation Expense

The Company initially estimates the fair value of stock options and warrants issued to non-employees, other than non-employee directors, on the grant date using the Black-Scholes model. Thereafter, the Company re-measures the fair value using the Black-Scholes model as of each balance sheet date as the stock options and warrants vest.

In December 2014, the Company granted warrants to purchase 51,000 shares of common stock to two outside third parties at an exercise price equal to the fair market value of the stock on the date of each grant. One grant will vest 25% on each anniversary date over four years. The other grant vests 100% on the one-year anniversary of the grant. The Company recognized compensation expense for these warrant grants of approximately $197,000 and $613,000 for the three and nine months ended September 30, 2015, respectively.

In February 2015, the Company granted a stock option to purchase 60,000 shares of common stock to a consultant at an exercise price equal to the fair market value of the Company's common stock on the grant date. This grant was made from the 2013 Equity Plan. The stock option vested with respect to 25% of the underlying shares on the grant date with the remainder to vest quarterly over three years. The Company recognized third party compensation expense for this stock option grant of approximately zero and $362,000 for the three and nine months ended September 30, 2015, respectively. In July 2015, this consultant became an employee of the Company.

In August 2015, the Company granted a stock option to purchase 40,000 shares of common stock to a consultant at an exercise price equal to the fair market value of the Company's common stock on the grant date. This grant was made from the 2013 Equity Plan. The vesting of this stock option is contingent on the achievement of a performance milestone by the end of 2016, at which time any unvested shares underlying the option will be canceled. The Company recognized compensation expense for this stock option grant of approximately $38,000 for the three and nine months ended September 30, 2015.

Stock Option Valuation

The fair value of each stock option award is estimated on the grant date using a Black-Scholes option pricing model (the “Black-Scholes model”), which uses the assumptions noted in the following table. Expected volatility is based on historical volatility of the Company’s common stock. In determining the expected life of employee stock options, the Company uses the “simplified” method. The expected life assumptions for non-employees were based upon the contractual term of the stock options. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the stock options in effect at the time of the grants. The dividend yield assumption is based on the expectation of no future dividend payments by the Company.

The Company estimated the fair value of each stock option grant on the grant date using the Black-Scholes model with the following weighted-average assumptions:



	Nine Months Ended September 30,
	2015		2014
Volatility	147	%	188	%
Expected life (years)	4.91 years		6.73 years
Risk-free interest rate	1.4	%	2.2	%
Dividend yield	—	%	—	%

Restricted Stock Awards

Restricted stock awards ("RSAs") are grants that entitle the holder to acquire shares of common stock for no cash consideration or at a fixed price, which is typically nominal. The Company accounts for RSAs as issued and outstanding common stock, even though: (a) shares covered by an RSA cannot be sold, pledged, or otherwise disposed of until the award vests; and (b) any unvested shares may be reacquired by the Company for the original purchase price following the awardee's termination of service. The valuation of RSAs is based on the fair market value of the underlying shares on the grant date.

In September 2013, the Company issued RSAs consisting of approximately 1,327,048 shares to the CEO, 79,622 shares to a director and an aggregate of 336,185 shares to three non-officer employees. The grants to the CEO, director and one of the employees were for the replacement of canceled stock options and restricted stock units granted in April 2012, which was done in order to complete the capital restructuring that took place in September 2013. These RSAs were granted outside of the 2013 Equity Plan, but are governed in all respects by the 2013 Equity Plan. These RSAs were granted with a combination of performance-based and time-based vesting components. As of September 30, 2015, all performance-based vesting conditions had been satisfied, but the time-based service requirements, which provided for vesting in 2016, subject to continuous service through the vesting and delivery date, had not yet been satisfied. In July 2015, the vesting conditions for 1,042,680 shares of unvested and outstanding RSA’s awarded to the CEO were amended to provide that vesting and delivery of the shares shall be deferred until March 15, 2017, subject to the CEO's continued service with the Company through such date.

On January 25, 2014, the Company granted RSAs representing 2,976 shares of common stock with a grant date fair market value of $25,000 to a consultant for services. The RSAs vested immediately and were issued from the 2013 Equity Plan.

In August 2015, the Company issued a fully vested RSA representing the right to acquire 4,000 shares of common stock with a grant date fair value of approximately $92,000.

The Company’s RSA activity for the nine months ended September 30, 2015 and the year ended December 31, 2014 was comprised of the following:



	Number of Shares		Weighted-Average Grant Date Fair Market Value
Unvested at December 31, 2013	1,746,853		$	11.80
Granted	2,976		$	8.40
Vested	(423,693	)	$	9.18
Forfeited	(47,129	)	$	4.41
Unvested at December 31, 2014	1,279,007		$	12.86
Vested	(188,414	)	$	12.30
Unvested at September 30, 2015	1,090,593		$	12.95

As of September 30, 2015, approximately $178,000 of total unrecognized share-based compensation expense for research and development activities related to RSAs remains and is expected to be recognized over a weighted-average period of approximately 0.3 years. As of September 30, 2015, approximately $3,117,000 of total unrecognized share-based compensation expense for general and administrative activities related to RSAs remains and is expected to be recognized over a weighted-average period of approximately 1.4 years.

Share-Based Compensation Expense

Share-based compensation expense recognized in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2015 and 2014 is based on awards ultimately expected to vest.

Total share-based compensation expense related to all share-based awards for the three and nine months ended September 30, 2015 and 2014 was comprised of the following (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Research and development:
Stock options	$	636	$	98	$	1,609	$	142
Restricted stock	240		147		1,452		652
Warrants	15		—		40		—
Research and development share-based compensation expense	891		245		3,101		794
General and administrative:
Stock options	1,443		286		2,950		575
Restricted stock	545		1,212		3,719		5,226
Warrants	182		—		573		—
General and administrative share-based compensation expense	2,170		1,498		7,242		5,801
Total share-based compensation expense included in expenses	$	3,061	$	1,743	$	10,343	$	6,595

5. Income Taxes

The Company accounts for income taxes under the asset and liability method. Deferred income tax assets and liabilities are recognized for temporary differences between financial statement and income tax basis, using enacted tax rates in effect for the years such differences are expected to reverse. The Company recognizes deferred tax assets to the extent that it believes such assets are more likely than not to be realized. Due to uncertainties surrounding the Company's ability to generate future taxable income, the Company believes that it is more likely than not that deferred tax assets will not be realized, and consequently a full valuation allowance has been established. The Company continues to maintain a full valuation allowance against its deferred tax assets as of September 30, 2015.

The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has a 50% or less likelihood of being sustained. There have been no material changes in the Company's unrecognized tax benefits since December 31, 2014; and, as such, disclosures included in the Company's 2014 Annual Report on Form 10-K continue to be relevant for the nine months ended September 30, 2015.

6. Commitments and Contingencies

In January 2015, the Company entered into a 25-month lease agreement for 4,047 square feet of lab space. The lease term is from March 2015 through March 2017, and the Company's total lease payments through the end of the lease will be approximately $93,000. The lease contains options to extend the lease for two additional six-month periods.

In February 2015, the Company entered into a 32-month sublease agreement as a sublessee for 18,599 square feet of office space to be used as the Company's corporate headquarters. The lease term is through October 2017, and the Company's total lease payments through the end of the lease will be approximately $1,466,000. The Company also leases a total of 3,713 square feet of office space with a lease term through March 2018, and total lease payments through the end of the lease are approximately $300,000.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

In this report, all references to “we,” “our,” “us,” “La Jolla” and the “Company” refer to La Jolla Pharmaceutical Company, a California corporation, and its subsidiaries.

Forward-Looking Statements

The forward-looking statements in this report involve significant risks, assumptions and uncertainties, and a number of factors, both foreseen and unforeseen, which could cause actual results to differ materially from our current expectations. Forward-looking statements include those that express a plan, belief, expectation, estimation, anticipation, intent, contingency, future development or similar expression. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Forward-looking statements include, but are not limited to, statements regarding our expectations around timing of commencement and completion of future clinical trials, the ability to successfully develop drug candidates, our ability to obtain orphan drug status or other regulatory approvals, and the expected duration over which our cash balances will fund our operations. The outcomes of the events described in these forward-looking statements are subject to the risks, uncertainties and other factors described in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the “Risk Factors” section contained in our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the Securities and Exchange Commission, or SEC, on March 16, 2015, and in other reports and registration statements that we file with the SEC from time to time. We expressly disclaim any intent to update forward-looking statements.

Introduction

Management’s discussion and analysis of financial condition and results of operations is provided as a supplement to the accompanying unaudited condensed consolidated financial statements and notes, included in Item 1 of this Quarterly Report on Form 10-Q, to help provide an understanding of our financial condition, the changes in our financial condition and our results of operations. Our discussion is organized as follows:


•	Business Overview. This section provides a general description of our business and significant events and transactions that we believe are important in understanding our financial condition and results of operations.


•	Program Overview. This section provides a current status overview for each of our four product candidates in development.


•	Critical Accounting Policies and Estimates. This section provides a description of our significant accounting policies, including the critical accounting policies and estimates, which are summarized in Note 2 to the accompanying unaudited condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q.


•	Results of Operations. This section provides an analysis of our results of operations presented in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss by comparing the results for the three and nine months ended September 30, 2015 to the results for the three and nine months ended September 30, 2014.


•	Liquidity and Capital Resources. This section provides an analysis of our historical cash flows, as well as our future capital requirements.

Business Overview

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. We have several product candidates in development. LJPC-501 is our proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is our novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia and sickle cell disease. LJPC-30Sa and LJPC-30Sb are our next-generation gentamicin derivatives for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

Program Overview

LJPC-501

LJPC-501 is our proprietary formulation of angiotensin II. Angiotensin II, the major bioactive component of the renin-angiotensin system, serves as one of the body’s central regulators of blood pressure. We are developing LJPC-501 for the treatment of catecholamine-resistant hypotension, or CRH, which is an acute, life-threatening condition in which blood pressure drops to dangerously low levels in patients who respond poorly to current treatments. Angiotensin II has been shown to raise blood pressure in a randomized, placebo-controlled clinical trial in CRH, which was recently published in the journal Critical Care, as well as in animal models of hypotension. Preclinical pharmacology studies that we have conducted have demonstrated that catecholamine resistance may be in part a result of reduced endogenous production of angiotensin II. In October 2014, we presented positive data from a preclinical study of LJPC-501 for the treatment of CRH.

We initiated a Phase 3 clinical trial with LJPC-501 for the treatment of CRH, called the ATHOS (Angiotensin II for the Treatment of High-Output Shock) 3 trial, in March 2015. In February 2015, we reached agreement with the U.S. Food and Drug Administration, or FDA, on a Special Protocol Assessment, or SPA, for this multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical trial. In accordance with the SPA, the primary efficacy endpoint for the ATHOS 3 registration trial is increase in blood pressure at three hours. The ATHOS 3 trial is designed to enroll approximately 315 patients. Patients are to be randomized in a 1:1 fashion to receive either: (i) LJPC-501 plus standard-of-care vasopressors; or (ii) placebo plus standard-of-care vasopressors. Randomized patients are to receive their assigned treatment via continuous IV infusion for up to seven days. The primary efficacy endpoint in the study is to compare the change in mean arterial pressure in patients with CRH who receive an IV infusion of LJPC-501 plus standard-of-care vasopressors to those that receive placebo plus standard-of-care vasopressors. Secondary endpoints include comparison of changes in Cardiovascular Sequential Organ Failure Assessment, or SOFA scores, and the safety and tolerability of LJPC-501 in patients with CRH. Results from ATHOS 3 are expected by the end of 2016.

LJPC-401

LJPC-401 is our novel formulation of hepcidin. Hepcidin, an endogenous peptide hormone, is the body’s naturally occurring regulator of iron absorption and distribution. Hepcidin prevents excessive iron accumulation in vital organs, such as the liver and heart, where it can cause significant damage and even result in death.

We are developing LJPC-401 for the potential treatment of iron overload, which occurs as a result of diseases such as hereditary hemochromatosis (HH), beta thalassemia and sickle cell disease (SCD). HH is a disease caused by a genetic deficiency in hepcidin that results in excessive iron accumulation. HH is the most common genetic disease in Caucasians and causes liver cirrhosis, liver cancer, heart disease and/or failure, diabetes, arthritis and joint pain. Beta thalassemia and SCD are genetic diseases of the blood that can cause life-threatening anemia and usually require frequent and life-long blood transfusions. These blood transfusions cause excessive iron accumulation in the body, which is toxic to vital organs, such as the liver and heart. In addition, the underlying anemia causes excessive iron accumulation independent of blood transfusions.

LJPC-401 has been shown to be effective in reducing serum iron in preclinical testing. In October 2015, we initiated a Phase 1 clinical trial of LJPC-401 in patients at risk of iron overload due to conditions such as HH, beta thalassemia and SCD. We anticipate preliminary results from this Phase 1 clinical trial by the end of 2015.

LJPC-30Sa and LJPC-30Sb

LJPC-30Sa and LJPC-30Sb are our next-generation gentamicin derivatives. Despite kidney toxicity, gentamicin has become one of the most commonly prescribed hospital antibiotics due to its broad spectrum of antimicrobial efficacy. Gentamicin consists primarily of a mixture of four distinct but closely related chemical entities that may contribute differentially to the product’s toxicity profile.

LJPC-30Sa and LJPC-30Sb are purified components of the currently marketed gentamicin product that retain the biologic activity of gentamicin, yet appear to lack the traditional kidney toxicity associated with it. We are developing LJPC-30Sa and LJPC-30Sb not only for the potential treatment of serious bacterial infections but also for the potential treatment of rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

We believe that gentamicin’s ability to induce a lack of fidelity in gene transcription, intrinsic to its antimicrobial mechanism of action, can also be leveraged in the correction of certain human genetic mutations that lead to rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. In spite of favorable short-term clinical proof-of-efficacy data in cystic fibrosis, development of gentamicin as a chronic treatment for these genetic diseases has been limited by its toxicity profile.

Following a pre-IND meeting with the FDA, we have received guidance that we may proceed with a proposed Phase 1 clinical trial following the submission of an IND.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. We base our estimates on historical experience and on other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.

There have been no material changes to the critical accounting policies as previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2014, which was filed on March 16, 2015.

Recent Accounting Pronouncements

Recent accounting pronouncements are disclosed in Note 2 to the accompanying unaudited condensed consolidated financial statements included in Item 1 of this Quarterly Report on form 10-Q.

Results of Operations

Three and Nine Months Ended September 30, 2015 and 2014

The following summarizes the results of our operations for the three and nine months ended September 30, 2015 and 2014 (in thousands):



	Three Months Ended September 30,						Nine Months Ended September 30,
	2015			2014			2015			2014
Contract revenue - related party	$	647		$	—		$	647		$	—
Research and development expense	(7,781		)	(2,625		)	(19,637		)	(6,218		)
General and administrative expense	(3,353		)	(2,436		)	(11,122		)	(8,259		)
Other income, net	13			9			33			13
Net loss	$	(10,474	)	$	(5,052	)	$	(30,079	)	$	(14,464	)

Contract Revenue - Related Party

During the three months ended September 2015, we entered into a services agreement with a private company that is a related party. Pursuant to the services agreement, we provide certain services to this related party, including, but not limited to, research and development and clinical trial design and management. In exchange for providing such services pursuant to the services agreement, we receive payments at a negotiated, arms-length rate. As a result, the consideration received by us for our services under the services agreement is considered to be no less favorable to us than comparable terms that we could obtain from an unaffiliated third party in an arms-length transaction. The services agreement may be canceled by either party upon 60-days' written notice to the other party. Additionally, we anticipate receiving a non-voting profits interest in the related party, providing us with the potential to receive a portion of the future distributions of profits, if any.

Research and Development Expense

The following summarizes our research and development expense for the three and nine months ended September 30, 2015 and 2014 (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Clinical development costs	$	3,097	$	1,836	$	9,137	$	3,969
Personnel and related costs	1,857		419		4,131		854
Share-based compensation expense	891		245		3,101		794
Technology in-licensing costs	404		40		439		218
Other research and development costs	1,532		85		2,829		383
Total research and development expense	$	7,781	$	2,625	$	19,637	$	6,218

For the three and nine months ended September 30, 2015, research and development expense increased to $7.8 million and $19.6 million, respectively, from $2.6 million and $6.2 million for the same periods in 2014, respectively. The increase was primarily due to increased clinical development costs associated with the initiation of the Phase 3 clinical trial of LJPC-501 in CRH and preclinical costs associated with LJPC-401 and LJPC-30Sa and 30Sb. Increases in personnel and related costs and share-based compensation expense, which were mainly due to the hiring of additional personnel to support the increased development activities noted above, also contributed to the increase in research and development expense. Additionally, the increase in other research and development costs was partially due to increased spending for exploratory early-stage research of approximately $0.2 million and $0.8 million for the three and nine months ended September 30, 2015, respectively. We anticipate research and development expense to continue to increase throughout 2015, due to planned increases in personnel to support our ongoing clinical trials, the initiation of additional clinical trials and ongoing development programs.

General and Administrative Expense

The following summarizes our general and administrative expense for the three and nine months ended September 30, 2015 and 2014 (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Personnel and related costs	$	598	$	241	$	1,831	$	752
Share-based compensation expense	2,170		1,498		7,242		5,801
Other general and administrative expense	585		697		2,049		1,706
Total general and administrative expense	$	3,353	$	2,436	$	11,122	$	8,259

For the three and nine months ended September 30, 2015, general and administrative expense increased to $3.4 million and $11.1 million, respectively, from $2.4 million and $8.3 million for the same periods in 2014, respectively. The increase was primarily due to increases in share-based compensation expense, personnel and related costs and facilities costs, which were mainly due to the hiring of additional personnel to support the development activities discussed above. In addition, there were increased expenses for professional and outside services. We anticipate general and administrative expense to continue to increase throughout 2015, due to planned increases in personnel and additional facility costs to accommodate our operations in light of the additional programs that we have acquired or are developing.

Liquidity and Capital Resources

Since January 2012, when La Jolla was effectively restarted with new assets and a new management team, through September 30, 2015, our cash used in operating activities was $36.5 million. From inception through September 30, 2015, we have incurred a cumulative net loss of approximately $516.7 million and have financed our operations through public and private offerings of securities, revenues from collaborative agreements, equipment financings and interest income on invested cash balances. From inception through September 30, 2015, we have raised approximately $586.0 million in net proceeds from the sales of equity securities.

As of September 30, 2015, we had $135.1 million in cash and cash equivalents, compared to $48.6 million of cash and cash equivalents at December 31, 2014. Cash used in operating activities for the nine months ended September 30, 2015 was $16.7 million, compared to $7.5 million for the same period in 2014, and such increase was primarily due to increased research and development expenditures for clinical trials and exploratory early-stage research. For the nine months ended September 30, 2015, we used approximately $1.7 million of cash for investing activities related to purchases of property and equipment. In addition, cash provided by financing activities was $104.9 million for the nine months ended September 30, 2015, primarily from the common stock offering completed in September 2015. At September 30, 2015, we had positive working capital of approximately $131.8 million, compared to positive working capital of approximately $48.2 million at December 31, 2014. The increase in our cash and cash equivalents and working capital was primarily due to cash provided by financing activities partially offset by cash used for operating activities for the nine months ended September 30, 2015.

Based on our cash and working capital as of September 30, 2015 and our current operating plans and projections, we believe that the available cash and cash equivalents will be sufficient to fund operations into 2018. To fund future operations to the point where we are able to generate positive cash flow from the sales or out-licensing of our drug candidates, we will need to raise additional capital. The amount and timing of future funding requirements will depend on many factors, including the timing and results of our ongoing development efforts, the potential expansion of our current development programs, potential new development programs and related general and administrative support, as well as the overall condition of capital markets, including capital markets for development-stage biopharmaceutical companies. We anticipate that we will seek to fund our operations through public and private equity and debt financings or other sources, such as potential collaboration agreements. We cannot assure you that anticipated additional financing will be available to us on favorable terms, or at all. Although we have previously been successful in obtaining financing through equity securities offerings, there can be no assurance that we will be able to do so in the future.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in our financial condition, expenses, results of operations, liquidity, capital expenditures or capital resources.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We do not hold any marketable securities at September 30, 2015.

ITEM 4. CONTROLS AND PROCEDURES

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports, filed under the Securities Exchange Act of 1934, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

As required by the SEC Rule 13a-15(b), we carried out an evaluation under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

There has been no change in our internal control over financial reporting during our most recent quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

In the ordinary course of business, we may face various claims brought by third parties. Any of these claims could subject us to costly litigation. However, as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a material adverse effect on our financial condition or results of operations.

ITEM 1A. RISK FACTORS

No material changes to risk factors have occurred as previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2014, as supplemented by those risk factors set forth under the caption "Risk Factors" in our Prospectus Supplement, dated September 9, 2015, filed with the SEC on September 11, 2015 pursuant to Rule 424(b), which are incorporated herein by reference.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION

The disclosure set forth above in Note 3 to the Notes to the Condensed Consolidated Financial Statements is incorporated by reference herein.

ITEM 6. EXHIBITS



		Incorporated by Reference Herein
Exhibit Number	Description	Form	Date
31.1	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith
31.2	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith
32.1	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed herewith
101.INS	XBRL Instance Document	Filed herewith
101.SCH	XBRL Taxonomy Extension Schema Document	Filed herewith
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document	Filed herewith
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document	Filed herewith
101.LAB	XBRL Taxonomy Extension Label Linkbase Document	Filed herewith
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document	Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



		La Jolla Pharmaceutical Company

Date:	November 6, 2015	/s/ George F. Tidmarsh
		George F. Tidmarsh, M.D., Ph.D.
		President, Chief Executive Officer and Secretary

		/s/ Dennis M. Mulroy
		Dennis M. Mulroy
		Chief Financial Officer
		(As Principal Financial and Accounting Officer)

EX-31.1 2 ljpc-2015930xexhibit311.htm EXHIBIT 31.1 Exhibit

EXHIBIT 31.1

SECTION 302 CERTIFICATION

I, George F. Tidmarsh, certify that:


1.	I have reviewed this Quarterly Report on Form 10-Q of La Jolla Pharmaceutical Company;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):


a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.




Date:	November 6, 2015	/s/ George F. Tidmarsh
		George F. Tidmarsh, M.D., Ph.D.
		President, Chief Executive Officer and Secretary

EX-31.2 3 ljpc-2015930xexhibit312.htm EXHIBIT 31.2 Exhibit

EXHIBIT 31.2

SECTION 302 CERTIFICATION

I, Dennis M. Mulroy, certify that:


1.	I have reviewed this Quarterly Report on Form 10-Q of La Jolla Pharmaceutical Company;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):


a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.




Date:	November 6, 2015	/s/ Dennis M. Mulroy
		Dennis M. Mulroy
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-32.1 4 ljpc-2015930xexhibit321.htm EXHIBIT 32.1 Exhibit

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Each of the undersigned, in his capacity as an officer of La Jolla Pharmaceutical Company (the "Registrant"), hereby certifies, for purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:


•	the Quarterly Report of the Registrant on Form 10-Q for the quarter ended September 30, 2015 (the “Report), which accompanies this certification, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


•	the information contained in the Report fairly presents, in all material respects, the financial condition of the Registrant at the end of such quarter and the results of operations of the Registrant for such quarter.




Date:	November 6, 2015	/s/ George F. Tidmarsh
		George F. Tidmarsh, M.D., Ph.D.
		President, Chief Executive Officer and Secretary

		/s/ Dennis M. Mulroy
		Dennis M. Mulroy
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

Note: A signed original of this written statement required by Section 906 has been provided to La Jolla Pharmaceutical Company and will be retained by La Jolla Pharmaceutical Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 5 ljpc-20150930.xml XBRL INSTANCE DOCUMENT 0000920465 2015-01-01 2015-09-30 0000920465 2015-10-31 0000920465 2015-09-30 0000920465 2014-12-31 0000920465 ljpc:SeriesFConvertiblePreferredStockMember 2014-12-31 0000920465 ljpc:SeriesCOneConvertiblePreferredStockMember 2014-12-31 0000920465 ljpc:SeriesCOneConvertiblePreferredStockMember 2015-09-30 0000920465 ljpc:SeriesFConvertiblePreferredStockMember 2015-09-30 0000920465 2015-07-01 2015-09-30 0000920465 2014-01-01 2014-09-30 0000920465 2014-07-01 2014-09-30 0000920465 ljpc:BiotechResearchB.V.Member 2015-01-01 2015-09-30 0000920465 ljpc:SeriesCOneConvertiblePreferredStockMember 2015-01-01 2015-09-30 0000920465 ljpc:ConversionOfSeriesC1AndD1PreferredStockIntoCommonStockMember 2014-01-01 2014-09-30 0000920465 ljpc:SeriesFConvertiblePreferredStockMember 2015-01-01 2015-09-30 0000920465 ljpc:SeriesCOneConvertiblePreferredStockMember 2014-01-01 2014-09-30 0000920465 ljpc:SeriesFConvertiblePreferredStockMember 2014-01-01 2014-09-30 0000920465 2013-12-31 0000920465 ljpc:ConversionOfSeriesC1AndD1PreferredStockIntoCommonStockMember 2015-01-01 2015-09-30 0000920465 2014-09-30 0000920465 2012-01-01 2015-09-30 0000920465 us-gaap:MinimumMember 2015-01-01 2015-09-30 0000920465 us-gaap:MaximumMember 2015-01-01 2015-09-30 0000920465 2014-01-13 2014-01-14 0000920465 ljpc:BiotechResearchB.V.Member 2015-07-01 2015-09-30 0000920465 2014-01-01 2014-12-31 0000920465 us-gaap:WarrantMember us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0000920465 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0000920465 us-gaap:RestrictedStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-09-30 0000920465 us-gaap:WarrantMember us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0000920465 us-gaap:RestrictedStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0000920465 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-09-30 0000920465 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0000920465 us-gaap:RestrictedStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-09-30 0000920465 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0000920465 us-gaap:WarrantMember us-gaap:GeneralAndAdministrativeExpenseMember 2014-07-01 2014-09-30 0000920465 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-09-30 0000920465 us-gaap:RestrictedStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2014-07-01 2014-09-30 0000920465 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-09-30 0000920465 us-gaap:WarrantMember us-gaap:ResearchAndDevelopmentExpenseMember 2014-07-01 2014-09-30 0000920465 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2014-07-01 2014-09-30 0000920465 us-gaap:ResearchAndDevelopmentExpenseMember 2014-07-01 2014-09-30 0000920465 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2014-07-01 2014-09-30 0000920465 us-gaap:RestrictedStockMember us-gaap:ResearchAndDevelopmentExpenseMember 2014-07-01 2014-09-30 0000920465 us-gaap:WarrantMember us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-09-30 0000920465 us-gaap:RestrictedStockMember us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-09-30 0000920465 us-gaap:RestrictedStockMember us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0000920465 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0000920465 us-gaap:WarrantMember us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0000920465 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-09-30 0000920465 us-gaap:RestrictedStockMember us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0000920465 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0000920465 us-gaap:WarrantMember us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-09-30 0000920465 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-09-30 0000920465 us-gaap:WarrantMember us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-09-30 0000920465 us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0000920465 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-09-30 0000920465 us-gaap:GeneralAndAdministrativeExpenseMember 2014-07-01 2014-09-30 0000920465 us-gaap:RestrictedStockMember 2013-12-31 0000920465 us-gaap:RestrictedStockMember 2014-01-01 2014-12-31 0000920465 us-gaap:RestrictedStockMember 2014-12-31 0000920465 us-gaap:RestrictedStockMember 2015-09-30 0000920465 us-gaap:RestrictedStockMember 2015-01-01 2015-09-30 0000920465 ljpc:TwoThousandandThirteenPlanMember 2015-09-30 0000920465 ljpc:UnderwritingAgreementMember 2015-09-01 2015-09-30 0000920465 ljpc:TwoThousandandThirteenPlanMember us-gaap:ChiefFinancialOfficerMember 2015-04-01 2015-04-30 0000920465 us-gaap:IPOMember 2014-07-31 0000920465 ljpc:GrantOneMember 2014-12-01 2014-12-31 0000920465 ljpc:TwoThousandandThirteenPlanMember ljpc:ConsultantMember 2015-02-01 2015-02-28 0000920465 ljpc:SeriesCOneConvertiblePreferredStockMember us-gaap:CommonStockMember 2015-01-01 2015-09-30 0000920465 2014-07-31 0000920465 ljpc:GrantTwoMember ljpc:OneyearAnniversaryDateofGrantMember 2014-12-01 2014-12-31 0000920465 ljpc:GrantOneMember ljpc:OneyearAnniversaryDateofGrantMember 2014-12-01 2014-12-31 0000920465 ljpc:TwoThousandandThirteenPlanMember us-gaap:DirectorMember ljpc:OneyearAnniversaryDateofGrantMember 2013-09-01 2013-09-30 0000920465 ljpc:TwoThousandandThirteenPlanMember 2013-09-01 2013-09-30 0000920465 us-gaap:IPOMember 2015-09-30 0000920465 ljpc:UnderwritingAgreementMember 2014-07-01 2014-07-31 0000920465 ljpc:TwoThousandandThirteenPlanMember ljpc:OneyearAnniversaryDateofGrantMember 2013-09-01 2013-09-30 0000920465 2014-08-31 0000920465 2014-12-01 2014-12-31 0000920465 ljpc:SeriesCOneConvertiblePreferredStockMember us-gaap:CommonStockMember 2014-01-01 2014-12-31 0000920465 ljpc:SeriesFConvertiblePreferredStockMember us-gaap:CommonStockMember 2015-01-01 2015-09-30 0000920465 us-gaap:RestrictedStockMember 2015-08-01 2015-08-31 0000920465 us-gaap:PerformanceSharesMember ljpc:TwoThousandandThirteenPlanMember ljpc:ConsultantMember 2015-08-01 2015-08-31 0000920465 ljpc:TwoThousandandThirteenPlanMember us-gaap:ChiefFinancialOfficerMember ljpc:OneyearAnniversaryDateofGrantMember 2015-04-01 2015-04-30 0000920465 us-gaap:RestrictedStockMember us-gaap:CommonStockMember us-gaap:DirectorMember 2013-01-01 2013-09-30 0000920465 us-gaap:RestrictedStockMember us-gaap:CommonStockMember ljpc:EmployeesMember 2013-01-01 2013-09-30 0000920465 ljpc:TwoThousandandThirteenPlanMember ljpc:ConsultantMember 2015-07-01 2015-09-30 0000920465 us-gaap:RestrictedStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2015-09-30 0000920465 ljpc:TwoThousandandThirteenPlanMember ljpc:ConsultantMember 2015-01-01 2015-09-30 0000920465 ljpc:TwoThousandandThirteenPlanMember us-gaap:DirectorMember 2013-09-01 2013-09-30 0000920465 ljpc:TwoThousandandThirteenPlanMember 2014-08-31 0000920465 us-gaap:RestrictedStockMember us-gaap:ResearchAndDevelopmentExpenseMember 2015-09-30 0000920465 us-gaap:RestrictedStockMember us-gaap:ChiefExecutiveOfficerMember 2015-07-31 0000920465 us-gaap:RestrictedStockMember ljpc:ConsultantMember 2014-01-25 2014-01-25 0000920465 ljpc:TwoThousandandThirteenPlanMember 2014-01-02 0000920465 ljpc:TwoThousandandThirteenPlanMember ljpc:ConsultantMember ljpc:UponGrantMember 2015-02-01 2015-02-28 0000920465 ljpc:SeriesFConvertiblePreferredStockMember us-gaap:CommonStockMember 2014-01-01 2014-12-31 0000920465 us-gaap:PerformanceSharesMember ljpc:TwoThousandandThirteenPlanMember ljpc:ConsultantMember 2015-07-01 2015-09-30 0000920465 us-gaap:RestrictedStockMember us-gaap:CommonStockMember us-gaap:ChiefExecutiveOfficerMember 2013-01-01 2013-09-30 0000920465 us-gaap:PerformanceSharesMember ljpc:TwoThousandandThirteenPlanMember ljpc:ConsultantMember 2015-01-01 2015-09-30 0000920465 ljpc:TwentyfiveMonthSubleaseAgreementExpiringMarch312017Member 2015-01-31 0000920465 ljpc:ThirtytwoMonthSubleaseAgreementExpiringOctober312017Member 2015-02-01 2015-02-28 0000920465 ljpc:TwentyfiveMonthSubleaseAgreementExpiringMarch312017Member 2015-01-01 2015-01-31 0000920465 ljpc:ThirtytwoMonthSubleaseAgreementExpiringOctober312017Member 2015-02-28 iso4217:USD xbrli:shares iso4217:USD xbrli:pure ljpc:option xbrli:shares ljpc:party utreg:sqft false --12-31 Q3 2015 2015-09-30 10-Q 0000920465 18241509 Accelerated Filer LA JOLLA PHARMACEUTICAL CO P4Y 0.25 1 3713 P6M 2 P32M P25M 1528000 360000 P60D 3500000 6800000 56600000 111400000 0.1 P10Y 0.00 197000 613000 51000 2

730000

2567000

926000

1145000

528353000

643651000

1743000

286000

98000

1212000

147000

1498000

245000

6595000

575000

142000

5226000

652000

5801000

794000

3061000

1443000

636000

38000

545000

240000

182000

15000

2170000

891000

10343000

2950000

1609000

38000

3719000

1452000

573000

40000

7242000

3101000

362000

8100000

9100000

18599

4047

50536000

137944000

50257000

136136000

8629000

54131000

48555000

135055000

45502000

86500000

3047710

0.0001

100000000

12000000000

15225980

18241509

15225980

18241509

2000

-5052000

-14464000

-10474000

-30079000

3099000

452000

11000

61000

1724

286

6735378

782032

5061000

14477000

11134000

30759000

5000

10000

114000

209000

-0.37

-1.58

-0.70

-1.99

424000

629000

P2Y11M25D

P17M

P4M

3117000

178000

19856000

2436000

8259000

3353000

11122000

-151000

1837000

713000

219000

-68000

205000

57000

110000

347000

-1168000

200000

1013000

50536000

137944000

2080000

4341000

53063000

104883000

-86000

-1681000

-36500000

-7475000

-16702000

-14464000

-30079000

-5061000

-14477000

-10487000

-30112000

300000

1466000

93000

57000

9000

13000

33000

86000

1681000

0.0001

11000

10000

8000000

11000

10000

3917

2798

3906

2737

3917

2798

3906

2737

3917000

2798000

3906000

2737000

137000

484000

53063000

104596000

287000

279000

1751000

P7Y

P2Y

2625000

6218000

7781000

19637000

37000

237000

-486614000

-516693000

647000

53100000

104600000

5395000

2932500

10.50

6595000

9330000

P4Y

P3Y

47129

4.41

2976

8.40

1746853

1279007

1090593

1042680

11.80

12.86

12.95

2976

423693

188414

9.18

12.30

1.88

1.47

0.022

0.014

3100000

1100000

1613525

440441

211408

10.60

641000

752000

24465

10.19

60000

40000

567876

942285

8.38

9.49

21.49

21.13

15765631

54000

618900

1494185

6.00

9.54

18.54

15765631

1494185

18.54

9.74

9.88

23.83

0.33

0.25

P6Y8M23D

P4Y10M28D

3643505

P8Y8M3D

P9Y2M17D

2976

4000

336185

1327048

79622

5341670

129105

19134

17360

35035

42535

25000

92000

48456000

133603000

0.02

3906000

2737000

1000

13646000

9131000

14899000

15129000

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Clinical Trial Expenses</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments in connection with the Company's clinical trials are often made under contracts with multiple contract research organizations that conduct and manage clinical trials on the Company's behalf. The financial terms of these contracts are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Generally, these contracts set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. Payments under these contracts depend on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the prepaid clinical expenses of </font><font style="font-family:inherit;font-size:10pt;">$360,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1,528,000</font><font style="font-family:inherit;font-size:10pt;"> on the condensed consolidated balance sheets represent the initial upfront payments to clinical research organizations for two clinical trials that commenced in 2015. The Company amortizes prepaid clinical trial costs to expense based on estimates regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expenses related to clinical trials are accrued based on estimates regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the contracted amounts are modified, the accruals are modified accordingly on a prospective basis. Revisions in the scope of a contract are charged to expense in the period in which the facts that give rise to the revision occur.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contract Revenue - Related Party</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">During the three months ended September 2015, the Company entered into a services agreement with a private company that is a related party. Pursuant to the services agreement, the Company provides certain services to this related party, including, but not limited to, research and development and clinical trial design and management. In exchange for providing such services pursuant to the services agreement, the Company receives payments at a negotiated, arms-length rate. As a result, the consideration received by the Company for its services under the services agreement is considered to be no less favorable to the Company than comparable terms that the Company could obtain from an unaffiliated third party in an arms-length transaction. The services agreement may be canceled by either party upon </font><font style="font-family:inherit;font-size:10pt;">60</font><font style="font-family:inherit;font-size:10pt;">-days' written notice to the other party. Additionally, the Company anticipates receiving a non-voting profits interest in the related party, providing the Company with the potential to receive a portion of the future distributions of profits, if any.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized approximately </font><font style="font-family:inherit;font-size:10pt;">$647,000</font><font style="font-family:inherit;font-size:10pt;"> of contract revenue for services and costs provided under the services agreement.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses include salaries and benefits, facilities and other overhead expenses, research-related manufacturing expenses, contract services and clinical and preclinical-related services performed by clinical research organizations, research institutions and other outside service providers. Research and development expenses are charged to operations as incurred when these expenditures relate to the Company's research and development efforts and have no alternative future uses.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with certain research and development agreements, the Company is obligated to make certain upfront payments upon execution of the agreement. Advance payments, including nonrefundable amounts, for materials or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition or milestone payments that the Company makes in connection with in-licensed technology are expensed as incurred when there is uncertainty in receiving future economic benefits from the licensed technology. The Company considers the future economic benefits from the licensed technology to be uncertain until such licensed technology is incorporated into products that are approved for marketing by the U.S. Food and Drug Administration (the "FDA") or when other significant risk factors are abated. For accounting purposes, management has viewed future economic benefits for all of the Company's licensed technology to be uncertain.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share-based compensation expense related to all share-based awards for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> was comprised of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="54%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and development:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">636</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   Restricted stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,452</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">652</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   Warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development share-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">891</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,101</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">794</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">General and administrative:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   Stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,443</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   Restricted stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">545</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,212</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,719</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,226</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   Warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">573</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative share-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,170</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,498</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,242</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,801</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total share-based compensation expense included in expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,061</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,743</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,343</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,595</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s stock option and 2013 Equity Plan restricted stock award activity for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> was comprised of the following:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="44%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding Stock Options and 2013 Equity Plan Restricted Stock Awards</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="padding-bottom:2px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock Options and Restricted Stock Awards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average Exercise Price per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="padding-bottom:2px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="padding-bottom:2px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">567,876</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.88</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock awards vested</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,976</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">618,900</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.54</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">942,285</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$23.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,535</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.74</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,465</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,494,185</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$18.54</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.21 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,765,631</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,494,185</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$18.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.21 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,765,631</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211,408</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10.60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.67 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,643,505</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company estimated the fair value of each stock option grant on the grant date using the Black-Scholes model with the following weighted-average assumptions:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="75%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.91 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.73 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s RSA activity for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> was comprised of the following:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average Grant Date Fair Market Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,746,853</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.80</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,976</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(423,693</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.18</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47,129</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.41</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,279,007</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.86</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(188,414</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,090,593</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.95</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shareholders’ Equity</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2015 Common Stock Offering</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2015, the Company offered and sold an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,932,500</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock in an underwritten offering at a public offering price of </font><font style="font-family:inherit;font-size:10pt;">$38.00</font><font style="font-family:inherit;font-size:10pt;"> per share, with gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$111.4 million</font><font style="font-family:inherit;font-size:10pt;">. The Company received net proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$104.6 million</font><font style="font-family:inherit;font-size:10pt;">, net of approximately </font><font style="font-family:inherit;font-size:10pt;">$6.8 million</font><font style="font-family:inherit;font-size:10pt;"> in underwriting commissions, discounts and other issuance costs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2014 Common Stock Offering</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2014, the Company offered and sold an aggregate of </font><font style="font-family:inherit;font-size:10pt;">5,395,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock in an underwritten offering at a public offering price of </font><font style="font-family:inherit;font-size:10pt;">$10.50</font><font style="font-family:inherit;font-size:10pt;"> per share, with gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$56.6 million</font><font style="font-family:inherit;font-size:10pt;">. The Company received net proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$53.1 million</font><font style="font-family:inherit;font-size:10pt;">, net of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;"> in underwriting commissions, discounts and other issuance costs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2014 Reverse Stock Split</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2014, the Company enacted the 2014 Reverse Stock Split. The 2014 Reverse Stock Split was approved by the Company's shareholders in June 2013 and resulted in every 50 shares of the Company’s issued and outstanding common stock to be automatically combined into one share of the Company’s common stock. No fractional shares were issued in connection with the 2014 Reverse Stock Split. Shareholders who were entitled to fractional shares instead became entitled to receive a cash payment in lieu of receiving fractional shares equal to the fractional share interest. The 2014 Reverse Stock Split affected all of the holders of the Company’s common stock uniformly. Shares of the Company’s common stock underlying outstanding stock options were proportionately reduced, and the exercise prices of outstanding stock options were proportionately increased in accordance with the terms of the agreements governing such securities. Shares of the Company’s common stock underlying outstanding convertible preferred stock were proportionately reduced, and the conversion rates were proportionately decreased in accordance with the terms of the agreements governing such securities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Amendment to Articles of Incorporation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, at the Company's annual meeting of shareholders, the Company's shareholders approved an amendment to the Company's articles of incorporation to reduce the number of authorized common shares available for issuance to </font><font style="font-family:inherit;font-size:10pt;">100,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares from </font><font style="font-family:inherit;font-size:10pt;">12,000,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company is authorized to issue </font><font style="font-family:inherit;font-size:10pt;">8,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of preferred stock, with a par value of </font><font style="font-family:inherit;font-size:10pt;">$0.0001</font><font style="font-family:inherit;font-size:10pt;"> per share, in one or more series, of which </font><font style="font-family:inherit;font-size:10pt;">11,000</font><font style="font-family:inherit;font-size:10pt;"> are designated as Series C-1</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></font><font style="font-family:inherit;font-size:10pt;"> Convertible Preferred Stock (the "Series C-1</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2 </sup></font><font style="font-family:inherit;font-size:10pt;">Preferred") and </font><font style="font-family:inherit;font-size:10pt;">10,000</font><font style="font-family:inherit;font-size:10pt;"> are designated as Series F Convertible Preferred Stock (the "Series F Preferred"). During the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company issued </font><font style="font-family:inherit;font-size:10pt;">19,134</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">17,360</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock upon the conversion of Series C-1</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2 </sup></font><font style="font-family:inherit;font-size:10pt;">Preferred and Series F Preferred, respectively. During the year ended December 31, 2014, the Company issued </font><font style="font-family:inherit;font-size:10pt;">5,341,670</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock upon the conversion of Series C-1</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></font><font style="font-family:inherit;font-size:10pt;"> Preferred and </font><font style="font-family:inherit;font-size:10pt;">129,105</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock upon the conversion of Series F Preferred. The Series C-1</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></font><font style="font-family:inherit;font-size:10pt;"> Preferred is convertible into common stock at a rate of approximately </font><font style="font-family:inherit;font-size:10pt;">1,724</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock for each share of Series C-1</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></font><font style="font-family:inherit;font-size:10pt;"> Preferred, and the Series F Preferred is convertible into common stock at a rate of approximately </font><font style="font-family:inherit;font-size:10pt;">286</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock for each share of Series F Preferred. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">3,906</font><font style="font-family:inherit;font-size:10pt;"> shares of Series C-1</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></font><font style="font-family:inherit;font-size:10pt;"> Preferred and </font><font style="font-family:inherit;font-size:10pt;">2,737</font><font style="font-family:inherit;font-size:10pt;"> shares of Series F Preferred issued and outstanding. As such, as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the issued and outstanding Series C-1</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></font><font style="font-family:inherit;font-size:10pt;"> Preferred and Series F Preferred were convertible into </font><font style="font-family:inherit;font-size:10pt;">6,735,378</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">782,032</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, respectively.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holders of preferred stock do not have voting rights, other than for general protective rights required by the California General Corporation Law. The Series C-1</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></font><font style="font-family:inherit;font-size:10pt;"> Preferred and the Series F Preferred do not have dividends.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Series C-1</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></font><font style="font-family:inherit;font-size:10pt;"> Preferred and the Series F Preferred have a liquidation preference in an amount equal to </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> per share. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the aggregate liquidation preference was approximately </font><font style="font-family:inherit;font-size:10pt;">$3,906,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2,737,000</font><font style="font-family:inherit;font-size:10pt;"> on the Series C-1</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></font><font style="font-family:inherit;font-size:10pt;"> Preferred and Series F Preferred, respectively.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2013 Equity Incentive Plan</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2013, the Company adopted an equity compensation plan entitled the 2013 Equity Incentive Plan (the “2013 Equity Plan”). The 2013 Equity Plan is an omnibus equity compensation plan that permits the issuance of various types of equity-based compensation awards, including stock options, restricted stock awards, stock appreciation rights and restricted stock units, as well as cash awards, to employees, directors and eligible consultants of the Company. The 2013 Equity Plan has a </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">-year term and permits the issuance of incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended. The administrator under the plan has broad discretion to establish the terms of awards, including the size, term, exercise price and vesting conditions. Generally, grants to employees vest over </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> years, with </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> vesting on the one-year anniversary, and the remainder vesting either quarterly or monthly thereafter; grants to non-employee directors generally vest over </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years, with </font><font style="font-family:inherit;font-size:10pt;">33%</font><font style="font-family:inherit;font-size:10pt;"> vesting on the one-year anniversary, and the remainder vesting either quarterly or monthly thereafter.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2013 Equity Plan previously allowed for automatic annual increases to the number of shares of common stock authorized for issuance under the 2013 Equity Plan on the first day of each year, with such increases based on </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding shares of the Company’s common stock as of the last day of the previous year. On January 1, 2014, the total shares available for grant under the 2013 Equity Plan increased to </font><font style="font-family:inherit;font-size:10pt;">440,441</font><font style="font-family:inherit;font-size:10pt;">. At the 2014 annual meeting of shareholders, the Company's shareholders approved and adopted an amendment to the 2013 Equity Plan to increase the number of shares of common stock authorized for issuance up to a total of </font><font style="font-family:inherit;font-size:10pt;">1,100,000</font><font style="font-family:inherit;font-size:10pt;"> shares and eliminated the automatic annual increase on the first day of each year. At the 2015 annual meeting of shareholders, the Company's shareholders approved and adopted an amendment to the 2013 Equity Plan to increase the number of shares of common stock authorized for issuance up to a total of </font><font style="font-family:inherit;font-size:10pt;">3,100,000</font><font style="font-family:inherit;font-size:10pt;"> shares.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">1,613,525</font><font style="font-family:inherit;font-size:10pt;"> shares available for future grants under the 2013 Equity Plan.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share-Based Award Activity</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s stock option and 2013 Equity Plan restricted stock award activity for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> was comprised of the following:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="44%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding Stock Options and 2013 Equity Plan Restricted Stock Awards</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="padding-bottom:2px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock Options and Restricted Stock Awards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average Exercise Price per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="padding-bottom:2px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="padding-bottom:2px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">567,876</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.88</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock awards vested</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,976</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">618,900</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.54</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">942,285</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$23.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,535</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.74</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,465</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,494,185</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$18.54</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.21 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,765,631</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,494,185</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$18.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.21 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,765,631</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211,408</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10.60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.67 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,643,505</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, the Company made a stock option grant to the Company's recently appointed Chief Financial Officer to purchase </font><font style="font-family:inherit;font-size:10pt;">60,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at an exercise price equal to the fair market value of the Company's common stock on the grant date. This grant was awarded as an Inducement Grant outside of the 2013 Equity Plan. The stock option will vest and become exercisable with respect to </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> of the underlying shares on the first anniversary of the grant date, and then with respect to the remaining shares, on a quarterly basis over the next three years, subject to continued service during that time.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company has reserved </font><font style="font-family:inherit;font-size:10pt;">3,047,710</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock for future issuance upon exercise of all outstanding stock options granted or to be granted under the 2013 Equity Plan, which excludes the </font><font style="font-family:inherit;font-size:10pt;">60,000</font><font style="font-family:inherit;font-size:10pt;"> shares underlying the stock option discussed above that was issued in April 2015.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted-average grant date fair values of the stock options granted during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$21.49</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$21.13</font><font style="font-family:inherit;font-size:10pt;"> per underlying share, respectively. The weighted-average grant date fair values of stock options granted during the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$8.38</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$9.49</font><font style="font-family:inherit;font-size:10pt;"> per underlying share, respectively. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;">$19,856,000</font><font style="font-family:inherit;font-size:10pt;"> of total unrecognized share-based compensation expense related to non-vested stock options remains and is expected to be recognized over a weighted-average period of approximately </font><font style="font-family:inherit;font-size:10pt;">3.0 years</font><font style="font-family:inherit;font-size:10pt;">. During the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, stock options to purchase </font><font style="font-family:inherit;font-size:10pt;">35,035</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">42,535</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, respectively, were exercised with an intrinsic value of </font><font style="font-family:inherit;font-size:10pt;">$641,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$752,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> stock option exercises occurred during the year ended December 31, 2014.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Third Party Share-Based Compensation Expense</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company initially estimates the fair value of stock options and warrants issued to non-employees, other than non-employee directors, on the grant date using the Black-Scholes model. Thereafter, the Company re-measures the fair value using the Black-Scholes model as of each balance sheet date as the stock options and warrants vest.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2014, the Company granted warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">51,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> outside third parties at an exercise price equal to the fair market value of the stock on the date of each grant. One grant will vest </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> on each anniversary date over </font><font style="font-family:inherit;font-size:10pt;">four years</font><font style="font-family:inherit;font-size:10pt;">. The other grant vests </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> on the one-year anniversary of the grant. The Company recognized compensation expense for these warrant grants of approximately </font><font style="font-family:inherit;font-size:10pt;">$197,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$613,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2015, the Company granted a stock option to purchase </font><font style="font-family:inherit;font-size:10pt;">60,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock to a consultant at an exercise price equal to the fair market value of the Company's common stock on the grant date. This grant was made from the 2013 Equity Plan. The stock option vested with respect to </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> of the underlying shares on the grant date with the remainder to vest quarterly over </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;">. The Company recognized third party compensation expense for this stock option grant of approximately </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$362,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. In July 2015, this consultant became an employee of the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2015, the Company granted a stock option to purchase </font><font style="font-family:inherit;font-size:10pt;">40,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock to a consultant at an exercise price equal to the fair market value of the Company's common stock on the grant date. This grant was made from the 2013 Equity Plan. The vesting of this stock option is contingent on the achievement of a performance milestone by the end of 2016, at which time any unvested shares underlying the option will be canceled. The Company recognized compensation expense for this stock option grant of approximately </font><font style="font-family:inherit;font-size:10pt;">$38,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Option Valuation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of each stock option award is estimated on the grant date using a Black-Scholes option pricing model (the “Black-Scholes model”), which uses the assumptions noted in the following table. Expected volatility is based on historical volatility of the Company’s common stock. In determining the expected life of employee stock options, the Company uses the “simplified” method. The expected life assumptions for non-employees were based upon the contractual term of the stock options. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the stock options in effect at the time of the grants. The dividend yield assumption is based on the expectation of no future dividend payments by the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company estimated the fair value of each stock option grant on the grant date using the Black-Scholes model with the following weighted-average assumptions:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="75%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.91 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.73 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Awards</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock awards ("RSAs") are grants that entitle the holder to acquire shares of common stock for no cash consideration or at a fixed price, which is typically nominal. The Company accounts for RSAs as issued and outstanding common stock, even though: (a) shares covered by an RSA cannot be sold, pledged, or otherwise disposed of until the award vests; and (b) any unvested shares may be reacquired by the Company for the original purchase price following the awardee's termination of service. The valuation of RSAs is based on the fair market value of the underlying shares on the grant date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2013, the Company issued RSAs consisting of approximately </font><font style="font-family:inherit;font-size:10pt;">1,327,048</font><font style="font-family:inherit;font-size:10pt;"> shares to the CEO, </font><font style="font-family:inherit;font-size:10pt;">79,622</font><font style="font-family:inherit;font-size:10pt;"> shares to a director and an aggregate of </font><font style="font-family:inherit;font-size:10pt;">336,185</font><font style="font-family:inherit;font-size:10pt;"> shares to three non-officer employees. The grants to the CEO, director and one of the employees were for the replacement of canceled stock options and restricted stock units granted in April 2012, which was done in order to complete the capital restructuring that took place in September 2013. These RSAs were granted outside of the 2013 Equity Plan, but are governed in all respects by the 2013 Equity Plan. These RSAs were granted with a combination of performance-based and time-based vesting components. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, all performance-based vesting conditions had been satisfied, but the time-based service requirements, which provided for vesting in 2016, subject to continuous service through the vesting and delivery date, had not yet been satisfied. In July 2015, the vesting conditions for </font><font style="font-family:inherit;font-size:10pt;">1,042,680</font><font style="font-family:inherit;font-size:10pt;"> shares of unvested and outstanding RSA’s awarded to the CEO were amended to provide that vesting and delivery of the shares shall be deferred until March 15, 2017, subject to the CEO's continued service with the Company through such date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 25, 2014, the Company granted RSAs representing </font><font style="font-family:inherit;font-size:10pt;">2,976</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock with a grant date fair market value of </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;"> to a consultant for services. The RSAs vested immediately and were issued from the 2013 Equity Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2015, the Company issued a fully vested RSA representing the right to acquire </font><font style="font-family:inherit;font-size:10pt;">4,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock with a grant date fair value of approximately </font><font style="font-family:inherit;font-size:10pt;">$92,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s RSA activity for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:normal;text-decoration:none;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> was comprised of the following:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average Grant Date Fair Market Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,746,853</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.80</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,976</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(423,693</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.18</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47,129</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.41</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,279,007</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.86</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(188,414</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,090,593</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.95</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;">$178,000</font><font style="font-family:inherit;font-size:10pt;"> of total unrecognized share-based compensation expense for research and development activities related to RSAs remains and is expected to be recognized over a weighted-average period of approximately </font><font style="font-family:inherit;font-size:10pt;">0.3 years</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;">$3,117,000</font><font style="font-family:inherit;font-size:10pt;"> of total unrecognized share-based compensation expense for general and administrative activities related to RSAs remains and is expected to be recognized over a weighted-average period of approximately </font><font style="font-family:inherit;font-size:10pt;">1.4</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation Expense</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense recognized in the condensed consolidated statements of operations and comprehensive loss for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> is based on awards ultimately expected to vest.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share-based compensation expense related to all share-based awards for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> was comprised of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="54%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and development:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">636</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   Restricted stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,452</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">652</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   Warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development share-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">891</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,101</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">794</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">General and administrative:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   Stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,443</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   Restricted stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">545</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,212</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,719</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,226</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   Warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">573</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative share-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,170</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,498</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,242</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,801</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total share-based compensation expense included in expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,061</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,743</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,343</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,595</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

EX-101.SCH 6 ljpc-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - Business link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Business (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Commitments and Contingencies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Contract Revenue - Related Party (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Contract Revenue - Related Party (Notes) link:presentationLink link:calculationLink link:definitionLink 0002000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Shareholders’ Equity link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Shareholders’ Equity (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2404406 - Disclosure - Shareholders’ Equity (Share-based Compensation Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Shareholders’ Equity (Stock Option and Restricted Stock Award Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Shareholders’ Equity (Stock Options, Valuation Assumptions) (Details) link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - Shareholders’ Equity (Summary of Restricted Stock Awards) (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Shareholders’ Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 ljpc-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 ljpc-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 ljpc-20150930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block] Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Clinical Trial Expenses Clinical Trial Expenses [Policy Text Block] Clinical Trial Expenses [Policy Text Block] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Share-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Equity [Abstract] Summary of Stock Option Activity and Related Data Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Stock Options, Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of restricted stock activity Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Summary of Share-based Compensation Expense Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Shareholders’ Equity Stockholders' Equity Note Disclosure [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Restricted Stock [Member] Restricted Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Beginning balance, in shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted, in shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested, in shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Forfeited, in shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Ending balance in shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Beginning balance, in usd per share Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted, in usd per share Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested, in usd per share Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Forfeited, in usd per share Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Ending balance, in usd per share Related Party Transactions [Abstract] Contract Revenue - Related Party Related Party Transactions Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Series C-1 Convertible Preferred Stock [Member] Series C One Convertible Preferred Stock [Member] Series C One Convertible Preferred Stock [Member] Series F Convertible Preferred Stock [Member] Series F Convertible Preferred Stock [Member] Series F Convertible Preferred Stock [Member] Statement [Line Items] Statement [Line Items] Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Restricted cash Restricted Cash and Cash Equivalents Prepaid clinical expenses Prepaid Clinical Expense Prepaid Clinical Expense Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Other assets Other Assets Total assets Assets LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Accrued payroll and related expenses Employee-related Liabilities, Current Total current liabilities Liabilities, Current Shareholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Common Stock, $0.0001 par value; 100,000,000 shares authorized, 18,241,509 and 15,225,980 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively Common Stock, Value, Issued Convertible preferred stock, value Preferred Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Total shareholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and shareholders' equity Liabilities and Equity Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Document And Entity Information [Abstract] -- None. No documentation exists for this element. -- Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Estimated useful lives of the assets Property, Plant and Equipment, Useful Life Reverse stock split ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Property and equipment, net Depreciation expense Depreciation Potentially dilutive common shares related to the outstanding preferred stock, stock options, restricted stock units and warrants Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Subsidiary, Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock, Name of Transaction [Domain] Sale of Stock [Domain] Underwriting Agreement [Member] Underwriting Agreement [Member] Underwriting Agreement [Member] IPO [Member] IPO [Member] Series F Preferred Stock [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2013 Equity Plan [Member] Two Thousand and Thirteen Plan [Member] Two Thousand and Thirteen Plan [Member] Vesting [Axis] Vesting [Axis] Vesting [Domain] Vesting [Domain] One-year Anniversary Date of Grant [Member] One-year Anniversary Date of Grant [Member] One-year Anniversary Date of Grant [Member] Upon Grant [Member] Upon Grant [Member] Upon Grant [Member] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Consultant [Member] Consultant [Member] Consultant [Member] Director [Member] Director [Member] Chief Executive Officer [Member] Chief Executive Officer [Member] Chief Financial Officer [Member] Chief Financial Officer [Member] Employees [Member] Employees [Member] -- None. No documentation exists for this element. -- Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Grant One [Member] Grant One [Member] Grant One [Member] Grant Two [Member] Grant Two [Member] Grant Two [Member] Award Type [Domain] Performance Shares [Member] Performance Shares [Member] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis] Income Statement Location [Axis] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Income Statement Location [Domain] Research and development [Member] Research and Development Expense [Member] General and administrative [Member] General and Administrative Expense [Member] Shares of common stock to be issued and sold in underwriting agreement Sale of Stock, Number of Shares Issued in Transaction Price per share of shares sold (usd per share) Sale of Stock, Price Per Share Proceeds from the underwriting agreement, including additional shares sold, gross Sale of Stock, Consideration Received on Transaction, Gross Sale of Stock, Consideration Received on Transaction, Gross Proceeds from the underwriting agreement, including additional shares sold, net of cost Sale of Stock, Consideration Received on Transaction Issuance costs Sale Of Stock, Issuance Costs On Transaction Sale Of Stock, Issuance Costs On Transaction Common stock, shares authorized Common Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, par value (usd per share) Preferred Stock, Par or Stated Value Per Share Shares of common stock issued Stock Issued During Period, Shares, New Issues Shares issued upon conversion, per share Convertible Preferred Stock, Shares Issued upon Conversion Preferred stock, shares issued Preferred Stock, Shares Issued Shares reserved for future issuance Convertible Preferred Stock, Shares Reserved for Future Issuance Liquidation preference per share Temporary Equity, Liquidation Preference Per Share Liquidation preference Temporary Equity, Liquidation Preference Equity plan, term Share-based Compensation Arrangement by Share-based Payment Award, Plan Term Share-based Compensation Arrangement by Share-based Payment Award, Plan Term Period of share-based payment awards Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Award vesting rights, percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Automatic annual increase based on outstanding shares of Common Stock as of the last day of the previous year end, percent Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percent of Common Stock Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percent of Common Stock Outstanding Shares available for grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Shares of common stock authorized for issuance Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Stock options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Shares of common stock for future issuance Common Stock, Capital Shares Reserved for Future Issuance Weighted-average grant date fair values of stock options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Unamortized share-based compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Recognized weighted average period Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Stock options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Intrinsic value of stock options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Warrants granted to purchase common stock Warrants Granted To Purchase Common Stock Warrants Granted To Purchase Common Stock Warrants issued, number of third party recipients Warrants Issued, Number of Third Party Recipients Warrants Issued, Number of Third Party Recipients Warrant vesting rights percentage Class of Warrant or Right, Award Vesting Rights, Percentage Class of Warrant or Right, Award Vesting Rights, Percentage Warrant vesting period Class of Warrant or Right, Award Vesting Period Class of Warrant or Right, Award Vesting Period Third party share-based compensation expense Warrant Grants to Third Parties, Compensation Expense Warrant Grants to Third Parties, Compensation Expense Share-based compensation expense Allocated Share-based Compensation Expense Number of shares of unvested stock awards Stock issued during period, value Stock Issued During Period, Value, New Issues Unamortized share-based compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Net cash used for operating activities Net Cash Provided by (Used in) Operating Activities Schedule of Capitalization, Equity [Table] Schedule of Capitalization, Equity [Table] Schedule of Capitalization, Equity [Line Items] Schedule of Capitalization, Equity [Line Items] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Property Subject to or Available for Operating Lease, by Major Property Class [Table] Property Subject to or Available for Operating Lease, by Major Property Class [Table] Property Subject to or Available for Operating Lease [Axis] Property Subject to or Available for Operating Lease [Axis] Property Subject to or Available for Operating Lease [Domain] Property Subject to or Available for Operating Lease [Domain] Twenty-five Month Sublease Agreement, Expiring March 31, 2017 [Member] Twenty-five Month Sublease Agreement, Expiring March 31, 2017 [Member] Twenty-five Month Sublease Agreement, Expiring March 31, 2017 [Member] Thirty-two Month Sublease Agreement, Expiring October 31, 2017 [Member] Thirty-two Month Sublease Agreement, Expiring October 31, 2017 [Member] Thirty-two Month Sublease Agreement, Expiring October 31, 2017 [Member] Property Subject to or Available for Operating Lease [Line Items] Property Subject to or Available for Operating Lease [Line Items] Lease agreement period Operating Leases, Sublease Agreement Period Operating Leases, Sublease Agreement Period Area of space, in sqft Area of Real Estate Property Total lease payments through the end of the lease Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals Number of options to extend lease Operating Leases, Number of Options to Extend Lease Operating Leases, Number of Options to Extend Lease Lease extension period Operating Leases, Extension Period Operating Leases, Extension Period Office Space Office Area Covered Under Operating Lease Agreement Office area covered under operating lease agreement. Approximate total lease payments Operating Leases, Future Minimum Payments Due Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Stock Option [Member] Employee Stock Option [Member] Warrant [Member] Warrant [Member] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected life (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term EX-101.PRE 10 ljpc-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`"0^9D=]NN!1C`$``!\0```3````6T-O;G1E;G1?5'EP97-= M+GAM;,U8RT[#,!#\E2I7U+@.4!YJ>Z%W!/B\@HD0&#AST0:T\39HS@.?-<*U*KHE5UJ,N2 MYU#H?"U#2NH#-5P$/!DLF/5/3(829"M(`^R?-(TX.0^A,Q98X2H`+T7J_$Z` MZ^+?(Q_,^39.`NJ,8VHF_*>,R-LVH MY;>,./_C6EJ;6$LQMVS#6P1U;VV*8RH95UVMVFB[>M-Z=+%V]#?[KOQ-:`_';&OS?M/ M36]`1YJA1Y,X24>&1,`5!+`P04 M````"``D/F9'2'4%[L4````K`@``"P```%]R96QS+RYR96QSK9++;L)`#$5_ M)9I]<4HE%A%AQ88=0OR`.^,\E,QXY#$B_?N.V(#"0ZW$TJ][CZZ\#JFL#C2B M]AQ2U\=43'X,JQW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH`A3&^.R6:E((C M-Z."N[_8_`)02P,$%`````@`)#YF1P%O5.A$`0``GPX``!H```!X;"]?QTZ:WS;C3YY'WKC\^E] M(=H0QEQ*7[8X:+^Q(YIIM;9NT&%Z=(T<=7G7#4J5IIETRSGB-! M*AZD6(*V\:`M2]`N'K1C"=K'@_8L05D\*&,).L2##BQ!QWC0D27H%`\ZL01! M2LB8\B116/-H#037P.,U$&`#C]A`D`T\9@.!-O"H#03;P.,V$'`#C]Q`T`T\ M=@.!-_#HK0B]%8_>BM!;,9VUJ<,VC]YJH;=OMEP_99Y*-BRT#M-.*.?KZE_-//4S1/[Z%[U\`%!+`P04````"``D/F9'=KUQ M_4L"``"0!P``$````&1O8U!R;W!S+V%P<"YX;6R]55%OVC`0_BL63^R!!MA6 M:8A&:@%IE;85%=H]3E?G`A:.G=D7!/OUNR20A1)0ZM)5$Z"`(OEYB`OV*(X=W8N@2(EVX1V#A6$L=69@D: M"OK=[G6`&T(38=1)JZ"M<)AGN4U3K220LB;\KJ2SWL8D)AN)>AB\!A0,CCQ# MF3E%V[!;8NJN`C.3H''$N<(8M,<2]<]98$8V2<%L@W+U39F5?TKG=@R$==;A M1AE]"0XC3GH0O7(6F*];KE/GW-$2S`*C.O9XF^7(BOSIOOG.9_/M\0+>,S-F]8:G`)#+>'5 M'U[V6V7:TEO8.O7DPI_6K?P2D?PPJ)R%6[<:7$KI]>8\^5U<6AWQK?DE M)K\S[D0C\-Y(FZ"8PP:;3\R/1*(H;ZHONIJ?AD<0C50G&&=K[/7??%[1GL,+ M#_>'LS*+]A@)E#X!.W^8Y@Z>%;QW?4$!/\`YGOQU\W0U&ULS9/!3L,P#(9?!?7> MI=W&$%'7`R!.3$)B",0M)-X6UB91XJGKVY-YI67`93=N=>W_\^\X*:3CTGIX M]-:!1PWA8E]7)G#IYLD&T7'&@MQ`+<(H5IB87%E?"XRA7S,GY%:L@8VS;,9J M0*$$"G8`IJXG)F6A))<>!%K?X97L\6[G*X(IR:""&@P&EH]REI3/9FML8PHV MZ,LB.JY$P(55>J5!W;1#V>]4[(S@ZW"4@^K;T]\_/5"&)5WE/NB^JFF:43.A MNCAPSEX7#T]T-JDV`861$%5!7$E:VM;X^I']')JRH_`5!+`P04```` M"``D/F9'F5R<(Q`&``"<)P``$P```'AL+W1H96UE+W1H96UE,2YX;6SM6EMS MVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8- M[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P" MI`DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L' MI4;1]E6\W*.76!4!EQC?-*HU+,76>)7`\:V@S&L%&KQMUAVC2/'K^!?F<-0H< MD1L=`F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T M$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG! MZ(++9OVX?H;5,VPLCO='U!=*Y`\FIS_I,C0'HYI9";V$5FJ?JH,@H% M\;D>/N5Z>`HWEL:\4*Z">P'_T=HWPJOX@L`Y?RY]SZ7ON?0]H=*W-R-]9\'3 MBUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU M^_9==N0CI3!3ET.X&D*^`VVZG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7 M;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W M8+C7\2P4X&1@+:`'@Z]1`O)256`Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U M;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*POFH]M!5.S_Y9KF4Q M9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[V MW>/Z;I,[2$R<><41`71%`B.5'`86%S+D4.Z2D`83``>LX=SFWJXPD6L_UC6'ODRWSEPVSK>`U[F$RQ#I'[!?8J*@!&K8KZZKT_Y M)9P[M'OQ@2";_-;;I/;=X`Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&M MQMHQ#'F`6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8V MH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0````(`"0^9D?("BY97@(``%`+```- M````>&PORC\)*;2A^6&&L0,,HKR*X M4JK\XGE5NL(,55-18JYGWLB'[^0OI_D8^HK_=0M^Z:J8L[DI]>*X MX-B)M'X'O`N)-L'L:BO`#CIO(F2&99\Y@!T4AQ3G2@=(4JS,J$1II`NE!--& M1E`A.**&LHMH#4V;8DH?S$?V*]_A;G+@?,P>^Q`8%9VI"]&:PS&P1?6VV1SW M-NWL*%[0Y'T"'8W*DFZ^4E)PAIU8!RU$^W:(/MA#'X>H8P4K(WT'W-$BP7 M]K?W3_ MI'EMS]IJC#MML4=!4A.J".\T('.1N3>ZZ4['&EJBYLR:H1O:6842?;W=R:+) M,IRCFJJ?9"V4G8S@8'\W\H-Y[[7L*2(XV#]P1FIV8Q4,=^CX+U!+`P04```` M"``D/F9'WJI\O.0"``"2"```#P```'AL+W=O)S>Y$@O'SFR'`G_]SBF%ZVHJ>(KMY+[8 MY\^^(S=:&'LW,^:./=1*NY'-D\K[9M3KN:*"6KC/I@&-[^;&UL)CU][VS'PN M"S@S15N#]KTL38<]"TIX:;2K9..29YI[#\TU%D3I*@!?JR6L%E(GQT=N-)<* M;L`Z!#/1-!>BACQY4`E3POGS4GHH\Z2/7;.`M0';-B>M5*$S2`=)+\!62[VR MK#`E+&'32KK?SR\25L)"0_?K&D;J6^1E;"YM,Y/PG*[+VNI92V?PKRQYRJS^&ZL M?#+:"S4IK%&JBPHONB#\@WL9P3EZ6:Q]Z,7L.NQ$G@Q3!-Y+)V=22?^8)UU; M05A)[[^E=.E_;3'=)6>UQ4SHDIUKCQ0VULO-P]2$.>#'X[+[L1U);-AQR9>I MHJ!3HTO0#DJ&+6>4+#$K)3L12N@"&`%E!)1]%+1'0'L$M+<)^J5%V^G"HD@" MZA-0_Z.@`0$-"&BP"3IIG=3@'(D8DHCA9L2DK6MA'YF9LXF\U1)/I<#-^E(4 MIL7-(J!]`MJ/9M5;%)A=PSWH%M@NME27V2MA/0$=$-!!9$:5L%`95>+9^4Q<:/)N1#6BG")4A0UET?4C:,FWA1W[+*AZG+J+G^G MO"\H?DA15&0>,?D-U&HSZ'U'Y6?06WG).V`Y%K5W# MV7/%>"T26"=1RC*44-?]!FM0$>HJ/I;'HS\(20K]GUAK\R041*Q]K5*G.':I M?QC1E8TE>55)C_\!4$L#!!0````(`"0^9D?E(.CC00(``(T'```8````>&PO M=V]R:W-H965T&UL?55=DYL@%/TKCC]@%?Q(S!AGDG0Z[4-G M=O:A?2:&1&=!+)"X_?<%-*X%[(O`]9Q[+G"YMQP8?Q<-QC+XH*03^["1LM]% MD:@;3)%X83WNU)\KXQ1)M>2W2/0^55R>Z2M!U^ MY8&X4XKXGR,F;-B'('P:WMI;([4AJLIHYEU:BCO1LB[@^+H/#V!W`HF&&,3/ M%@]B,0]T\&?&WO7B^V4?QCH&3'`MM0NDA@<^84*T)Z7\>W+ZJ:F)R_G3^U>S M717^&0E\8N17>Y&-BC8.@PN^HCN1;VSXAJ<]9-IAS8@PWZ"^"\GHDQ(&%'V, M8]N9<1C_I,E$\Q/@1(`S`6[^2T@F0C(30&IV.D9F]O4%2525G`T!'R^C1_K. MP2Y1)U=KHSDH\T_M3"CKHXK+Z*'=3(CCB(`+!)@1D?(]"T"?P!$Z=/BOP,E% M)'Z!Q+N#Q-"3!3WUTU,O/37T=$'/K`-P$;E?(/,*9`Y]8PF,B,P@.H,H8)SF MF5\E]ZKDCLK64G$1A5]@XQ78.'1@9XH'LI(J6Z_$UN5;N7+T0%:2I?!*%"X_ MM20*YS9@#%;N0E<(WZ.*71D[JR9,OL2LY!58>;K`5;%3RX?9KJAXW^\!0-=# M8:NX&!BOJ/@?,4A<#\"J$Q-F>3-@"U.0Q78B1XOJ1S&_F:X@@IK=.].$%M:Y M\QR@J9Z?\*KLT0W_0/S6=B(X,ZEJL*F45\8D5@'%+RJ41O7&>4'P5>KI1LWY MV"W&A63]L_G-';CZ"U!+`P04````"``D/F9'AQ3^K%8#```B#P``&````'AL M+W=ON.SX&0;LYF"IO'^S1U.[+SC95WKG'9A^TQ\;DVR&H*@,(PRBH\J+V5XOA MW5.S6MA35Q:U>6J\]E15>?,W,Z4]+WWA7U_\+/:'KG\1K!;!+6Y;5*9N"UM[ MC=DM_<_B<0UQ+QD4OPIS;B?W7F_^V=J7_N'[=NF'O0=3FDW7%Y&[RZM9F[+L M2W(U_[D4^K_./G!Z?RW]Z]!<9_\Y;\W:EK^+;7=P;D/?VYI=?BJ[G_;\S5S: MH/L"-[9LAW]OIO*X!%\-J7E(+R!@YH9J)Y,Z&9FUH:@-5D6E:110B&U0C M-"2\D8@U$E$C"3(2D4I4HI`1JA%S"8E9'S'UD2(?,5-'Y'[("I7I$/2,F80U MDQ`S$F4^2ZB96`MDA8H@3GDC*6LDI490'5E*FXL'*Y6$O(D>J1R%0FJ#8"CD M1D"J\$!A=&ZB3SKQWM`,%@5!DIQ!FN"9)H`V2>$F`>T^'>'D,JI8SN67!Z2@ MA)28D!?-77Z%PH!D5"G,Y98'I*"$Q%,L$Q1_$9ZN:T:DYA8.P5-24$QB$F>" M,E!)A6LF'I4BHJ-NAK6"AYR@E).8_,B;?5&WWK/MW,%H.+[LK.V,*S%\/4/4$L#!!0````(`"0^9D?&ANV,D@(``/0* M```8````>&PO=V]R:W-H965T&ULE9;=CILP$(5?!?$`B\T_ M$8G4I*K:BTJKO6BOG<0):`&GV$FV;U_;$`KV)&1S$<"$O[$0;^>;`VIH(^=@>/7YJ*=GKH+KR?(1BKR9E MXZYR/?;:KG)V%E79T-?6X>>Z)NW?-:W8=>EB]S;P5AX+H0:\5>X-.T]+!TO^#%!B=*HA6_2GKEHWM'P6\9>UCKM7L3)WT8'.#W`?X0@,.'`4$?$!@!7D>F MY_65"++*6W9UVFXS3D3M.5X$6$*0290HLI,BJM0[M2ZH=V4"/8K M#!B6U7^`$0&>/BN;\L!NA0&[LOHOM@KY29"8.)`J2^_0P*:&`5>S^L^V-8@& M4EDTWNA\=31!Y(#8X+*C.A%YBKD$71XJ.A!J-M$WK?= MH:Q[$.QT.V,.!]W5/U!+`P04````"``D/F9'MG8\E2H#```;#0``&````'AL M+W=OL^SHEK:I[H^ MSQVGVIU4GE0S?59%\^6@RSRIF]?RZ%3G4B7[EI1GCF#,=_(D+>S5HFU[+E<+ M?:FSM%#/I55=\CPI_ZY5IJ]+F]NWAI_I\52;!F>U<`;>/LU54:6ZL$IU6-I/ M?+[EKH&TB%^INE:C9\N(?]'ZU;Q\WR]M9C2H3.UJ$R)I;F\J5EEF(C69__1! M/W(:XOCY%OUK:[>1_Y)4*M;9[W1?GQJUS+;VZI!UJT]VOW)60]C2:(GB`&PI"')LB>(#\([D."VQ/<_\W@ M]00/9'`Z[VWE-DF=K!:EOEIEU]WGQ(PJ/O>:OMF9QK8KVF]-[:JF]6WE^0OG MS<3I(>L.(L:08`K98`@?$$Z3?Q`A*!%K@>ABFB#&""\$&CX-LGT89")3DK62 M+5^.^1'-=TF^V_+=$=]GH-8=)&@A10=Q0;%CC`%1MH\0$YT>J=/#.CG0V4&\ MASHQ!NC<>)^[W3Z*,O'BDUY\U&>^H/D!R0]P+22H18`4!D$("A9CD/"%!^J! M03SR):P(1OF"WQG((6DJQ*9<8"I$2:3T@/,8@X0KP?*QP2#.N8!S$Z-"<6]V M1:2I")L"]5U'E!0)K,<8Y3$X`388)%DP$MRY(A*Z;A#0MLR&1JW0#!M#2S1# MB;YPYH9P2E(XPAP%DZSI-6"/3/O`X)TMB&.#`33(<27A:"0P$32&(5)"4P]3 M30V1V]D3%]A0"`T)M/:9'@O@8*1P'O,$-$;`)&,!')!D6M<=3?^I07HCY!(; MC*#!#A.-,[$9&I`D"BYY&PK&9Q%R1\+N;?*F()) MWX4K)`7SN$#N,"SB$AZTG-')+U?EL3US5]9.7XK:;(2CUN%<_R3,R1&TK_D\ MYD3[QOP'M"?-C_"KQ3DYJA])>4R+RGK1=7->;4^5!ZUKU8AGLT;VJ?E3&5XR M=:C-8]`\E]W9O7NI]?GV*S+\#ZW^`5!+`P04````"``D/F9'<,.[7_4#``#I M$@``&````'AL+W=OJZ\V,ZFJO/E_XTI_?5K(Q=O`]^)XZH:! M>+V*[W'[HG)U6_@Z:MSA:?$L'[W=:5Y3!3O_+/VZ3O:PZ!\^.WV3^/Z?;V7_+6;7WY7['O3KU; ML8CV[I!?RNZ[OWYQMQS,,.'.E^WX&>TN;>>KMY!%5.6_IN^B'K^OTR]6W,+X M`+@%P#W@O@X?H&X!ZCU`CYE.SL:\/N5=OEXU_AHUT\4XY\,UEX^JK]QN&!P+ M-?[69];VHZ_K5*[BUV&>FV0S26`F>5?$_>3W%8!;80,D'#XNL*4*8_D5%)N# M&N/5/`?@XS4;K\=X/8]7J`:3)!TE]2A9*B'2#&7"R*36B>;=&-:-H=D$XA,V M/J'9&)3-)#$SFYE2`N5"18G)#.\D99VDU$F"G*1D$2DD*OZ6B@1OP[(V++61 M(AN6K``"7UNJD0$;&6LCH]HFL(E:H:BE-X!X@>:A)0]U@*MTT'[I0XBYD1.D, M&!^]\("4E)`*4>!9W$U"8@<68840! MX@%//*#$PXML@"&>T!;_);:,[D^EX:$'%'H6WYJ`\LPFAMRQ&9DV1@0>?4"? M%'6H.WGV`7W(RP(>%,\K17F587HJ"B*)8<5H`MVD>%0I^HBG`[!3/*H4_'TQ M`B]VE"VT&!0;"2D&U6@3Z!W%PT51N&0!&BB>!HJ^V`7+P?>OHOU+RY&05U#, M$D:B1(9[-Y[M(%2N.8X[*VVT\Y>Z&U[69Z/WW9MG&'8@T/A&/FZG/9CW:=:K M&PO=V]R M:W-H965T&UL?5/!;MP@$/T5Q`<$+^M-VY774C95U1XJ13FT M9]8>VRC`N(#7Z=\7L->Q$JL78(;W9MX,0S&B?7$=@">O6AEWHIWW_9$Q5W6@ MA;O#'DRX:=!JX8-I6^9Z"Z).)*T8S[)[IH4TM"R2[\F6!0Y>20-/EKA!:V'_ MGD'A>*([>G,\R[;ST<'*@BV\6FHP3J(A%IH3?=@=SWE$),`O":-;G4G4?D%\ MB<:/^D2S*`$45#Y&$&&[PB,H%0.%Q'_FF&\I(W%]OD7_EJH-ZB_"P2.JW[+V M71";45)#(P;EGW'\#G,)AQBP0N722JK!>=0W"B5:O$Z[-&D?IYO/V4S;)O"9 MP-\1V)0HR?PJO"@+BR.Q4VM[$5]P=^2A$55TIKK371#J@O=:?LD+=HUQ9LAY M@O`59+<@6`B^9.!;&<[\`YUOT_>;`O>)OE\+/&SS\TU^GOCY_PK<@-R_2\%6 M_=1@VS0VCE0XF#2D*^\RF0\\O<<;O"QZT<)/85MI'+F@#Z^:>M\@>@A*LKL# M)5WX.XNAH/'Q^"F<[31.D^&QOWV.Y8>6_P!02P,$%`````@`)#YF1TH.H&R= M`0``K0,``!@```!X;"]W;W)K9=^8%M+0 M(D^^9UODV'LE#3Q;XGJMA?U[`H7#D6[HU?$BF]9'!RMR-O,JJ<$XB898J(_T M?G,X[2(B`5XE#&YQ)E'[&?$M&D_5D691`B@H?8P@PG:!!U`J!@J)_TPQ/U-& MXO)\C?XS51O4GX6#!U2_9>7;(#:CI():],J_X/`(4PG[&+!$Y=)*RMYYU%<* M)5J\C[LT:1_&F[MLHJT3^$3@7PAL3)1D_A!>%+G%@=BQM9V(+[@Y\-"(,CI3 MW>DN"'7!>RF^W^;L$N-,D-,(X0O(9D:P$'S.P-;\/9CN,T&AZ[Z^>8?VCQ`5!+ M`P04````"``D/F9'?T.2ZJ$!``"P`P``&````'AL+W=OC3*1.JZI[6*GJ8??,)$Z""C@%,NG^ M_0+)I&F;"V#C]_QL3#&B>;4=@"/O2FI[H)US_9XQ6W6@N+W"'K2_:=`H[KQI M6F9[`[R.("59EB0W3'&A:5E$W[,I"QR<%!J>#;MS\.X+$\4!3>G&\B+9S MP<'*@BVX6BC05J`F!IH#O4OWQSQ$Q(`_`D:[.I.@_83X&HQ?]8$F00)(J%Q@ MX'X[PSU(&8A\XK>9\R-E`*[/%_;'6*U7?^(6[E'^%;7KO-B$DAH:/DCW@N,3 MS"5B"LY8=[SS0JWWGLO;VX*=`\\<23(/Q&D7TK6_>#$,^HGFQ+8`C;UIU M]DA;Y_H#8[9L00M[@SUT_J9&HX7SIFF8[0V(*H*T8CQ)OC$M9$>+//J>3)'C MX)3LX,D0.V@MS-\3*!R/-*57Q[-L6A<$T:[.)&@_([X$XZ$ZTB1(``6E"PS";Q>X`Z4"D4_\.G.^IPS`]?G*?A^K M]>K/PL(=JC^RN"^$65PQKKCG1=J MO?=2I,DN9Y=`-,>2G*SIZ3U_V&UL?5/;;MP@$/T5Q`<$+]YVRC`.(#7Z=\7L-=Q M6ZLOP`QSSIP9AF)$^^8Z`$\^M#+N2#OO^P-CKNI`"W>#/9APTZ#5P@?3MLSU M%D2=0%HQGF5W3`MI:%DDWXLM"QR\D@9>+'&#UL+^.H'"\4AW].IXE6WGHX.5 M!5MPM=1@G$1#+#1'^K@[G/8Q(@7\D#"ZU9E$[6?$MVA\JX\TBQ)`0>4C@PC; M!9Y`J4@4$K_/G)\I(W!]OK)_2=4&]6?AX`G53UG[+HC-**FA$8/RKSA^A;F$ MVTA8H7)I)=7@/.HKA!(M/J9=FK2/TTV>S[!M`)\!?`$\9$GXE"C)?!9>E(7% MD=BIM;V(+[@[\-"(*CI3W>DN"'7!>REWV5W!+I%HCCE-,7P=LT2PP+ZDX%LI M3OP?.-^&YYL*\P3/_U!XOTVPWR38)X+]?TO1F@R/_?6#++^T_`U02P,$%`````@`)#YF1YQ['1F@`0``L0,``!D```!X M;"]W;W)K&UL?5/;;MP@$/T5Q`<$F]WM9>6UE$U4 MM0^5HCRTSZP]ME&`<0"OT[\O8*]CI59?@!GFG#DS#,6(]L5U`)Z\:67 M]T?&7-6!%NX.>S#AID&KA0^F;9GK+8@Z@;1B/,L^,2VDH661?$^V+'#P2AIX MLL0-6@O[YPP*QQ/-Z4C@PC;%1Y`J4@4$K_.G.\I(W!]OK%_2]4&]1?A MX`'5;UG[+HC-**FA$8/RSSA^A[F$0R2L4+FTDFIP'O4-0HD6;],N3=K'Z>;` M9]@V@,\`O@"^9$GXE"C)?!1>E(7%D=BIM;V(+Y@?>6A$%9VI[G07A+K@O99Y M]K5@UT@TQYRG&+Z.62)88%]2\*T49_X/G&_#=YL*=PF^6V?/LVV"_2;!/A'L M_UOB1DS^L4BVZJD&VZ;1<:3"P:1!77F7Z;Q/C\C>P\NB%RW\%+:5QI$+^O"R MJ?\-HH<@);L[4-*%_[,8"AH?CY_#V4XC-1D>^]L'67YI^1=02P,$%`````@` M)#YF1XM8E>@T`@``&0@``!D```!X;"]W;W)K&UL M=5;-;J,P$'X5Q`/4V"0AB0A2TE75/:Q4];![=L`)J#9F;2=TWWYMDU#J#)?X MA^]G##.>Y+U4'[IFS$2?@K=Z%]?&=%N$=%DS0?63[%AKGYRD$M38I3HCW2E& M*T\2')$D62%!FS8N'O`2P?QB-\-Z_5D'KG@CU)^N,7/:A&T`` M!R809B8Y76U#]9,`$F%Z@:"93X]GZA0#$F&&@:#5C`]8K'M,`(DL](%`ZQD? MN*IQ"DB$.0"!TIDDP'#U8Z"TTS`-0-!<'L`7``:J.WW(`P@4Y@&:7-V"J;/O M4#HJY:7U#7&R.W;!/?%7_Q>\R#MZ9K^H.C>MCH[2V`;BK_F3E(;96)(G&TMM M^_2XX.QDW#2S(_4$L#!!0````(`"0^9D?V``S@R@$` M`.`$```9````>&PO=V]R:W-H965T(# M%`=U[$XH8-%KW!XQ5T0"GZD;TT)F=2DA.M5G*&JM>`BT=B3-,PG"/.6V[(,]< M[$7FF1@T:SMXD4@-G%/Y[P1,C,=@%UP#KVW=:!O`>8877MERZ%0K.B2A.@9W MN\,IM0@'^-/"J%9S9',_"_%F%\_E,0AM"L"@T%:!FN$"]\"8%3+&[[/FIZ4E MKN=7]4=7K8GD)E`%L*M(^#)R*7Y0#7-,RE&)*>C[:G]@[L#,0=1 MV*"KV^V91)6)7O)=E&3X8H5FS&G"D#5F06"COE@0G\6)?*,3/SWR9A@Y>K1V M#V._0.P5B)U`_*7$_:9$'R;UFR1>D\0C<+LQ\6%^^4WV7I/]=X$XW)CX,#_\ MKM1KDGH$R,;$AXDV)GAU!3G(VG6:0H48.M?7J^C2S'?$7>%/>)[UM(;?5-9M MI]!9:-,([KI60F@PJ80WYE0;\]PL"P:5MM/4S.74@=-"B_[ZGBR/6OX?4$L# M!!0````(`"0^9D?\#<(;@`(``.,(```9````>&PO=V]R:W-H965T6<)]UU?")?Q#B.`X"OCF0&O,G>B2-?+.C MK,9"3MD^X$=&\%:3ZBJ(`$B"&I>-7^0Z]LJ*G)Y$53;DE7G\5->8_9N2BEXF M?NA?`V_E_B!4("CRH.=MRYHTO*2-Q\ANXC^'X]5((33@3TDN_&[L*>]K2C_4 MY-=VX@-E@51D(Y0"EH\SF9&J4D(R\=].\Y92$>_'5_6E7JUTO\:S7^;)]EHY^7]DT&.IJ; M$'6$J"?T>=R$N"/$-P+\E@`[`AR:`74$-#1#TA&2&R'YEI!VA'1HAJPC9`8A M:+=#;^8<"USDC%X\UC;@$:L^#\>9;)>-"NKNT._D=G(9/1L3,'9A'Q-*EDO280+KLK48NJ]/($H@>4\QL1`A3P^B/*@L;@3)C+3^* MO#@0\2-DY7*;N0L2._:#^_X&3"JU4)2#6E:CTD*S(K9 MJ!2F1H[%A,$,F:F6CLB3ZHDJILTJI5:40?;%/F5,@&[Y/(Z?`R.'`*-IT M9!<-P`08'3RS82@.K;8+[L[+FK"]OCRYMZ&G1JB5W$7[^_DY4N>M$9^&XUGH MB,_#\:*]?F_R17[$>_(;LWW9<&]-A3SE]5F\HU00:1X\R8X_R"^.?E*1G5## M5(Y9>PFW$T&/UT^*_KNF^`]02P,$%`````@`)#YF1SM1<6;``@``^PH``!D` M``!X;"]W;W)K&ULE59-<]HP$/TK'M^+)?E#D`%F M&H?0'CJ3R2$]*R#`$]NBE@CIOZ\D&\>6E@R]8%N\]_;M:KW6_"R:-WG@7`4? M55G+17A0ZG@717)SX!63$W'DM?YG)YJ**?W8["-Y;#C;6E)51@2A+*I848?+ MN5U[:I9S<5)E4?.G)I"GJF+-WWM>BO,BQ.%EX;G8'Y19B);SJ.=MBXK7LA!U MT/#=(OR.[]8X-1"+>"GX60[N`V/^58@W\_!SNPB1\I1'6AA$'%/MIK4=OKN?UGBCH:3"`=@?0$G'Q)B#M"W!,(_I*0=(3D M5D+:$=)/`OV2D'6$[%8"[0C4L12UU;5[\\`46\X;<0Z:MJ&.S/0MOJ-Z]S=F MT6ZV_4_OCM2K[TN*1P`P6B$&!V`HD0X$,.95M,>9=T:#:@M`$$3A, M`H9)O##$J5?>0N@@"(F=>JUNP*Q]S``RLIJ"5E//:NP4)&\AZ2`$IBEVO-X" M6OL@0J_L7P:ZS3RWU"E(GOE&L-OTF5IWB9L, M]6S$;K^NJ-\!+F;M8_1$N?+J34&S4^#-<7N@Q6`\"#.;.*!'`#0=@$969J"5 M&6#%&8_YS$OX&T8)=1L!@*7(G;4K`!4C1-U^@&(F29;`N9D!`\U^!&077Y&X M\OG`MX])#`]:3``73O%6("B]$@>>QQ@:R-D5"7C6XN0_LH5G(/:'()`M!')' M;33XQ!_9GO]BS;ZH9?`JE#XMV&_Z3@C%M2"::,&#/HGV#R7?*7-+]7W3GLW: M!R6.EZ-F?]Y=_@-02P,$%`````@`)#YF1Q@I,9T<`@``L08``!D```!X;"]W M;W)K&ULC55=1K'62F@IW=AYWI M]&'W.6(4I@FA293NO]]\("*FVA>37,XY]^3&W&0]9>^\1D@XGP2W?.760G1+ M`'A5(P+Y$^U0*[_L*2-0R"4[`-XQ!'>:1#`(/"\&!#:MFV&L.M5`!D&=@Y.T:@EK>T-9A:+]RG_WE)E4(#?C3 MH)Y/YH[ROJ7T72U^[5:NIRP@C"JA%*`<3JA`&"LAF?ACT+RD5,3I_*S^HG*ZQ#X:<:F MU6-OOL3I0+,3@H$0C(0QCYVP&`B+"R&\2P@'0OC=#-%`B&89@-F[KEP)!X@KGY'59W3CTT^^$(BM`O'W*Y58!1*+ M`W]6*ALFL"=)K4G2Q\>1/CZ.\C[&^`"3"TD0.^A6R)V*'ENA"C6)CMWV.5`7 M>A9?^\O"M\1+V9U-,[W(YUD'#^@W9(>FY&PO=V]R:W-H965T MTPX@XMC8QBO&J_4ZSC[+,!AB)<1*LMGS]T>7$6BJ,Z4>/Q@0V=75E\RJ[JGA M['DV_WMQWS3+DW^GD\?%^>G]RI>5S]YFXVGXZ7JQ_G M/P:+IWDSOMTTFDX&1JDPF(X?'D\OSC:?C>879[.?R\G#8S.:GRQ^3J?C^?_> M-9/9\_FI/MU]\/7AQ_UR_<'@XFSPTN[V8=H\+AYFCR?SYN[\]#_Z[3=MJC5F M`_GO0_.\V/O^9.W]]]GL[_4/GV_/3]7:B6;2W"S7-L:K+[^:]\UDLC:UZOJ? MUNIKI^N&^]_OK'_;_DYN?B^5LNFMR>C(=_[O]^O"X^?J\_4VEVF:X@6D;F)<&)AYL M8-L&]J6!=@<;N+:!>VE@#_?@VP:^U*70-@BO#0X/.K8-8FF#JFU0O8[!'VR0 MV@:I=-#K-=^NG"J=6/VRV+JXE]URZ]?UMOIPD]V":UON MB=XMNWY==WNDR6[A=?'*Z]W2ZZJXR6[Q=2IM8G:K;Y1H,M@2?B,7E^/E^.)L M/GL^F6]%[FF\UE+]UJP5Z6;]Z4:`-K]<*<9B]>FO"QWMV>#7VE*+>;?%F`[& M=3'O`<8+.Y?(CN]B/B!,Z&(^(DSL8CXA3-7%7"%,ZF(^`TRENIC?$$9W,<." ML5\C.Z:+J0OL?"FP\SO"B/4:(8Q8]S\01OCS%6'$FOZ),&)-OR',ZYH.5AO] M9;<;O-O-QH+M6$C8@L46[,:"V[<0Q'YXO\6LA7D%>MR`U!ME<#\.]^.R?IS8 MFI=;B-_K1:OVG]CHQ' M1:CZ&*KC<\(^)^"SF)H:81SN92U_,.%0P(:(&,,6M$\1ZY45L!K`G/$2-@(P M0C7-LB0-G)9+U8+V5R$XN04!*'H2&C2)8MH`;T2PO&I!^X/VFFJ,)N%.@WB7 MLCS*9EVQ$9%HI_-PIU.2\PLD7PZ[!J"PQ_"N-R0DZ#PFF$SL=:[B5@6QW-90F$JESC0237.6A M4D:+:P`R+I.*'&2U#!!?`"I2@2,ZJG.1-"SY,T0DC2J?8$,TR^2:E4^PR>7( MZ"A0URVJLS^=E($:V(K&B;#W!=CR%=N`AN7QN0(:15ANB+09VV..B6Z97+>, M$D>D#R:7)$>%V!!-,DB3Q":_-$A'DO(RCE\AH(E)J2CW1Z'%NA0X*NWZ&P)& M%RK/UID(GD&"%^0:A6SO)L99(HHFSVS-WJ"Z-H@HFJK'GB3Z8TH2.0`RBIRE M+1$IFV=RN<"TH([`.*DO-D_0M).1'5C2SDMY`:8"RZ\L44Z+LCV9OMM<[;(; MIJ$%PBE!]1%+79>)(%HDB.QF@UUM]!!$2P31HD1.;CX`,IKHH25Z:$MR-)M+ MB)>9P;4%*9K1\MX-H&S42>Z^'.6-(>05!)*XX(G\.R)\FN:(C2N-T^8`=H;Y# MU!]Z#)C=>(/0:81"_@9!1"$] MX8\'_#%.=@1`3(H]X8X'W#%>=H1`A&">$,R#2PLC]LJESR\1=-#62X^&I<"Z M%/@G`#JGG&.[C&B`!_0VE1QF0CCP2#438`A(VP?-/"&3)O@Q$_0)( M#*R1'8$;X`-;@XAD*#E?A#S=S]8:G!L".8\&]J0/2*0E$AF(1(8>5[:!J%\` MZB>G_T,`$G1@^HD"!70_D4U_RN=6'JX/8[H/+(E*1*`2EB3ZD5`U]DA4(J%J M1#F(#*<(Q&@6"9\CHBK)OR.A:NR1J$3"P0@X*/?;QYB?\0_0/1**140QDAQ$ M]F2[!\4BH5A$%(MRC0&(9=^1$"P"@C%B5(0858^G%!4A1H5BF!PP!+&."'LJ M0`Q'=DE%B%'UN"&K"#$J%,/$@#\B$%OABK"G`NQAB6!%:%&%'@,FM*A`WBT' M_`F!Z(!9T06@A2.AMB*TJ%+Y@!.A14+WXD*G?T]Y#AA3,,3=1-B3`#$=E`MJ:J!Q9YT08E``Y'(G'B9`C];@>2H0<"5T/98/. MKX>L#?LUDMV^"(E2S@\Z9$*/U.-R*+$:H3QJ9-5RB1S.Q(U*&6Q8!JO+8*.C M,%'"1&N84!&3++[;H8[5U5V5`H>EP+H4."H`BBEA%5(*29%\0+U#=1^(R21V M6`:KC\*$ZZR<2N6I@7>9Y_D-NDWR]OL*P[+G,F76ZC+8Z&BG8AY8K9<"*NY" M-A&YC(=HO?A8CZQ*D&`,K)%,H.,@;NAVJ\\POUYXR6'T4)EQG56<*)6SR MUFV'B@>WQ+`,5A^%"==939D"H9"5S&K%JLI4G[(RQ>K*%"HLRZ4#7*DF;5U& MK1SGK=,ATN5E96$*G+@\K4-ED4?W.'-I7LZ:BW7^MHX&Z@I>+BC$#0MQ=2%N M=!PG)H/)/RRGS8)YBSH>S`N!PU)@70H<%0#%E+!(`,I^03!'=;_RQ9YA$:H^ MAA)^,_4'=<1Y)`R4'9<:R, MDE=LPU)@70`4`V`!!54IY[%0YX4K^:0.RV#U49APG44Q#:XR/&4@BV*ZQVE- MTU)D6(NG+?C&]??I@T=\OUM^OG M1//M7\;8_K"&PO=V]R:W-H965TJ%\O"?GS2%Y2%Q<3?%6 MGK2NO(\LSH0_+V3-]VC+52*SB5Z*OY>#8:\R_&O/6G'S?+V>D\:!3O:N: M)N+ZYUUO=)HV+=69_W2-?N9L`H?'M]:_VN[6]E_C4F],^CO95Z?:+9EY>WV( M+VGUTUR_Z:X/HFEP9]+2?GN[2UF9[!8R\[+XH_U-\HTH7A`:P+8'U` MGP2C2NA8\7653`1]1J_-MD[99C3 M-7,;`";N*K:((L`]!&BU`AL?#.-#@C?`T0:X;8"/&@"5VK0:836YU814182` MOK@RP0F9<"-0-P)Q`XLJG#019TP)X,:5B5`J&>)V0M1.B-@)0)[0R?.%15-I M))I&(FDX&/+231,($H!>;Q`99P+*MJYLXC$IU+!"#$,G"JD+YP/9*$^$YHF0 M/"$H3.3DH3SB%(Z'S8.ZK:L#@WWDNT$X!C&"S$LYT<0$!RG2>04IUXJBX628 MBR`:?B#VVA`Y[."$,11[SY0AQB)HK!4U=>C3L&"NX.S!=-%<*3+XT`E[.!%I MX-J3$%6=Z($)0'%L4H2;$G*S$X'.23Z1"4),"EL'E&\Z= M!X1C4S@**<)""5G8B>X^FWNR\>('1QPCB"&X"D-%:B(/SD&&<%`"W*R9"S4J M9"C"`,[)1Y1C6S@%&7/'F9I@",-)Q1!2*<`P!GI*PV\IY[$'(ZS6H8^B^L#7E#[:$F2Z.=F]=>CMSR>U6 M?G"UW[\_,[NE_)2O%N?XJ'_$Q3')2^_55/7&U&X?#\94NO9#YO6@..EXWY^D M^E`UA[(^+MH]=WM2F?/M+X3^?XS5/U!+`P04````"``D/F9'9R][WOD!``#< M!0``&0```'AL+W=O.F:5ID`RE*T\*J.02\[WGL"ZI/_ MM#L6B4%8P.\.1KF:>\;[F?-7L_A9G?S`6``*I3(*1`]7*(!2(Z03_YTU[RD- M<3V_J7^WI]7NST1"P>F?KE*M-AOX7@4UN5#UPLLWPX9"BJQ&:,?F$P2O,;D$@K;ZDP*X4.?Y` MQ^\3%!\1T<&=(70>(K3\<&TPV+L%]DZ!O178OZO"XZ8*#LQCL#F("_-)K2*G MD<@AL*E6[L*$&R,NS"<5B9U&8H=`M#'BPL0;(RY,XC:2.(TD#H'M#^K";*ZO M^!HS&4&K5\-`-+:;2*_DEUZ9_W,571K6$S:O;A//=2.;^LY=)DL'TL`O(IJN ME]Z9*_VF[@+08/^M9:W6J7!85:F6FBYV+J/M-"\>'62Y>&GOT'4$L# M!!0````(`"0^9D>F&XD_L0(``/X)```9````>&PO=V]R:W-H965TQ,G00LXQZS=[ M,71,Z>%PB.5IX&QG@[HV)@CE<<>:/JPK._'OFK?B ML@IQ>)UX;@Y'92;BNHKGN%W3\5XVH@\&OE^%C_AA@PL#L8A?#;_(F^?`B'\1 MXM4,?NQ6(3(:>,NWRJ1@^O;&-[QM32;-_&=*^L%I`F^?K]F_6;M:_@N3?"/: MW\U.';5:%`8[OF?G5CV+RW<^>2)*<+MDVC@=8F`B1E[M)#`%>!R<+RPPMM``-4N=L' ML%]-1%%&$U<3`'1^CWM18%-XQ`3XE9=2P*L>)X"OTO4U@NB=W*C,75<`#$?E M@AZXB6"HBU"7:`29RLY,990N$,%M!/M]),%>8\]$NW<*R<`HQ%><@ZW)9P# M@KQ])/>9TBA=:%\8[E\8:W&PO=V]R:W-H965TCZ;@9>\FG8WTHDSA3+[E5'-(TRO_-5**/DQ&,3@.O\797U@/V=&R? MX]9QJK(BUIF5J\UD]`Q/2PQJ2(/X':MCT;NWZN3?M'ZO'WZN)R.GSD$E:E76 M%%%U^5!SE20U4S7SWX[T:\XZL']_8O_>E%NE_Q85:JZ3/_&ZW%79.B-KK3;1 M(2E?]?&'ZFJ0->%*)T7SUUH=BE*GIY"1E4:?[37.FNNQ?1,X71@?@%T`G@/. M\_`!H@L07P'NU0"W"W#OG4%V`=*8P6YK;Y1;1&4T'>?Z:.7MY]Y']:J")UE] MFU4]V'R*YEVE75&-?DP%B+']41-UF%F+P1Y&^I>0!87`&6%7"9RS0"Z+&9)P MO)Q@3A$R,'*X2;*\2G*1IF#%$DV\N!#+Y0E@2\-L5N(WT"R=@[' M`T,-"@+?-3[;@@$YPD0M*2+DFQ1DA2%SL#7]U@"[WY9?9;`ORUK"Y&] M,H/05)5BT#5X%A0CP#&(EA3DAP,%!6Q!`2,I\@0A2Q#>+VGMHYPQ.+=%[3`7 MBH'O&+(R*'!#<_'=HZS'% MFNXX9U`8>*:Z#"B4CJDN14E_:-GQ/@?4Z-#Q!RAX9X'@`75Y;X'P#G5#QDN) M,5`0N.1DP8$D\06*\N3`TD7>$`:'O:VR"4%[RP(]XN+O+,@WA:WPURL)/.' M:LZ``,'0;<&@A`^F,7`3(@YL:^3]#JG?"1A8N\B;"[H/R,N;"]+#"I574N6( MNA3CF-)2B+D#EE=I+NOAG0ZITPD8.-,B;RKH/Z`J;RI(SRM4U8`>1P-RRJ<@ M(BN%2-\\U%[E:2NR>QU2JO)MTYL6UDH?LK)6HS=Z[G^?L>ZPC/$9/,V!&5]4 M_7+;W7[13\?[:*M^1?DVS@KK39=57]=T7QNM2U5E[GRKUL*NZNC/#XG:E/6M M7]WG;8_;/I1Z?VK9S_\WF/X'4$L#!!0````(`"0^9D?=2A5;A`(``$,)```9 M````>&PO=V]R:W-H965T43;UFC_YRYJ*G20W'Q9"L8/5FGNO("WX^\FI:-FZ76 M]BRRE%]553;L63CR6M=4_-VQBG<;%[DWPTMY*90Q>%GJC7ZGLF:-+'GC"';> MN%NT/J#80"SB5\DZ.>D[)O@CYZ]F\..T<7T3`ZM8K@P%U\P!P(P(3TR"!W<<^/<2>PB#9F%`F``.!(/YP)8`WQ%@F("` M!,02D#L",HNRQX06T_28&"VHA*!*"*C,EZ3'Q%,5WX=%(E`D`D0BF"`&">*O M)W,%$JR`".+9MH`P*U@D`442@&!6`OOD8<6(3V)8Q9PS4*7YCSIXOL<'T'31 MDH6,H86"1H`,FLN@A_DL5`D"ZW6+`D`EF*M`H*79P.6(,$!!%BC@@D3DZ[L0 MP=6&H'*+YZ>>_;EMV59 M!5\W:5;^\XN[JMI^^\TWY?(NWD1E/]_&&3Q9Y\4FJN"?Q>TWY;:(HU5Y%\?5 M)OUF-!C,OME$2?8BJ+/DKW5\F==9]<\OQN/9B]_]MDQ^]]OJ=Z_S9;V)LRJ( MLE5PE55)M0O>9CQFDF=!+RCOHB(N?_M-];O??H/?\'?GP?=Y5MV5\,TJ7C6? MWL3;?C`>A,%H,)PV'WY85O!PZ'^HUW/A7\]?+A9E543+ZG\TOY27/\:W";X! M0[R/-G'SK7<7P7WGQ+KC\T#'>)2RFB%)8Q"K^ M&OPAWG6N^--NVYIN..C]L?.#Z[A(*GQ?=(%JJ@L8DZ3Y]4=G,+266KS MPT]Y!Z`)I5P('@H+B9+>)8&&1QU2(2-.6^J?S/%#S3)%HD:5(E<1NH M@#9(",M@&^VB1=I"27A>U/&J$T;J.7Q>Y&E*NRGBE'"DZQL7/-;J6K<>L?,N M3U=Q4?[C[_].8*IV;<1P4/KEH#\8#(:PHB(`!*GCWP3#P2`<\/^$A`=17=WE M1?*W>!4&PWDXF@S#Z>"3LL0]TO&;FQ)$50!TJ8HW"S@> M1>'I+4!S^550/02@E-MX625?XK1]=U>K!"DZ0`41K@T.D"U\`DQ/`G@"NS#J& MG^SUJX>-3KC(U'O9IWT_7K)M2/WD/KRX/; MZ/K"OY.NM_=LYG,6U7"%^'Q])WU3P7^0P,(PZ^##%ADE7#C&=P`=X.`=?`:W M,WB7ES8_4TNUF%IX@,F-CY8'6RSP8_PESMK(#WLA00^H"#V']2DB"\?6=:\+ M_V!70I9;=!3X)D@G2V:R*_@XS8DI-=_[?9S%*`;B:]%J`UP4A4PD;?YU=/$! M@O2ZR#=!K@_$S_N2;)EO8B]S?!\#"\&!2#)P3A)_;K[^*BJ3)6\P26L$8*8& MT!A_Z`*(T%0CEB&IADGK"AG"XHC!GXBZ)`2]2?/[XV4NP79D6,A_O)Q60;'- MF7ZHRXIGKW+`J&6>+4&Z-!N#7_%ODLD((J"?J/-TIFRA&X&Q!S"+^>!@[ZS7 M"+ZTD.DN*03?&90/^/9U#'BQ3/:^%*F0ON]#[\*O$\ MN$\J@":,7-:+,EDE$<(@)'Q\(5^\.`7$#J)@D>1;=\BE#+E&^P``!A:.'ZY` M_\\!;KO09JV*:VT0RZ-4(($[!63)OQ!3Q<\+4`>(-%4QRA1(=]H&) MQ!HF0%:"$I:*K!X&7]5+O%`@?R%?H@FLC?2#=]]=7_:FH'@!7"HSS*]+HDL` MP2HJ$"H%Z2^R2Z"X25XAO\Z"MV_I3N.W6_RMPF.N<)4$*20?,/$2%),(9(ZX M!ZB1H$!8!7>[+0^29[*.B6\=`-`X;:[@+MXNX8BS@W,#=TZ8\@#!16R+2=9% MJI(4.!9`*LTCT"?+&F6H$H:&BY'0MN_B3;Z\`^!'50ZK#H$<5!%,!PH(,)A- M$K'BE2Q_A$NUC$&1EC.1_8P'-_R*^M&,=G>+-V<#.B*> M5)$P-I6'-EHBD:E+$&9HB_`XR=9X-92X7.#,.`W@.RXS+U!1--M>[DI\LDX6 M!>Z5Z08\B[,L#C9UN03H%\$*W@*\N-NY2':F,7X?.9P% MH"+7AZ=:Q@!'>&D+B/TU@2-%FO%R.)CT9\$F25-<%,FJ=(\5^UOF)>J891P' M[P'RP>2T?=VBX`Y0.@>$(0J`)A*KS4IA$L&"(PP(:*8Q?>V2!31#YLHBVZ) M%@=5'&T0J$5>W][YK"-A`V>-).**79H[TXI>CF?]J89M$VZPCB]1DJ+YJIM9 M(T1?#L?3_E"/X[??](-7D=!M9:(RZ]JFD=P"./L?Y%:$-@06<9K$>,W@T MV6,6=P]+@D^)4L.%)5#FP;I&OF^452#_.2YRWF^QZ7JSB1AM;BQD$>L>KOP: M&.O29V,[^DN$2T)P=+@R[NTGK],5X@NZN%@'S7ZH,UJ-6:*"N!>T1#;RBA`5^!1BF_"% M';HH6,QHV3'A_@+DTGK%H'?O\D4&I"6%]0,9KO#^*)C\`9:0QA;P8*/X_'NR M-@QG?//X6C\.4>"-*D)<@&N4X8&A]4.1SPAMU%$J),O6:.&*AFH?^3;)1"8P MUSDD-IL!&,H2;PF`:C$?>((LF(U3?,+>->"KQZR#93+#<62^HV;I6]3B'A`0@+Z*V:J% M9P:`!JZPKM$ZC=049EHG7_$6$_=A([%66=$E+B+5TE*#T$N%,<"U!&E-L<)HX5 M#!CYU9?N\3[R'`ES\TIC;X)J`@BQ2Q85!!_5E`#P14Q[(2N&FA-.(&6*`#^0 M6E-7=1%K2LDJ*2S_2@D-6L)`KP?[/FR\9^&"9*QA#V8!E8$,E05`H]RF216< MD)Y%U.:C/&#E\@8?`X%$V:AR[,&NN'9R8\M8%VGJ/F8;'_%P;?&SR;S0@V=@ M7X9?D1A5L>(&*C.JFO!?$("54PBER92.ADD0KJ`+!'0X2.D$^(HDH2\K_HK< MCMXP!GVS3W6SLYIP!>^(MMJK5S;D$$39,`%LI[N):!3)P3%$75N,&E99ZEU+ M#T`/-(24`.D>6J<3B*>%"P!RTTYH-D/O%H'%2(3_W`>G?G`)PQ-;V(B3$S`- ME1L2;)%+&39V\`"7J*J!>,3+@+4CQJ@E*$F1;LK6$H]`[$:UR'R^E$L-:K0% M5FU/#;W>-[Q\AM#V00#3\@O:A!VSR3.)7L+F]56HA>T M?I_AF5IV%,$?2]8D6M)3=A.,5RDC2]\4-FJ?!LC8&UATI0SPUO[[@3;#T1]7 MEI1MJPWX48(PIIMTE]S>`5*D";R]$D/:1B1SD%DB)-\HO^V,91)A1T8YRP*; MHJT)I(I,:+60:*:M3:&?2?XR*@HZ)KZJKI0`0A4,`1(?B.@_`H:@0H!N,T<( M:QL,,T MV116X!H*T0/S`(.M^/(%:%Q#]H?6,3H[ MH)^.C0X(*#S`CEDA;74T/J.0!?SFI?SM!A*$I!U;8+0@K3BX#4?V8\@:G0B4 M*^4N"/R!*0@T86$@N:(M@Y$]<@(2C).E'S@NEZ04-QF\AC99AAU:;>'B5;V4 MY)D8.-&*[&AL^A?9:-62!(DFB6S'7(I04N[F?4[F471^$CU^S'%4WIOI=["P MJ8?,%,/P;#HT9S8Z._Q1UW61)2ALA0IVA?VXS-?5 MO>+I=*;(-)0A>,,4QN?WDJ6"8&86.N"%/EIC?-$;O!^(C MA_\N@4+@6B;<'VO7Q)@L(* M^7D9%U\2EZT5"`-X#%^.3_F&Q&D:%__X^[^C[`)O*WEC4>_0+5Z*4@3#K6*D M1,`409KZ#0'W9'(:*+<&.2YW^`&ZM?*,Q:JR!.Q:N>8TD612+[CH@FVC';-& M;0DE^0XHI]Y2=`LG3*`0]NE$*W10<:;(WE/C0 M;X,08*M&:]*\:<99Q'=1NF:L,**AS7;+V%H5+AKDNQ]$(%%W+YX!'I MU;+LS'_SJG:B@R*\ZHS(MARO$G=_KXQY86OV,B9E1T!;+H%`XR+O\^)'$;O@ MRJ*DSHPKD@NSCH&JUD`\Y%JA1QYY/W"<6);%ZGI)01W(+=6IU@IWG74`[R,G M;8;R1I47I7:'T+KJ)>K@R,3B#.,DV4)1N)X7[:]3G)O]$:(12N"I:YC8),"% M*Q`1'\ODMEW!L"2!C&<#BXJ'T]&<_BDHX96(7BD@OE M!=`V&EC7;4266,8OC5G**"J>"[0!I4ANK$.USCUL'*QZHZQ@A%A[%X`"EEK: M:6RY;ZB-(GM5&RXD'$A\[G_NW>@H+V2IE3X-:V_MB=WK8^^5F+K%YT0UZ`=O MUPIOZ=8B21##`#'Y?$7J?:AT7C$:6X]$R"!;/!.,K67"$4H!\DE2BK_&I4J1 M1?K0B0D:]"UO3R&=?,&&'?P7BXJLP"W%9,TV$!0;E3A0R)0L8)""9SC?:XOS M:;3IBO4S]U\9`$JXSH4ZR050XG6")3=[]`EH48)]5WNJ<,$-E3C M7EB%,B]JT!@A(+-N*>-1K/ZMA]-O&SJ_V!TB)699Y,A,DL!YD6 M^%?&EEXQV=:D]7DD9:4Z=TZ@I;'2%K47AZRWI(*!# MVT9./38PL-476I3ZPB9$69X5,9H_R)&J;93($@RKMJ5JNBC*K9&7S2EU)J>..D8F8CK%&S&,,6PTWR1+33^,&UY-6#`KY_2@$2H!*_&9+JO9*L!`M=!0%S$Y!>@NI"<^`>='KC:(E`'K@Y)++MDK&,BOP0@Z=6;'A&=YN&I&Q#8A>1XJ%, M(I)BPWQ,MD[?$=+8.MQ1K*?X]RUEH,K&,UEA#Q4O_`5DJS@%/-(^.R'.!=T$ M#)NLR])B&`8_.]VZ%*73#S"0EW(,KF$@PM.`P_\](?]HH(S2I5@RM;2,$][' M:*.,5[T(8R%O;>>9\G*U$E3ZP>ON]`)W+F,.?Z=+UM3M"3O:0/Q_G> M0@\FU>01B3M1BD4>H=1\'/X%D6^"'*YN%(D"B!STGN0,`R^4_LNZV,DT8C]6 MG`GP5=R$2CUE9LA85%P:P,!9OFHG^H8#(*NF9 M%>W5V[WV4.:[Y"+M/OEU<&[%NJD<+1ARWOJYPSX=$_,7:&C^>OQ)+>)E5)Q*OW)^<,!;E[=:>6]>`7N8I!BRVJ(1:F+C;GBU,AJWH`RLND?TT M`PN\/L/X(ZW@-)T3O4@VF8DU?]-0_LF@"6@$8C\R22[B6F9!N7W6^D`[HPU0 M%5K&C6!!D/ES%`^8;X*V<5'?UF5E18*8&'XO5W^5HY=19*.+FU<4:4_YM][7 M/V^)U2#[_PROOL_[-%4/@WN/RA[H!;_/<+1-:,'W,<%'DRZ("U3(X^=XR.Q^VN5QC_2!(&'ZZ0"$`DXP>XK1,60V$( M'^3L4$&25*W04E8HUTF66!;Y2(*GU$$#MZR7N`K*Q&']B<@#1CC<2F@?OE\Q MM=6+-<,Q#TAW3J93PQF0KR(]M`>D&AP6#!(K$IR)`,=W*CH02Q8\'9RV+^.] M@PLX4UQ$D3O+9D!JOSV6&@IN:=-./6.BV0@W4]C36)')L7K&1357=-8/KJ*" MHI)80L*OM^A[JZJF,VV5QZ4(%7CB=&'-M^+S$E+&7^I!M4M,'K-A`< M"%E#U%Y#H=>@#8J\A@6+L968B9Q9=Q<;>8LZ9P$#LH79N^.NS9"2Z3 M\]2`9BV8BBN*[]F>,JH9R%*9"IK0]2^UUQ55H+`LZDJQ"EN47)/915G8VX=$ M.3DI!MGO7`]]BW=[*25+JJ2ER80G1EU7)*W]DA`WCA"6'T\/$K?I+4#;]M#)TD[M%>?W;^\7VT.X9]#,Y#'<)#BL:E&^!P"=H"4(:B5"QD M-IB=-F@UP!Y#QDI.0`L#-`FD3>6.#$MT&V*%>)Q5H`R,%D=2`2Y`XTJ=)]N( MO%CJA1'UJ3$6*$89<8-D1D4`JY%L8Z`2(FUK79*M8+QBUT,41#.F?DNVB@?N M&XRW90)5X)R^Q+VRBK>PKBC=E8GDYG(\$/EW229&[U!NQJ20&46H&7DHF8^& M)V115D'?*DA%@=.IQ!(39>6:356PL@TIY.S9<'PRN05$$M_$;<*W2MA6J9RT M9$P2GX,\E M,[VL%:2(;`_^8IWWFD+C3M#, M7K:JVK@O?;*C\+L++!R:[,&+>VU%5MLA]$V[6#M[&[EIH9QU^V(1MY0*'VN* M0K1'8L*=*,7K&H,],YUG0M0N>G"9YXX%;;@9A'!$Q>,(P1B4,/C=?A MI.)`57-18FYE!8?J"#S?(5.DN?9#L&DHRSE8?1U]R0M;#[@T*,!UG")Y3"IH MRWO.&EZ^H,,E$2%"7S)HA$F:L)O.JE$D#,X"@Y7:(E2IO7ZA3TMD42D#@\5@ M&96B*&:#H+>*=N6O@_L"B7B&N&.%!^?F`PRK4-4%)8#2RM6!CY*M1(,IGWV$ MP1:]+[ED2N?D)"9>AV*LB*L-3#9X98^O0UZM4A.&;<--1+9I/'OBH5ZAAQPU M-J(]+%%PS%&"-@'848M(/"!2O8'%.D;#+>8PFW"Z!1?^<&NOK6V1ANUS)>66 MB?%M'WJV$_<;=1JOO-46Q2G=38?]PSC%7AD`SB\?5%V+`X4QJ/Z%TKHQR0#Q M^O86`PB9]X_"\_$HG)KRFLT,0+X+!!F%L::H!EE;ZD4*,K#^4<)R,09UWH=Q MM5=)S*RW!?F:5+THM!8URG$,A_U)1\D(36DRN^:49PQ_28\FKO3G^IW$VJ3* M2^7T?D!?*@%4*[V.[ZA;'H15I.Y#4F+:Y('G,PW'YU.[_.DSG@^ZP!YQ/M.9 M!=K''<]T[+C:_*I++EC%04"'%>,@92*,K7QP!J*/!H=Q6X==&&V&M45%C1"*22E MZCF+)%,"&(KS[`7V3&&/U0_>Y\!+F2NJPK52$D"6TI%'T0U*FQIB(JJX-]$* MD+)0T)X0XT`Q`#"F.:`5"SW"-YVG?DR^MAL60C#%C#AFXGS=V)NU,B4D M=/T^(ABLNSQL2%6*SUOKA40`.R'4A*H&MQB-G%FRKHK!>"H<#N:M'X3*TA3> M*TP%C.9GJ_CY=VXJY0-&2I4:&N)M9M?4:OKM74'XUZ6R16QBCGE4,6&"D\TJ M3PZ!TG2,S#_6,J)EU"$748QU,9G.3ZX4C] M;#WJM\H==H;NM.*DK;7!M$38@GES:I)U&[%82FF-+%>-+G%NF*ZXTLE"7)#D M20G/F`I%)J6AI*52G#&JBLKE9!5X'.TM[<@1&<[K^I47[&:7/,_.2?87[W8F M>&,/[DC\CY#SA8\,S\/A>,(K/0O'LTYIB'2LQCVE<_;M7<*TFJMN!N-8.]A7 M8,F[,&M+;)?*MC(M;%]8&38.!,0Z)E(4*J*[@- MP[/1I&MY9-2/D+0I$<._`D-QVRM_TNI&\]F#U^9`;3_E4&%;X_!\8$^TYT!' MX=GXK/VJNV&?9&94;@ZL8-0J,LT7J*!%3$5?_E)IQR(DAYZXX#1DNI+YE1:-9R M"%4M1;-C'JV[6$H9XK55?@!QU\XL?1*E[LT MREKFD''#;":^@TC'4+:BSRW]X2[>-Q4QO7_\_7_9K^"#?_S]?Y]JG"^!&4AQ4C88^'I-^L8+K*"DQ6(LC36Z)F*#I M%Y3=J%T\L@.87'45[1T]8LLH4JO:8%[()?K\7-V%K7XWHJ1.1B,U_]N,,O%2 M[?*XS%QNM@B3G&I5">C M"'5()I8.XNA!!LE:B\E5<$I18M`8A=>3<,->70(8Z9AF-3IW9CCXE;H#CLI_ MG.YM0FK2R,Q--T$`1&OH!Q^,ZVCEY%."5S4Q:RG!K7:@ZJLX$3SOR+7G>!4A(C,)AHT$6DU559HTX?1<* M[D<3&V[3_VIP&S?@=JQD#^H(*$Y+6C:FNM,/1LA?2[L&VJ=/] MLAD6ZPQ-./E9N6X@\;`*KXH^[JTGW"J"17BDJC!]Z^2LN?*;=P-693NQT'"8 MG!C\/AN#7GNPKF__K-+R+B0M[THQS>M"(GDENU"_&:A7/Q)OD*0/B'*I.K9P6XG9/W%HV1H7'_`.-1K"8(,Y M;6LV".;]V9D>:!S.)G#9!U.RJP*NIQXG*Y5\BMQ+RHS*4PEBR26Z@"+F"1W% MY5T2VPE.'["./!*-W!2HG#6-C2UK1]84"%WG!<:+2R7*CFJ5SHC"%4S$N8K` MHQ](+42DC%6%A+=8JXJC(`C#=!&.?-U!_"B&P@88Q5?Q@5.U$HPQ5WNBPR.) M1?1%W!?*IS*\9>U7(++9FB7[N8G-N#,M#6:M&8R(:$8.N7B,$1`77%I?E3[$ M3AZN:&I5V%(96KHPA"E'B6;Z9'-89U53_PY7CXY1H4S/T;`_.1?KR+`/$$$NT\10GR7L M`8M_WH5+BNJ\/V8C'E!^V,$QR]Z#K,V`C/-P/IVIR!P6PNK,"N,Y6.G=JJ=` M44[,,EQ(\&UEH0!3.RQ>XF:WT'V-VB"7"-V6U7C<'PA/>%H,D[MJI%4FD0T+`JNX=AO M:PC;S,\J7/`JC98_]FZPE16E#U`!C$_:,-`,4NMMJ,Y!>_5[1Q0-FM0PMQ,% MK495)NS>_1<*2WAKQ9>W'52*:.B/;&244K@=W`19XWVN>;R)G*2LZL<+(X[L MH8+3"0JT6#08J&,QT@*)`1F_9C-Z_MZU;$FT$N,`#X1CE.A,_M4^DY$C-K1" MGA11\9(M4;RH>"]!6JF&GJ"U!&4 M5&MCPOU91%(2PW6QBR-$3F$ACQ$L+>*@8SJ,-5&I+I89L6&Q;,?-*22RXY#W M(%12^O2-%D[]+2YRJ6XQ&STS/CF9)Q*\+<NTY4@8I/J<2`JJW">71ZCXY3J:CJ2,GWD[I/BK9^)7*F.52N3M3&\@O MC=N:F178_ACZ=R2ZOAS/GX*D?<37ZHKFU,F-%>0);'V2XZ) M3*H^N#;?-1`INZS@U/HGU[]8Y@\V4"'U`: M%NS9R;-RA[8WCX?O2&TLX_+V[/`6;94CUY]/IY/>3$GY8V^-F*1S(0I)_G;* MA5'=OT^J--4NB5-QX"BU@-)3RDIG)#D@ZEP$1>]R/2L)QJ,+:(L4LE`5-B!S M&Z"TELJSZO(X66Y2,&0(G=[CQAR[E]>@>ENZ;M\0N;0/$X\-I`P>M]0NZ_B_ M#=[C5?^>K_I5UU4GM?5/!KN'D[/@5\%P/H?_OW)0ZX08[FDPZ9\K`^&L?S:6 M/S]VX`:F(/PJ&/5'\/^OW6/YQ]__)_S(_]]E>>XRXIZ\^'AS46+0G?$1D%U# MH@X(4.PU(2:VY#S>/68=.'IRMKL968BUIF8Z\3M%<>Z_+)SZ)W,0#IKZ;RZ0F4C)"TQ["%4GE)#J MN:-\?H^,>I646!F3F!A7_B1*292:)'?IE[`X]?(SRWDY9XPAQL]T*=^P-/*2) MA5Z)A-&,TAN/0-V8S-54RE9]]2$,SL[#V6AD/8FT@LPNO$:6RG@\(UN\/13> M*23CN=BS-3EG,!F?OY[5F8)B8B5CV64$ZM"*>`ODQFIG*'EW1U33I(`5+6;: MAL21W>-EA8O`^-Q"[N.2"Z;S-95*PCQZK`:*RU9$JQR)&-'+B6 M_--$FFR`'W/#FGVV0*Y!UQBS':Y"'8&I6@L*D267=*?\32@9A:>%_[!X MKZMD,Z&5#J]O2X]!H]DK1,*58$Z9@5MS':.H+GE;82?BJJP3A M1MCYV<$.!9F;9O,FI7TYXH2ZII)H9X)4P[R=AFI3GMT?+V MJ;F*I5()@YV:"+FCLV>B=2@PV1+!9)_ZVP$(#8&&TG7.EH%^*^P`E_(S1A"\ MU[$>$@30\N>SL_$U[O`-[O![/FIVQG_6M\GGB1^&9Y-9.)^.T5T\[,^-.YYQ M[&4P[T\&RC-],AF-P]GY&+W?6)UU;CO&)V?A<'1.CR;]R7#OQ!.8F)N+G>'$ MH_Y\IN<`Z36C[F#\ZG#W'(G,V?XHW9VZ7)JK]O M>6WD-O]$'II!?ZQ-:\=#81P.AV=/A8.*/N?@)E,H'D.X?P9(H.HBW?,..EUN M#GO=FA7A?MX6UQ([-'&$:E&NL+^6P*`910*TS005'NEE1+YHOR^S/'7A^ZD> M5BDB#:J$#\K3;X$FXS1[U.'CU67S5U#Y'"A/.!N?X MW\FHK=^.@%:B#CX,)]-1,(/__5DYEF!25);A!?Q/9P^6@T_?!>1N'P;$!!3//@+!P!1*?A''9U));:E<#U>K%(E=T3T%US`MR!U(O]YBZ$2_BZA[% M=E\U72Y9JZ>BZ![5^D%7`X`'G/QK+'N**C`+8F'7FC(J8H<=?JUC57:-JG"DZ!'37.@8-=;XJ,+'G1ZJ0R/[N2C,7U0#G=4W)M*8+ M3$(C%2"S9\VB,+]VJDTSTZMT[1=8:,1)80@\5]#5:U2+3LJ.Y>%SW]YU]2UK M]:&P%D#^O]8253RO*ARVY@(>JO24A7VFA!BS7NM1$0/4LV"#FD6C9Q&KRRE6O<3@ M-ZM,7R?8"2M*&"NB.A!D9*?6X\JB`&PQ_D(1C;@]#K&F"D6'5NX>G)$EUH@& MG,(S1=][P76>:&7)71UA'HZ%*K_CDE MI@1Y1'2R*E*"#V=7VK6[FTTFS#STZ04'R7^DPH)X;F^PU_QPT/N#J<^N+J&` M]$&*E:=HW&:35*;HZ*5R&2Z3-EG?^_)QE'[_$&XUE?UUWD;3H$?;Y1[(5B4M MA,@$8QJ#$EWH,3;]I(N"?99+N#5"./D[FQIT?PFGCC)^%;`%Y'OE368W9##]#-Z%*>J+]:E2-? M^H` M6\3>LBKDO36)@O`XYC0CJ]&:Z?!P\@*[C+\X%;F4R\&:Q209&:OU3K59$QD^ M&OO5=5;D_8_TFI1E">9J"S>F?1`^OU(5'2]U_2I8R"K($3DCN3:::H+]_"]/2QO MG:2Q!3S8*#X7T_(LM"*W'X&/I",$J5C-ZZ#RPI:#^`&&%Z*X9J M'_D6%#=V>]@=0?`J9C&V?L9+1G9U+E6/EE0I?WY,%^4F+OL->>&^\?Z#+"M. MC:.]ZV!O6WG'3;X?*+]8U(),Z!0F15874C>HS#=VVTZI2"G,Q"YL%JE#GQR. M:=(`W*3005'R[D$UFA!#80ENHU&:57R'^WO&XDVMN.(T%_GE6J.L_6GQ--TI M+P$6EM91S1*@XBL/_&A#DW1#4]B;4"6N%75;_**=BVI*9NM:-55SDLY#%('< ML3N=/>)V?2X^HQHE5S)<+7?L711\EZ=I M%%P#!FV`Z]=4*L^JOKHBI>_^#M[:]?)[5)JP:U.R2JCC,N`$&@\MODR`ZRV5 M4\RNT4SY3DPS2HO762F\3.G-_MM*`)5;0&D<_[@RS>2.?K&C<2L2UKOD%M/? MN48(K`7MJ0P_D87@I)')[8P?3`5OZW`*E-U1OR.5TRD/S0A(Y,1J@B*=\N]AB^%2&L!J3M4J"J'6,I5:\=UP]BP1+RKR*[(-308+55\#.FD+%.P1XZL/M:< M`+F.)8JPB[1;]/76VDUG\&-7BZ6`J)$KGB#VBZ4X*O;AM!&2 M:Y%\-"T=CGC%USP".JLJE+IG,#2A,Z4KCJ%C"\2)K8V-C7'T;G`Q/D3&4 M=43"2$Q1."O-4E:\8E(XW8)+J,K57A MHJV8&P5I6`,*P<7.;72C`IKH;U[53F0\KIU,%$75OR6YW:D-U)P='3*`(0+: M<@ED%1=YGQ>JA+#N9F\'FJYC[),-)$=5F2XX75HR#E9:'"[9L](WIZK=0H-!?&)TB?- M55W!7R=2[(MKP_WX-&6<@PP5B=7K07OI,`!I+,E4E)@S#*>CN5U"[1BUT@J+ M$K,$)4P&]1;0`L4%J_VY7D,'1BL#9!.#5;>X#1+QE<3031MFM`V6O44*V-HQ M0Y(K[)/=DW4N[;0WF9T81TJ6#L8OC5EV^2N)]$^12%F':IU[V#A8]499P0AB M?P'J!72SU(RXL>6^H396'("/G)#6&*_^D^_F`^$VJE$KM-MY.M.W)W:OC[U7 M$@4L[BAB9#]XNU9X2[<62<)&ZK&3'Y+[\(1*S1*CC/5(1!.R=3'!L'K&*4H! M4DU2JGP*ARI%%NG#$I5WZ/I:V4C7T@T@)`U`L1%3%JWEQ?AZ]]2"S%L'JGD1P5\1!?#7F3 M2`YEL=ZN4W),<"&7J[9*C$I(/L,)>07;)`/]U]FVHWR-XNP$"H"BN-7>4Q>;8RQ$XQ#N62(9R$WT!@,, MB`@7]2T@N`G>RC/5P/[UQ8O3@+K,8DL5HCZV00^3"K502M,N(NK)]P8MII;/ MJ2XPA0DNA7$OD*K[)8FI0F0GY'`^UQW391O9E7YA MV[U\KCK+27DCW?U*+*[*IB1VBEW^I/QH-JP%:[_.L=V7*@H@EQC22=GMF>#67:K7G\7$`:DJN:?4D%3=/]G:++T:E8#:,'B2.>"8K[#FYST![XSC`9H7!1&@ZMZ*6DDX6GVD4C/1Y:[!^;ML.]AXTU'?H M[KI61?P.OX%X`%<,VPV1ITR7RB8;7Y0NQ1CH9.NUXJY-"9]G0LB\WOA M!K"2[B``$31,%0"7`JZ2G5]36$;!"H!/'`?):CJ1]X_/H''J_U1`& MUVBJ#7I)\:L]SJ;0)#`RH_TV]J*B#]`@(^F1P^JT=FP:C?';B5:-%7E.!CRM,HN;4 MI0L3J7JIXNXH\,F9J=4,GKO2,H4&R9),^YIMT\"8:XF(;L:/V2=-MO**JTN) M_(4N04PMHS:?.>S)+-76>SBUSPRX=!9\F\N%)=!(?V+=<]>I8IO(MRQ\R-OL,MEL05/#AJ41#Z=1$Q077>5YA+(H=7\E")K8= MUY9FW?890]L\D+/#-KCYN_$@\."`>8%^9I;JV[5TDGZ MIVU*/0LE*MYQ_2OL::SH)^F4?;A-=E+:;;%M8?7A#:=;':!U!^HC>D`W'*H/ MZ`;-JSJ^5D,V6ZD)75]$>UU1Q6V![0;. MBF"L2<56UMCV(5&.0(H!CSO7!]SBW5Y*65!4(DG*,N&)T;$426N_),2-H[7D MQ].#Q&WZ7!3W)Z-O)"$E4AH%630;170=?C&N&[AR0PPNYF(9Y=.=RI`4!<`J M#VRL^OKNF:/!07^#;V'-EB*N]@S)O+R%B1;7M14ATW7"G)*J'P+P2+BRM`U_ MP5ES13H#9F5=67SO[H_7637Z@OR,_./[:'<,^QB(Y_6Q:VU`LCZE-CM$F\HE)3<+P2F:%'LBTX2HBT32Q)MH+QBET/41!M M3_HMV2H>N&\PWI8)A8!S^A+W0$'>PKJB=%>2)N%44V.9&#T!N1F3@C(4H6;D MP2E5W2RJ[,*F'-\J2$6!TY'R*!A2N&9S`:QL0]G%;,5V[.^Y!42GCQC=*F%; MI7+H626EHD!%+W*T:&DWV*4\5(EM9^*'A+,UO2J2J"1ZS(56M9@HBHK],DG%(#:63AV M*H]=OU*W@XFHQPDKS:^C*FH,$'S=I-]2=M(_O]A*4X`7O[,.ZY<>,K_TD/FE MA\S/WT.F=?%M+`RM>K47IAYF\QN;!O]2OO-IY3OW$.(V+10JN.<\?JF9]?]C MS:Q]W-AR2?K*)[5PX9<:0[_4&/JEQI"=.X[,!4-43U['592D0,A[P>>;U\') M2[RQ"0:6"!XV/QTZ"-=\"F#<]QB4J;XF'\V'0%_TPW'K^B_OXE6=$@^]5.%D M$G`OX7[;*8Y",>8_.7KAG%SK+XR_?TV5IO7Y=Y,LX7EEQ4K4] M@)7E804/6X4BI(8GE5#..-L8+:Y/*1;P'G$1,>S4.C3WJ$(U,?SX/:A3/CGE M.ZQ^B98HWPD`]>AKPB'HL.^=R1'OJ'%X:<>,YG_3QHZN>56>64AZ1]7(0MN' M'Q^Y\)-0@W(+TD]`:F1KBAP=CIPYK((%&G$@%A]!S''"0O;&='@Z?W-%Y,CN M(O1O@1]`EZV4\^8;WP.=VM2;3JR_.B([KOG-B"6^UE31U[U3G?D_4_J8-H/V MM(+-[:H>3J_<[S^9#-^]^/`JR3&,S["L5_T_]3MW\TEZ#"!]J*C^4<5ERHMF M27)-.9I#@':RBG;M^]%ALNB@!M]8%.`S=W_?#QTB!ZK:[]$W5=UI,Z'_FXOZ M5M_9_73@8EN8T?VOO(D7L-3YOE<<&D'Y=(=6Z#"D(W=E0Z+-ISP$S0RX=Z@C M]O20[73`R#Z32<XMS>=T&OFY04 MCENT[).Z7)GXKU,@F-T'\.>G-G?<-_CG3.5A'5&Q%@;RQ)`I;['2[0.WRFP' M-08M4"DEHZF?KCB;T7T*V_4C6^T*2_^7OO5K\5D!R^X49<+VGUJ'E='&//)N^G=81DL_=@D+DVI+,`(&@KB^.'DWP.\_&`83@3?'S+)(^`^/.N8 MAZTWV`BQZU/!:1TUH\9ZX/JPWAA M]6%\+9XN!H,-XP?#A4KJ4U@%!M`"J6O1N&E_,&C9"!^SK$_W>?=)#P:^:5J^ MC4Y9FM_94H,0%`+;$_B/^EJ7#^^._V_S]"K'0*:EKK M\YB/F:28L/$F27G(6`^XNRW,USVG#.T(]Q&/YUG&,=`;CQ]$0!Z\@.<\@<^8 M;-J>X3#B.P1D'W0>Q*XZ!GU.-M8UATX^>]2H=G&34K_8I^2#; M,>R;SH$>_,'1,W>VIC69$A3%EJ90!S(G*Z`T5TL,ZISW38DEY&>[T73[9H MA":HP(ZP^,O'/$W1"XOOM`5NZTT3)R=E9T(E`-@]"H]-4?4J,:AN/^.8^T-> MGG4J'>GRK*-JY_BSCFH?JH0K_A0G^A-A;*C#%X*.\*ON0O4'T%D/W-.F+K<_ M>"?2/OC+0ZCYX`$M!'SPMQ::/?C;?$V6LV*\K*_8+?]Z#(?LBQAYX M5YXR](,A]\3!"QV5V.JA?;(KVN&IYV+K'2E3[_#,:^I]R+),^&/B6GY_2BRY M,"+*:RN)\S@2\A,`=M_P1P/(CDU$M+N&^JQ-.K8P1X*N[D@Y5PAY=B+D_M6 M\3`6>#@Y\ZGTP_G<][,W7K+#WAL,!]IA,_=";-8$ M[,@/V8[(R]::^Q./;:(_:O_HAFDVGW:;^WP'8$=.L*Z72G]@%;P-/(CBWI+ MC2,XI^R#E`F(,H,][_-,R0.M&,[]SP+>EDC9C(CE4-ANMN"'IZ-K[@/KWA>MP]S[GGL*>U^]:M"]0^]W MWJH#T;!>S?=`6(BR@NF\<%VGIX41:9I+<:@/>*VUQUK\&)=D/]CGR7H2?3SFEGK(_(B[4/?=@('-Q@GE7+.V`Z M"OC;/GGL6I_NXRK(WQC MVN%>OBCBB*QHN$LF\']=MXR0GQ[&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$" M%`,4````"``D/F9'=KUQ_4L"``"0!P``$```````````````@`$G!```9&]C M4')O<',O87!P+GAM;%!+`0(4`Q0````(`"0^9D=N7MP97)PC$`8``)PG```3``````````````"``0X(``!X;"]T:&5M92]T:&5M M93$N>&UL4$L!`A0#%`````@`)#YF1\@*+EE>`@``4`L```T````````````` M`(`!3PX``'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L!`A0#%``` M``@`)#YF1^4@Z.-!`@``C0<``!@``````````````(`!Z1,``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`)#YF1[9V/)4J`P`` M&PT``!@``````````````(`!M!P``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`)#YF1TH.H&R=`0``K0,``!@````````````` M`(`!$B8``'AL+W=O4G``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`)#YF1\,M:FN@`0``L0,``!D``````````````(`!D2L``'AL+W=O&PO=V]R:W-H965T+6)7H-`(``!D(```9``````````````"``3\O``!X M;"]W;W)K&UL4$L!`A0#%`````@`)#YF1_8`#.#* M`0``X`0``!D``````````````(`!JC$``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`)#YF1Q@I,9T<`@``L08``!D````` M`````````(`!63D``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`A0#%`````@`)#YF1V][Y`0``W`4``!D``````````````(`!O4D` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@` M)#YF1]U*%5N$`@``0PD``!D``````````````(`!@U(``'AL+W=O&PO XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 R9.htm IDEA: XBRL DOCUMENT

Shareholders’ Equity

9 Months Ended

Sep. 30, 2015

Equity [Abstract]

Shareholders’ Equity

Common Stock

2015 Common Stock Offering

2014 Common Stock Offering

2014 Reverse Stock Split

Amendment to Articles of Incorporation

Preferred Stock

Share-Based Compensation

Stock Options

2013 Equity Incentive Plan

As of September 30, 2015, there were 1,613,525 shares available for future grants under the 2013 Equity Plan.

Share-Based Award Activity

The Company’s stock option and 2013 Equity Plan restricted stock award activity for the nine months ended September 30, 2015 and the year ended December 31, 2014 was comprised of the following:



	Outstanding Stock Options and 2013 Equity Plan Restricted Stock Awards
	Shares Underlying Stock Options and Restricted Stock Awards		Weighted-Average Exercise Price per Share	Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at December 31, 2013	54,000		$6.00
Granted	567,876		$9.88
Restricted stock awards vested	(2,976	)	$0.00
Outstanding at December 31, 2014	618,900		$9.54
Granted	942,285		$23.83
Exercised	(42,535	)	$9.74
Forfeited	(24,465	)	$10.19
Outstanding at September 30, 2015	1,494,185		$18.54	9.21 years	$	15,765,631
Vested and expected to vest at September 30, 2015	1,494,185		$18.54	9.21 years	$	15,765,631
Exercisable at September 30, 2015	211,408		$10.60	8.67 years	$	3,643,505

Third Party Share-Based Compensation Expense

Stock Option Valuation

The Company estimated the fair value of each stock option grant on the grant date using the Black-Scholes model with the following weighted-average assumptions:



	Nine Months Ended September 30,
	2015		2014
Volatility	147	%	188	%
Expected life (years)	4.91 years		6.73 years
Risk-free interest rate	1.4	%	2.2	%
Dividend yield	—	%	—	%

Restricted Stock Awards

In August 2015, the Company issued a fully vested RSA representing the right to acquire 4,000 shares of common stock with a grant date fair value of approximately $92,000.

The Company’s RSA activity for the nine months ended September 30, 2015 and the year ended December 31, 2014 was comprised of the following:



	Number of Shares		Weighted-Average Grant Date Fair Market Value
Unvested at December 31, 2013	1,746,853		$	11.80
Granted	2,976		$	8.40
Vested	(423,693	)	$	9.18
Forfeited	(47,129	)	$	4.41
Unvested at December 31, 2014	1,279,007		$	12.86
Vested	(188,414	)	$	12.30
Unvested at September 30, 2015	1,090,593		$	12.95

Share-Based Compensation Expense

Total share-based compensation expense related to all share-based awards for the three and nine months ended September 30, 2015 and 2014 was comprised of the following (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Research and development:
Stock options	$	636	$	98	$	1,609	$	142
Restricted stock	240		147		1,452		652
Warrants	15		—		40		—
Research and development share-based compensation expense	891		245		3,101		794
General and administrative:
Stock options	1,443		286		2,950		575
Restricted stock	545		1,212		3,719		5,226
Warrants	182		—		573		—
General and administrative share-based compensation expense	2,170		1,498		7,242		5,801
Total share-based compensation expense included in expenses	$	3,061	$	1,743	$	10,343	$	6,595

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

+ Details

XML 14 R8.htm IDEA: XBRL DOCUMENT

Contract Revenue - Related Party (Notes)	9 Months Ended
Contract Revenue - Related Party (Notes)	Sep. 30, 2015
Related Party Transactions [Abstract]
Contract Revenue - Related Party	Contract Revenue - Related Party During the three months ended September 2015, the Company entered into a services agreement with a private company that is a related party. Pursuant to the services agreement, the Company provides certain services to this related party, including, but not limited to, research and development and clinical trial design and management. In exchange for providing such services pursuant to the services agreement, the Company receives payments at a negotiated, arms-length rate. As a result, the consideration received by the Company for its services under the services agreement is considered to be no less favorable to the Company than comparable terms that the Company could obtain from an unaffiliated third party in an arms-length transaction. The services agreement may be canceled by either party upon 60-days' written notice to the other party. Additionally, the Company anticipates receiving a non-voting profits interest in the related party, providing the Company with the potential to receive a portion of the future distributions of profits, if any. During the three and nine months ended September 30, 2015, the Company recognized approximately $647,000 of contract revenue for services and costs provided under the services agreement.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

XML 15 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 135,055	$ 48,555
Restricted cash	237	37
Prepaid clinical expenses	360	1,528
Prepaid expenses and other current assets	484	137
Total current assets	136,136	50,257
Property and equipment, net	1,751	279
Other assets	57	0
Total assets	137,944	50,536
Current liabilities:
Accounts payable	2,567	730
Accrued expenses	1,145	926
Accrued payroll and related expenses	629	424
Total current liabilities	4,341	2,080
Shareholders’ equity:
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 18,241,509 and 15,225,980 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	2	2
Additional paid-in capital	643,651	528,353
Accumulated deficit	(516,693)	(486,614)
Total shareholders’ equity	133,603	48,456
Total liabilities and shareholders' equity	137,944	50,536
Series C-1 Convertible Preferred Stock [Member]
Shareholders’ equity:
Convertible preferred stock, value	3,906	3,917
Series F Convertible Preferred Stock [Member]
Shareholders’ equity:
Convertible preferred stock, value	$ 2,737	$ 2,798

XML 16 R6.htm IDEA: XBRL DOCUMENT

Business	9 Months Ended
Business	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business	Business La Jolla Pharmaceutical Company (collectively with its subsidiaries, the "Company") is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is the Company's proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is the Company's novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia and sickle cell disease. LJPC-30Sa and LJPC-30Sb are the Company's next-generation gentamicin derivatives for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. The Company was incorporated in 1989 as a Delaware corporation and reincorporated in California in 2012. In September 2015, the Company completed a common stock offering and received approximately $104.6 million, net of issuance costs (see Note 4). The Company has a history of incurring significant operating losses and negative cash flows from operations. Since January 2012, when the Company was effectively restarted with new assets and a new management team, through September 30, 2015, the Company's cash used in operating activities was $36.5 million. The Company had available cash and cash equivalents of $135.1 million at September 30, 2015. Based on current operating plans and projections, management believes that the available cash and cash equivalents will be sufficient to fund operations into 2018.

XML 17 R22.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Narrative) (Details) $ in Thousands	1 Months Ended		9 Months Ended
	Feb. 28, 2015 USD ($) ft²	Jan. 31, 2015 USD ($) ft² option	Sep. 30, 2015 USD ($) ft²
Property Subject to or Available for Operating Lease [Line Items]
Office Space			3,713
Approximate total lease payments \| $			$ 300
Twenty-five Month Sublease Agreement, Expiring March 31, 2017 [Member]
Property Subject to or Available for Operating Lease [Line Items]
Lease agreement period		25 months
Area of space, in sqft		4,047
Total lease payments through the end of the lease \| $		$ 93
Number of options to extend lease \| option		2
Lease extension period		6 months
Thirty-two Month Sublease Agreement, Expiring October 31, 2017 [Member]
Property Subject to or Available for Operating Lease [Line Items]
Lease agreement period	32 months
Area of space, in sqft	18,599
Total lease payments through the end of the lease \| $	$ 1,466

XML 18 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 19 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation and Use of Estimates The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission ("SEC") Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2014, included in the Company's Annual Report on Form 10-K filed with the SEC on March 16, 2015. The unaudited condensed consolidated financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the condensed consolidated balance sheet of the Company at September 30, 2015, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2015, and the condensed consolidated statement of cash flows for the nine months ended September 30, 2015. Estimates were made relating to useful lives of fixed assets, valuation allowances, impairment of assets, share-based compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ materially from those estimates. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the full year or any future interim periods. Effective January 14, 2014, the Company effected a 1-for-50 reverse split (the "2014 Reverse Stock Split") of its outstanding common stock (See Note 4). All common stock share and per share information in the accompanying unaudited condensed consolidated financial statements have been restated to reflect retrospective application of the 2014 Reverse Stock Split for all periods presented, except for par value per share and the number of authorized share amounts, which were not affected. All stock options and the shares of common stock underlying outstanding convertible preferred stock were ratably adjusted to give effect to the 2014 Reverse Stock Split. Certain amounts previously reported in the financial statements have been reclassified to conform to the current year presentation. Such reclassifications did not affect net loss, shareholders' equity or cash flows. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of La Jolla Pharmaceutical Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity from the date of purchase of less than three months to be cash equivalents. The carrying value of the Company's money market funds is included in cash equivalents and approximates the fair value. Restricted Cash Under the terms of the Company's credit card arrangements, there is a requirement to maintain a collateral cash account pledged as security for such credit cards. Under the terms of the leases of certain of the Company's facilities, there is a requirement to maintain a certificate of deposit as security during the terms of such leases. As of September 30, 2015 and December 31, 2014, restricted cash of $237,000 and $37,000, respectively, was pledged as collateral for the credit cards and leases. Property and Equipment Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from two to seven years. As of September 30, 2015 and December 31, 2014, the carrying value of property and equipment, net was $1,751,000 and $279,000, respectively, which was comprised of lab equipment, furniture, computer equipment, software and leasehold improvements. Depreciation expense was $114,000 and $209,000 for the three and nine months ended September 30, 2015, respectively, and $5,000 and $10,000 for the three and nine months ended September 30, 2014, respectively. Revenue Recognition In accordance with GAAP, the Company recognizes revenue when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the seller’s price to the buyer is fixed or determinable; and (4) collectibility is reasonably assured. The Company currently recognizes revenue from payments received under a services agreement with a related party. Under the terms of this services agreement, the Company receives payments from this related party for research and development services that the Company provides at a negotiated, arms-length rate. Clinical Trial Expenses Payments in connection with the Company's clinical trials are often made under contracts with multiple contract research organizations that conduct and manage clinical trials on the Company's behalf. The financial terms of these contracts are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Generally, these contracts set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. Payments under these contracts depend on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. As of September 30, 2015 and December 31, 2014, the prepaid clinical expenses of $360,000 and $1,528,000 on the condensed consolidated balance sheets represent the initial upfront payments to clinical research organizations for two clinical trials that commenced in 2015. The Company amortizes prepaid clinical trial costs to expense based on estimates regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Expenses related to clinical trials are accrued based on estimates regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the contracted amounts are modified, the accruals are modified accordingly on a prospective basis. Revisions in the scope of a contract are charged to expense in the period in which the facts that give rise to the revision occur. Research and Development Expenses Research and development expenses include salaries and benefits, facilities and other overhead expenses, research-related manufacturing expenses, contract services and clinical and preclinical-related services performed by clinical research organizations, research institutions and other outside service providers. Research and development expenses are charged to operations as incurred when these expenditures relate to the Company's research and development efforts and have no alternative future uses. In accordance with certain research and development agreements, the Company is obligated to make certain upfront payments upon execution of the agreement. Advance payments, including nonrefundable amounts, for materials or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed. Acquisition or milestone payments that the Company makes in connection with in-licensed technology are expensed as incurred when there is uncertainty in receiving future economic benefits from the licensed technology. The Company considers the future economic benefits from the licensed technology to be uncertain until such licensed technology is incorporated into products that are approved for marketing by the U.S. Food and Drug Administration (the "FDA") or when other significant risk factors are abated. For accounting purposes, management has viewed future economic benefits for all of the Company's licensed technology to be uncertain. Share-Based Compensation The Company accounts for share-based payment arrangements in accordance with Accounting Standards Codification ("ASC") 718, Compensation - Stock Compensation and ASC 505-50, Equity - Equity Based Payments to Non-Employees, which requires the recognition of compensation expense, using a fair-value based method, for all costs related to share-based payments, including stock options and restricted stock awards. These standards require companies to estimate the fair value of share-based payment awards on the date of the grant using an option-pricing model. See Note 4 for further discussion of the Company's share-based compensation plans. Net Loss Per Share Basic net loss per share is calculated based on the weighted-average number of common shares outstanding. Diluted net loss per share is calculated using the weighted-average number of common shares outstanding plus common stock equivalents outstanding. Outstanding convertible preferred stock, stock options and unvested restricted stock awards are considered common stock equivalents and are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Common stock equivalents are not included in the computation of diluted net loss per share if the inclusion of these securities is anti-dilutive. As of September 30, 2015 and September 30, 2014, there were common stock equivalents of 9.1 million shares and 8.1 million shares, respectively, which were excluded from the calculation of diluted net loss per share because they were anti-dilutive. Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company's net loss. The comprehensive loss for the three and nine months ended September 30, 2015 was $10.5 million and $30.1 million, respectively, and for the three and nine months ended September 30, 2014 was $5.1 million and $14.5 million, respectively. There were no other changes in equity that were excluded from net loss for all periods presented. Recent Accounting Pronouncements In August 2014, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This update is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable) and to provide related footnote disclosures. The ASU provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. The ASU is effective for annual periods ending after December 15, 2016, which for the Company is the annual period ending on December 31, 2016, and interim periods within annual periods beginning after December 15, 2016, which for the Company is the annual period ending December 31, 2017. Early adoption is permitted. The Company does not intend to early adopt this standard. The adoption of this standard will not have a material impact on the Company's financial position or results of operations. In June 2014, the FASB issued ASU No. 2014-12, Compensation - Stock Compensation (Topic 781): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period. This update requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. This update is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2015, which for the Company is the annual period ending on December 31, 2016. Early adoption is permitted. The Company does not intend to early adopt this standard. Entities may apply the amendments in this update either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of this standard will not have a material impact on the Company's financial position or results of operations. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). This update outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. This guidance was originally effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016, which for the Company is the annual period ending on December 31, 2017. Early adoption was not originally permitted. In July 2015, the FASB approved the deferral of the effective date of the new standard by one year, but to permit companies to adopt one year earlier if they choose. The Company does not intend to early adopt this standard. The standard may be adopted using a full retrospective or a modified retrospective (cumulative effect) method. The adoption of this update will not have a material impact on its financial position or results of operations.

XML 20 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Common stock, par value (usd per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	18,241,509	15,225,980
Common stock, shares outstanding	18,241,509	15,225,980
Preferred stock, par value (usd per share)	$ 0.0001
Preferred stock, shares authorized	8,000,000
Series C-1 Convertible Preferred Stock [Member]
Preferred stock, par value (usd per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	11,000	11,000
Preferred stock, shares issued	3,906	3,917
Preferred stock, shares outstanding	3,906	3,917
Series F Convertible Preferred Stock [Member]
Preferred stock, par value (usd per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	2,737	2,798
Preferred stock, shares outstanding	2,737	2,798

ZIP 21 0000920465-15-000077-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000920465-15-000077-xbrl.zip M4$L#!!0````(``\P9D<;6.0OWJ(```*T!P`1`!P`;&IP8RTR,#$U,#DS,"YX M;6Q55`D``TZ(/%9.B#Q6=7@+``$$)0X```0Y`0``[%U;<]NXDG[>K=K_X/7S MVL:5%U?&I\#;K.JS/^YBXZAUCVEW^MJ>[:."?IW\>@>!!?.Z%HR")GG\Y?DB2X?G9 M65IT&DOO]#[\<584GA&$Z0G")Q0?E\U&403C7-2N*$T;LFK#GO3GMX&".=7E MD_=F1[*,ZAT`K5DY'OC=J\WJC:(9'_A>)4S*"TKQKXW?PA0,&<` M<3*,%M2'DCD-1O')O>L.QVWZ;GR7"5(4S($$E$3A0,9SVV0E\QNE>IC?*"N9 MURB)Y/U"/>EG4%Y630MZ,TMAK,^\L%(UF5N5YU63Z:K^2S`.XL0-O#$PGVI` M_DFSVEC7];.L=%PU[LVK"*_%9__Z]/'&>Y"/[J2R_WKED[$T8)G^XT/:V7F< ME7R5_:.L\_.'#'CIDCDIE\LI2')<%*<3\RUFMFZ*7(2RML%?I)1:X@XL25@B7+YB43;>006^JOGY" MT:3#WKAV^6S29?FDT-`"G5UF*F-77@+P;JK2<@`EN0HP@I4X?FM1LHX*G%P' MM!W#KR!@8\-G7U@;AL].,-G&[,/P_RP9`S>.K_HW2>C])9[\ M^,_4//UY`^^7L6.&0#*BQ+\;R&NP71*(4"^K^4D^WLGH/94Y-BWR/A4[?Y8_ M[$'G3\.![_E)+M=1SXSN1T6$I[516P]!LRK M0!X<#)88=.N1`+Z@0T*KD+`MM_AF)'1^8:\P4`047UH44*@[#B@RG;$6!6'L MC4$8VY[.6H,S]D:<;4MG>;`_-M%?Y2!-M%Z#-,^WD1O$KI>`28N-Y^F2BFEQ]T8;<7CGJ[IKIIF8]Y`,I]6:K?PMT9S]\" M_^^1M&3L1?XP5>R>D[]E5=`L+MA(<+%UP%6IG2L9"Y`,5Y5[&22A&3X^AL%A MX&T=M;PC!)M"*C9@W_8II%G)N.TVPMD_R]:YS6:ZS:;8K`V`J[-9':QFBR' M-=DYV\=@%H'VI'\VEZ'5*2VF;Z&T4)]M8YU\Z;8_VKG]T9!]6K;'^[250&I; MBT[\=*/>[?.PZJ#^<"/`8H&@\=/+P`L?Y?ACYQMW((O/W4UF^UO0D]'/R$_\X%[<1S(+ M9-HWT0M'6_\/OC2#*G?8C MYH,O^XX?N('GNX.K?M_W9-0^;&W:B+RAZ[GZG3BT%Q3\OJAF;T0UVS"JBZ]. M_C8:4+R$Y1LGK:ZOV@?'%TS=."]5CNL=XP^D;CC^*'(*EO32OTR,RL"-XZM^ ML8%V%7WU[Q^2B>GZ-7L:M#"9N'!@A1X-$C<-G*@YOFI\N/)%96^KV=Z$W*S^D3;QN[R=-0]WC`HEOP,)2^^,`U+ M_96/N]=?:/\]`A69X>,P#."?<96.M?F+W0MU5J!L::5M"O(OZGR*HAWV]\"G MB5EC/S_96!X#YGMFI?\NXRR$'=<#P#]+-Q)!X*>?J`=6F,Y9V/\U:J4/6XH$ MC=6RJ;4\I=6BGR74>G@,;%TVWJ'X[52^0_&F44RS!.GVLU^6'TDO":,#PW[S MHI"RN#HAA[+JZ!MSSG0[.>>U5]TAKX&]0T1M&[++U;9^XS$/\YXK]+#;?&S. MYN,*YS[51M.OCDEMC4EUI&;9S)88W;E<8T-Z(`6TK!UF6P,"UC/IA M].@&GKQY<",9S]BX[OC+DJ!;H,A-F;[FI;L;<.BF&:MLYX>YD@8+K<6++?-V,U-Y@$MMYO*P+C1K/C]L0)"T\VO+UKC?X;"O?6KL MO>4-N&KJ_>^PZ,QM9VY;DOW?S='C#KIM#RB;=-:E.\*[\YMCMG"4Y]W(X&%< M[[U[*KCS:[ZW2P0+N%8O_%@%LTML[MA/TANE-+JU-]CL`J7+;,S,U^Q[XG([ M/_;%O[D!X2>$.]\KQ^$W!]#6QR@-@N2N@Y/L3![A2Q.\F?J;(W@9;#M^UP1^ M!]$JV;1=VLD%.HO/0'P;AD%WWF%G-FRM$PXS<_>^F9Q&7.FSROG][@!S=X!Y M/9;0C)/[KW\%M#N]NB$^W)U>/<"-V48?W^E2(\WT-GN0FFGJX9[7%V+G[SI_ MUUI_M^N=\3R7GR:?IG<7HQ#>DSS?C.[^+;WD-KR*Q`_7'[@0"3AA=`6%;AJ4 M?I1N7%E6H(+G/MBM3]##`[0>9!7*6S?LIZ$?0;-/Z=X(Q="SVKZU\V;=C*&^ MHG+>,R./MY"1G\U\K8BMU#8\)S_#E[5WY24A*.?@P+6R=@XK>V2-K5UGZP[/ MUJWK>_&&4SJ78^M(M,X^'J)]K'K?:6NWJO<=!7X.KE'<`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`1K=T/=?%FI4I51Q5(<)T"(EX,44V\@TJB%$=$69HU&\OCKS'2412=<, M06;9R^Y'G@FQEA7,\Z:XW`1:N%%`),Q33PI1:&L5, M!W=>P@K3RDHI8R0R7W,O:62A&FM#6(RMW2:ZIVR+HE!%$]@PJ2(<1S549[(0 ML064\)J2!>A:,-Q-J*2[.Q@1H$&)Q. M`3Y+86!.P&F@0N+Y$KQ=0K#U"R4$.T\42]4`2S8$`=3044&B5%BAB,]*2!6T MO(!?Y2"ENM=I=N`6/%P,/<)R_2/R$UBMG\,$'$4_C&YEE*5_H"CLC^@?<,"K`$PAB.#9Q MB.JHV-0!-Z:%L&XH0JOY`8S9QC249CGNP-/UTB-R8*#SW[FF$<=])OO=\Z3* MM?N2*HN2/)OY?-5":DD4 M$UE,P[IM:+`6.:%&&=;:S*3&W+"V#,-VIZ(-3%.JG9JOW)"VQ^K5.='!WND: M(Q8BMB$TH96Y%LLV'?")&'U?5YWE4-Z@E7C1NZZ2!V"E#VY0A`AI0"U!Y3G- M^T.F@;7L"8A0(:RVGV":_%A>1^"NZZ0C_YG*-/C(M&YL8*'-:6"FV=7%/=G+0Z>3];V#84Z47*0?LF0'A%(I$#)"DW[W84JS=AMT1 MO*1X6[=LQ:28.U38C!B68I4H48E5#UP41I7"\JTZ@L$@O6E&]C)W;LRZ_(7^ MB+WL8U5.!-*XS86E60K(2#4BP.=R6Q@*"%Q#D,IF)F(IN38XE%=^"U+>AYL3 MYHS;K'!/TG*79BY2JF48I@TXX"D@%"`OP*E3I5(&P2XC-:4233D`G2YS]]3" M]6:KJH$L"BM-($M5.$1IJ481%DPS])J?T[5&*_2];G5=:("!=1J*#?Y8<`L3 M)(@C,H`ZC@"PBMJJ)U!IOQ6Z#CJ)IJ6')@C6#,,@#J;`Q3)T6AICV'%JZF1J MH[59$-KWAZ5.F0&L59@JN!]F&")W1LS@P`_4FA[W4H7K`-&B'#B@RCDGA.G( M4K"9.1YL:!`0.*21"MP^K@Q@\1J0>IM0$PFD@O%#&O8=L\;XCVTC M1ABZKA)'I1#V(F9"S$-XJAJBHRFP`\:Z:>2FS0JB!B`4,2\>`=`LF MEECI2!08BL&4^A8+UW<\E!8P669Q#:O"01`EZ$0E&&+WC"@(S4*.4F.R7#T$ MG:ZSX+"C4&XXE#H4%*@BK-LYDU6%39A6BQPQVR7S6O<2C.TC%`LDA`W*4VQL M82<+NS+.P#6@LV9]"Y',)FSV3J%K!5HZ2K<8%9:>1=.$9>I.!D_,@)2!LZA; MT6;#-V+U6X#A#34Y$VQEAENFHB M73,XUS-B@@UJ4,(:J/+-80;LD"W M'OPXNFYPA^K8)(9J":*BC``2DZI@TFJ(476V*\V\LO%)S?PPN`/D@&@*%8IA M9I-L4489KFV7`!1V-LE+74C7!"KK*)I*58,HX,<$\"TFN)%168*I;HK:SBMF MN\MTOZ-2UUEQS-8L00V>IF2IA1CA=IIN$([-5Z,>K7IWL2%W$SA MIF)K#M-`O88M@/$"IT"$()V:*JG9?KJS),92VMYUY&"#;:7$9II%J$XXH\#4 M,H-@.C`"O4;1^.Y2'^^DS[7B6DU'E@%T1#,L1\4*6-O,^R*AZ39E]3TOAAJM MS5T%#HQSINC:_[-W;!8!V;OVUQ2^ M60!V9CL>LQN5DQ3(2>-!:09')>FG1#A"@*2Z*@YX+T?[`H\L`*CX]@`O@#>: M*GR7K,"E2M&E_K%*@GLO)_7X'= M;XQ,*O&"(X*"5,%?MB*6=>V0JPP M0A;3E$(]:81PA_C!<$5!2KR+J@MKE$ZQR=IA;*J,>56Z0 M)5]GT@8T,7-86XN+5E!+6Z>L[Y\S+8.(]VS2=QYW*=ZW"@BD1P7HI5*:KP6V MMK3:HPGO*NYZ_R\V4J]ZO+2-"E,$%+QK5PA7^@0D.@"B'+SO[?NV@1?C65"I M2*$S%<,F%79U;8'@7:M3E_8$_79/-J\RYUM%7D99((JID(;L&2&OJF)Y7V8M M^2]]5;)[W[?_&T5>)H7H`1D)0N'('RBL,#1DZXLI'11\TS3`9=]NE*_]7GQ! MYZQC+%;%C*O("Z-VV?0/%/+MWOX/,,Y194CLP8"BR46J9)S-AE:FD92T4;[+ M)"MXNV>M@6G>.BE,;#,3DU\1['"D6ARTT,M0Z9/"]O@]=?MP\_7FVVH^Q?\L MOCPN5XTC^=]?OCU^77PMR[M?ZR<\/JP^X.//^7IY>W/[RWUK8/2_UE:>5]5W MO6R%IOJ$;H#!F/)VV'L>;+>@"ME@NKC_^_/?%];=\7SU%(W@98QIZ:\KC M'?Q5!3V)H!F6ZB@H*%'6AD4`4OCR-#WQ5P$:HA=&W6&"@^WT?AB9Q%90;YVW MT124.FJ%V6-H9D+E>C-IH=V^5KJ_7PQ:.><;RXQ55-A#&!19&:49R;5^.*]5 M%UH8889/DJM_]56"3/6'B60\2%TSK5)A?18MK3'/4^Z+44$YTOIUDAS4UIA\ M\>PNO%`%4#I>)Z-;PQJ+VI?)"6GZR@RT'!-YCG6%:(>,(XV^K%^C,>9MU)@Z M`X:PVSJ/'D_D#PSVE_5^2(NG/_$H M6Z"RA/*Z9+F&)YX1:5_CK%D=^0J%QL4[H5XS+P2Q<&`+VFHP?/])&Y)332\C MH:L80&L&H.MPO9[;@M>-PD^9TAIT+;\S7KM;EL>'Q^6B$42-[L&S,.@42:4@ M!92,2'56F:^\QJ`3.:X=`:-U@SMX:9=]U=MEG$_7RX_+59SZ=;7I&UR=]2S; M.JEB,26;.()(BBBKH-?!!FD9U.`5?IN:I8X4V4.RXS49.)=M33+I1#JX*)QT M%"O3UAH284P.Y04T&5(;[;D6O%.L,U)CR&!%YO5`T=;"AF)']M=3K+-]\G;+ M<[CQ62H<-#0J?4 MX.+6F4+M!K,OR8)Q&`*?'BRXO@\H!:,ZLHLKT`SQ_SSFF6DVB12,9V\>2`L+ M4EK?>,\HD0I="N8*&'W]N_;=[YVKO4 M\T]SV+JXCU`?_.#3/MXOU/W'#J[MMK[F2&:$T6F`OKYT!%='DEG8, M[,FGNDG_"*8IA]K%H6&0830I4S+#.P9)99/(+#V1W+#TY>S&,>_OK(F4V:_[ M[(T3*7JA*M7;ZJSQM4==[OVG`)A4+8REHNRFZ$;Y9^`-M MIB-/6BS.6JLK:84NT0FE4DM]QH2Q9U[V^6.GTYV;PI7U MV*!^;5S[_1+&(648E*BJ:B<*I`FZ>1 MA%]"UBUG7QBQC10E:^=.*=],T.M=9,/%D&S.'+`Q'C+KJ(X= M$1^MD;D::ACS'BO?E/V"S[:.<0VZ!I[\E^`W4:>0(U-SA#/#D&A"OK3@@/3+ MS:JT:^^M9V/,E:!"DG5%$/(FS*WXS$3HLDW;3]4O_^G]9)JR%^^R0HS'E`T6 M2#O2L)Y&Y9,CZ@E-Q2F$FMED)0$?RF)D;:[T[*F%5LU0P=O^$(`^D513IO)> M8\;LB5VA<%@*R&8J#J!['BZOQ%_4BUJS&:F.UF!BO@<65<=CLQ_4REI1 M,^.R9=:$&W)KO]``_F+P0AKT6UANH=J$`9*5(:RJV4+"ID&=7*DFUL")RVDP ML0::%\#*(KU7QAA'7D6[T2`;F%B#EW6=>VFP;A!<3W@[=B`!2\RWCP2&Q9AY MXV070WNW2*;G^-=RVXO,BG.L\%./+L1H'@5EJ:B2&E5RN'Y7*' M"<\H\?O-NI>PJVC_4/%;G76SZIJY_WSW1+J_^7Z].#_ITOH\4[ M-.![Z5]\D3,S&B51+)+O30.>,?>FHL"5U1`K]^/_K^`[:YA\OHBM)16DED&& M'#,4HS=C!I&_7@>^_\F7[_F3GGYI-?[K\_/XK^FH_'TV$EO&_`:4QXC1F+`: M6-)2(2F$GB8/P(W>+A>W]G_SFA_57&J=C5HZJ0)H#NPPX::T*UGLPW:'_U4+ M_DQ)L6>_BB(C19)1")`N@PV&6C8V%S'2AT%H[(5,^T*I+3/..(^]\QKD*_&6 MD`%],K5:UFYJ?HLDZ#:7U(-.E!F!CA9^*JK77LM)>^\H(3]J'8.YN3!T@^;!'ZX'8S&JY_2#77;>SOYC!)EB9&QKJ&0 M>?^WAW5O)78%!UL+*;E:,BBD*#H&=OOK,:2\OH*U[J@(0,WKO(?`9]9^ M9LG9JWB)#!U=5IDT)H[J6K98V]+U)\D!`]5$.2L' M(;5USC)WFEY9G-%TMW`GU&IF_4RVI2ID1"K)AVABF[[HB>^2CMU1"G,NK;;7 M>*Q5^!6K9%-&B!B")ZQMKYY\\[;)6M>MTJ0J8Q*=1(FY0DG#3M1[I1P94K98 MAN3M72'G'CZ9.2]Z@"*?EHO?KF\XKGAZEEU?H.TH'K@Z22`IYQA659(E9Y/= M>`LBC/UTM\'CTF%BGD73.2@CR5O%$,Q+A9A#8HR_N?6-[[E$]-P:GD[3]HZY M^L7].U*S,XSI78*`19?,0+FM8>#;;ZKJ[742G42)V5)D=-*`KL-MM,Z,+Y]? M[J#D[H1=`4X!U#;6_:%E`ATJ=9X*'E7UXO4YM%A46EK1%U1/BK\M MRY&"SYA?$/*UXR@6YSC84DB4G@17QAGL3H<4'2G_0XVIM3@N^@'4IDPF&P99L_",RVW[\H4"Q2]JQ%\FC![R+6HDL MG6'D(;R2?'.U.>-\:DW/IJO%/(5V MKZK?0XJ2V+D6+$5KK?PFQ@J.H5:G5&V$>FN=YJ(I3,I"851BJ<0D&9ALFK;X MWN?O^UJ--;/`M?@@DN,?@0M'%RIE#O#_I^V2T! M]A%MKBQ6A2P@&>E(>`DZ1=SD&&SN:4)'FC%WB[:QZHSM)LNRC0V$60JEB%&9 M+UJU9Y@28:-F+SV8YW)>!XQ)\^+9-&B8)_L1/#`Q\:V_O(* MU_K^_UP?T^_0:0H27%XF5TJF:;-0! M-&K*3E,C<730GW,UN$5>*=0ABFQ]O=%5_IV_R5J\#W>W=]N>\-!:CLPF*HQBG"G&E)(J\5-[E*^'LEOY M7LB=PAPK]V09![@5[ZI"#8P7%!:[*;A76O4.0UU*\+D2#L""8"U)&='E%.H5 MW1J6?&_PBPH^&2M&P;Y98`RR]@-:&W.+?D5]R>EK3PX5O+F,SW?^R[\>;Y8; MVN-*LOA06[7XJZMBN/US+4FY$$"48AQ[1F2?UQY$??%]`0'BGT&P;PAZJT?-G1N1>9Y`5[@%/`0E9ZIWG31LMW M@VW-G](;&!RVW9R.K]/V;0QT>(^O81B;8IW?HF,,PF1K&A[7"OW.EI\WM,XT MCR0&Z7(LL9;'.5MB9?A?H1A1,Z;F?>ISR>.`"2T?!N+[WNKH)/@-/9XC>C7% MZ7LVT.''(90H#'``8FT)62E);N,L9`1_,>N\B@;V@MM&\[UB3,[55PB.R;./ MJFT;**,#10:,+]/Z7=84AV\08C^B)%#24F3MK1>A;1"=7%%C=A"7LL.D9[2@ MD(1Q%>@7#8PTUQD,5T)",SH29LCR>E[9+^D%P1A7D*0IJGAI:@34SKF06^Q% ME]_.%_1WHK+U%1F*MG765J1-CPA&(-A)77PR.TS0_UZ2)R:'*$/F."N05R%X MI,VI#CZ/\0DK`C=MA1%^WK-:X/!=H,`DSMX-[&*./K\M M#M\/*1.5)!CT08)36$H;-7'\:SR9*%TT,K6W M"Y]CZ5[GJP,XO;[G/NO;!0G11,-(("I?$T99BY:7=WSV3?T*)NMQWE??%P7SVYT,!Y6@%JJ3%'70D66F*JQI M$I,UOJ$^AX!:9>!(ME/*W1)^ND1EOG9VY>!,&XGJ`(]9$*W'U9++[> MUQ&EST7;+QB0]WX^^0][5]K;QM&D_XIA8-]O5KKZ;@<;H,\7!MXXAN-DX8^T M-+*)I2F#I))H?_U6DYP1Y^#PT)"2G`"Q'8G'5#W575U570=)22:MM%$,B);* M@"CK7H(GL=W1KI6JNI.FAW*P*S%5^P#`<[:<??N^A'!AFAO] M6!8V*_3C7\7LC)(BE^U*Y8CD4#84PY.K(P-;B6:0ZZ$T M_S8OKF\G_QE?[YX-_GXT_5SOG_+SZ*^<)M)N4405U]Y%)J/77B9094%VMDZY M?_G3._5Q#R[NB3L',ZN2'BOUJ&&"V*%CX)(2F3P MMKR_0)Y"1V\]T.N"$D^H'4F8XB1$#QY8ZH0U\FV$J.S'7$VPOMS19:# MEKC/4RZ)4*B,JJ[&NDOY&-DPU@ZB?*,VL#TS]#!-KWQ$+Y];KU#/N&",8:6- M9B"V(6^3W4O,`RG?,1TWSU[`-Z'VH,:@D:#*"BCW7V^7+0%"<3V^'!]XP`J:4`4Z;RAQDM&$9U;5N].#;BV85_@&V>@"O)NF M![/0.\G<@4K,Y)8+3*!+):VL)ID3KMNYXB)G@;&'L?!',;TMLC6T[L?P;C3; M6E;2IVE"@MS")O?&YJCDT>L/UN(A&X4,N;=0CTVYE8@'D-I;VB`L6O`2%[DB M-$4>%9=K4HF)MJ\'Q."D[FJ>GIQU(DF>6\4DEQR%M"(5;?9(6SZVY,TM>1)Z M-SK,56^_^S`;3>=(=#:GW=WF*_^61277TK=["Y^O]@190A1$BH9BW@< M,(U&*&'$>D]`22*,:RFE,3.Y\RY3-&]\'BP+IC[J<\MN.H"0WM8NU(J48O+H(DJ-IHY1L"*$ M@Z&TM5*.)V17,WHA;`YQBWSIKZ+'0V9-")/:M4L1M@CL`&IZ^W%H=))M=-$9 M8+AJK'0E-O[YI%63R.Y->Y M;I9TC0(6:/=L@V@GH\,A=)KET\C]<0'W$Z!C#!&/`/1UPG+]:"5$4*QKO`]% M3T@,C+$2FCX&?-\>T#\LGL]F/TL1IF[0%`7Z=S:`)2:@WMO$)Y$)TB[B'U#Q1 M%G)V>37C3X3842['R#"DVMQHY_-RB[N[^[>LBSB6S8*7?_V^ZKZPZJ,.+17# MEBKFO@YQ,IJ^'7VME1C>?/AR>[YSS_N8OTXOIX18-5'/XP7>4^]F5Z-_QA?W8XFM:T=QK/B.G-]/Y8G:[K.IJME=/-[/K8KS(I_/J MP5UJFA\YF*)GFB"CVH&0`9T8RZA2L1R/Y!FNY*X<6Z[0.AD`Z\,A.:\H;I'; M_RG&G[_D9N]_H`W^N?AW;J:66]NDT7C6D2@RG)0V!T`Y!H)(85-05LKH:568 MZGD0C&\S&?@%AS/*:2^\SB3"Y8/GY]U*C()%ZT-RSM!BU7E:5"DF%H+L\FNH M4?(<$JK#\2@R>!([*>)!+:SA)B5)0D(C_%Y$CO*T;2?I"[[31GP$R,XDR&KD MQ3P/#74T7S:DU+CH4W5/8J:2RW8.:34P..I2($/ M+06II>'H[7F"-A=EQJ&Z*J6@@U1=4ECFUZB_L12.G#_4=ZPDXX0(S-O<6L^H M:MBIY^!"EX4&Q!!A_J9[82V$>NCFF$E0_?Z@_S(NKN-?Q>5MGG/RR_7U^+*8 M[:S@2#8WG]$LI"12X$+)4%9[2E1SG;+D5.JSG#Z/+,L#+82!#IY-\\`89B*E MN9HB*:$BC>4$(L^8\'%K;`XNSBRA)V<:'"&\`T`!T2())RM M]"0CS5NI#>'1"WT6(_R[$MX`Q]RF\&12BG=+GJE>-=!9V<,GD>R^Y)2N'XV;P]W66LM2Q*14@RWN7^E:H\ M];DANM,HTYH#_YM(X4E$;@S++:@II4E%H;G#XR*4IIDG?FN_,',!^OQR>IJ' MQ!&"'&:_;0HRMW(Q7H8@*`@7H@FZ"BHDWRRUJYWT["PV]J-(LOHZ.Y_??BU+ MI[X5&=20W<]B>O4>'[O/W7U=N^7$6"FWD5TZ7; M5TO@.SE#CPU?.Y^@&7UQ20@98TB*<*`A-]Y8P<>3J54=?)_P_7XSP:^9X)[9 M=_UM[G:@*9#D)5.4>6N"C"%D^*1Q*3&G.^!#7WH(C;T_3X^/87L1;F(8##,J M633*`^%!":DU6V/HT'A7G1CR(6*P3P'#]^/Y_Z994;Q!S-#V6NR["FL)3"`5 M@!4RY:ESBD:C:$;0:*>]);%K$U\02D\$81=+CPU@>PG6:K.E,!Q(L-YXH4%R M;]4*0$^EM%L`',1"/B^`]73)?=O!'9.EM34[E@KE`R$1S2/B(T5#EUH?/:&@ M`^[[KL8VK?3JH=D_([CKS$M[^WFS'?^``)L8K"(2C<^DK=8(<'!E*I'RJ0M@ M>)X`;PPL6-JMYUO$+H@H`O&:!8$FIS>TO+-*CH`G71A+8+CVA\>XB<+YH5XM MZ3QA@IX$[>2U%\80JIU2)CCJ^/JV/'FA0M>*YOB.09*#S@)VO9=$_OZ>V]>> MG<^-%M$"N$`@<'1`^3HYV%O@J3.U'H"3(85*"4D6Q9/!1=:#;QD8QKF.9AZ&BCV#ADABFE)G6.: M)*2^6=;%5%Y^FCSQK%C1S+W%XDSQ%:?D-/CN.NT(;AR5*#9T7N M%,X".%=.-_566M/93I)S.<01O2]3YX5P?YVYVVGGT7A.4T[1$1Z$HKX<_.8M MMW)[F)-S:(_G#J[4 MTZZD4OY,!?COV9;)IOV9&1Z,]"YXQ,-9#==5II`#?@9"02@^2F[&=C_/C MM,M^"7ED5"36,\6\"MZ%&136V"6`XH2LPQWX,P#)&G]@00WNB&WQ>VZ`BDD5H&DY#`F?DJ M+)$8ZYIZ(OB@!F*+@W/CP_OP<J-J>@2\O3K2RSA:9.AI-OAU-3R)#HP3`>Z.2MMZ'<@U:Q_W6 MB97F0@R1-/$R[@[(2SP"3M5[2)%J+:[0*IJ:PM3<4Z&9= M?;C)O]H@Q7[^/"L^H_'S`-L$[;N@'8L"C!%,>*)=%7)P)K5Z&0YOFQS-YYG1 M/NY$8AZ854%3!4ZP&'39=-L;`-4YSW'H$VE?ULZ,YV`Z0J@@&!@TAVAP5`0K MRV&1/L_/V]HD96`=\3".#P-_?N@EY9`77$E[ZDTP!F0,3AD*J=3)#LVOGA-. M'0+WH#P."V^O2[H#VW8,N!8V,N@$V3S`3%`T8Y-PQ%:N8@Q;U[(Y+'5Z.`:? M#K#]BU811Z0,,H#(]]W"&5F%C#DU6PT)RB[T(<&,4R+[:;=R^M1\[&9;L_?Y M87-\\B6^BH][(AWUJE^OR;Q_W"_3XJX8S>QT.D:`YJ/970[UW%PO0=QY7YAG MZ%+.G>76H9RZPIZZ$Q?]92'59`X!.7TGDF@DHNHJ1T MU=G/N<`Z!=3*$_T.!/0H&1#;A?K;MYOI7@*D>-J;J'&;$:U2R+VUJNS3Z&N& MU_IX&J8N^^+KZ-QGJF$9]-BAIB@OMMW@04O%2X> MY8(%91*C:.*5Z"G@`A>8QHTWR+X[GI%!@=P>2=CV?+H'D!8X>!5]Q#_&$2H) MXZ5C%&@T"*3Y2'\&-2"21W`R*)('AVH>LE)EE"Q&;92,"JTE(HDOV^VXY)>J M<'"`AV.PCGMN\K":)!%N9U6C["4I\[?%G\N7YBWS:%T!)5Y1D3[6AHP M"YM';W!I;6Z\987VD+HN2AL7[6=A/ZW=UR,;D;2GMJ]:@.0]=3/-P9JZ=7T_ M+7K_)1>_?IO,R?I%P#^@/ZP) MI]`\>>$$HY:B!'+$HAQ]?@R^Z='`9QYP:PC M$(/H6KM@@/%G@^[CK5R+*Y5('9!R%KQV!KV-]HG$^H%)8O-FYO MC^A?FA(E`AP7!`U83O-U3I673&1G]<>^3'52.#B#[<3V1EQ=:`C@C3=`A771 ML$KG>`#:50;$!&'[JIRS,=G?7BU9Z13(2)UEACJ0ILJ,(?7IXI4+@D[;R9E< M1L">N"];*XC71C/3J,`P`W#!N;&/D7S0. M_5A-$LW*@`72K#0CL5?Z[)UD>5&3X MA^<<>1=!:\NY]2"#T$HXW=F^\8(T78X#**VQ^:'`XWLVFMVM/OF?,?YSM0SB MK8R`8KHER6UPVVV[K*F,2>8"0,^C=D"'0M0YT;81L*YUG]J(:[O1?'QIIU=A/+E==%N7O4UZ1&0$ M<@T2M3829%*Z=8V-28V3UG7$]RB*4]Y<$PF=!.<5\83OKZP<<8'T"]_^M=D\2.:T2_F MB[M)\=\OK_$K7UV/OHXG=Z\_C+^B18HVW8OW-U]'TQ^7K\W'_U>\!O)M\>/+ M?WU>_-CX.%)=O/JRY/TU4/)?6S^3?]_US/'T"^K<1?-SRQ__7'WO)S0N5E]4 M@O1BB=*+$J;\_3_D3Y0/^P$I/".QU><^S5Y<3HK1#&VEFVGQ\H>*GF.(RY)^ M-9J,/T]?3XKKQ>KG\?0*#Z_77'_[__:^;,EQXTKT>29B_@%1(UU71Z!*W)=N MRQ&L32%?2VIWM>P[CTD@2<("`1I+57.^_IYS,A,+EUH3)$BF'M1%$D@D3IY] M_:9U]S(X&EL>C10/N(.RQGKTDIF5S+B%?A86+/\$!HLZ@P3/(+90Y(:3A`?6 MG+D<2,65U1\8'HW%"G.PT+R%S[/O+:`B@),SL\)HR@+O?T7/)7@4H\Z0;@K7 M`,7`F@%EDJT\%+96WM68SY@_N;2LK_#U1*5^60F/YG#U!*^.>6%;N.LX'?\+ MWM-*0BO@TS#Q:!.V]0!BUYI$X3S?+ER2_2VVM<17@-="@*4!?X#W7P@86A,_ M?(QA*S_Q`'B![R_MM-N;4076J`G0%$&+S2 M-_ASPKE-S,A:4')W&"$DF)4`X#IR819XGX,('W3CQZ1$CKP^IS.&O" M'_@UQ.D!*P=H`3Z""0LT@EL+Q+2S_X/FR\^_7>SU_C4;M@6 M<`QD`T)&]P6/P'H!\@BB? M+H"EP'<+19#(4]2Y;&&'$Z2HQW"-_4DV.9^C&>`B"T(,E]Q/,D6+S8'!P'O$ MZV@@B-`)8[$-B146I)4L+S&N.'9=&<&GPN#O](,@0OO-SZD\O"K/BRCS,0Z?!+'`9L["\M MAT<)\P)XSL\3Q0Q(B**(GH=I(+6*>>AZ$P\A@!?1:@J.ZB?\-B2HP;HDP.'E M8LQ`\QYX)KF_\`L1!M\N#3X\QSA+(Q M(;E/'&2*CXL\N!YNQ=\B^4@K=)PT>IKDU-]__N'%]DO)N$-+*/YM,@)0`.S0 MK4P7O][DN6GW;CK-;J_7OKX%J_SZZO9.MHVY&K3`'JK-8 M2C#/&%(Y1XL!!7,D)+C@":1'D,WT^^7]I355)@3^C+JMX!V"8-`(@&V39#K/9]2\`( MSAAP)Q(*@1**<'C,_5<:)U(E!JEDJQ<)%R!1A#X@O`!"4T")%W`T2]%,1Z$N ME>T)\R(@E)?JZ:M4"?)PCVA2M>%J/P67,JL")4.VP*;S0>X7<5"&8M06?&Q$ MJBA,+[RV`R>915SX-P)@_WHLNCE\.8OWSQ^J/WB$VTL.'\_>8?%,^*]V?LCF M:%_[HL"@,V7/>N1H8*`'ENP=9+/`&].8H_/.!](EVA9N1!;'/(G1T>FG4B?P MX%L`"=0K%-9G(0+U>,'9%GQ=N`OV=N#OS@HCT8 M+NA!RB]%:@)9B\*[BH($502PFR9@VRGWIB_]L\DLA"=GUJB46.K6,B\S3.MP M,%L(^3#)!#W<`&J!"^A$)K(4W>J@A<>;?Q8HO,-<;;9S=U[RY M[=S>70U;[;NFFOMQ->@,A_WC,M=SL%D(L.-!M=HX,7]7<:U2L*\8L`0#VTM` MM8E`0!4Z$-G"8K0\T'.!E0`J1T(/`G:"59["?@&,]M%_&*$_$;4C:7];8':[ M4Q*F5BRLXB5Q'HJ?%9Z)4FG+'@'@,A8CG8OKFY\P!T?(>OS%V\6DI0DR2F*3 M+AA_,>RDN$N7LCC+VZ%=B_V\U.VG@U^\@/'\'D2Z6,]-N]$<7-_>=-N=UDWG MNG=[UQRIY(C&<#`\+M9S3=@:",9C%>!UQ.D253H"E:,`K2D) MS8;X#L\/4.JYP%TB\DH^4#O3-=X!:_`E/#_Z`[,-TL"-D7D4_46K"PLE?K&( MPF_2K!`1`R\2S]##&EY*T67F@!Y&`5F\/B1EA@<.<,8;+W;\,`;5[C5A@VZW MWQT`'^B!%G+=:[2N>TTY>:+9:#H0E8;`JL2*0T@6*C9?V.#42FQT:, M_YVBF3B1OER?C:UXP1PNN:-X!51PD.L1\Q7^;3P/Y+)A.IWE7_5S1UG.01.< M62E7RO,VY*UX*>5.%90Y8/H@$X!E%Y@H2`<].2W#MK:$EA*,I*\>],!%%@<" MVN`2'.(B;1B0/(::?`0NJ-BP7S@A+0O&WC>=)'1\WH6]:5_`3._X.-HA-VVW M=*)"G(Y7&2I#*XZ^CV.ND;J:`[L['%;"8$-J'B)XK%1,TU@8P"L&=QAA[0HH MN3/.7%P$#BC>R)85+_W-24+L&G\8C+AI=WH]W;PXBT/Z<:@\`TR^N*YLS;;= M;[:K1PYI^12.>DW<#N0IO_I<*46K@C-M-_3EL;[:3'J5;;-B%JE0'I:&O3IW MZOIZ>#-JWPZPYJ6-_>U&-\H9.VP.6D=F!'W.\V4`ITJ@.R$IO0,3:#/XM="6 MII0LZ051.9HB?1.0XF_,^BLZ?*W/,Q;-@9FE"<4P,^X,_,A#Y\X,KEI>A(\! MAM#3<>RY'L/:48Q@@N2)`<;DA@T2$6^ZD%NVDH@%,7/R!`N9E1(7\L*X[\UA MUPE725$YHKZ>MVQG$"5.)73(Q'\+!.H5E6//ONP-%;1D[<\ MR5KX:9S]C`7E)0=L>4^%PE&D/U60CBEOHB)=K&#+A93]CEPE)4\TIYP+%8$4 M5S%L*2(2TI4K6^1T;-X1N80I:E[.,U00D2EZ[G;PY0##3'O099;R,7.>S$*9 M:0\_>Y'%)Q.LR`.`TWK>`WISKK=N368)K&T-6&V:O&1KWD1FP<("L;Q:8K1MQ`);O(MO1*%OP,9RUQX9\#V#S_RKZ]S:G=NQXT>U?8[:EW,V@.6Z-1 MYU9VS[SNW5X=67!=`,L":!D?=L5!KTQ'$OGE!/<$X9[7E8I4,>(7OL?&&+9> M2A)']JHX5GZSS"TKW4&9Y1&F]C@A:%#_J])Y5#L,F0G&26$:\^01U:4-&IY0 MU/)'45&-+5D1#T39#OX049@+&(=D/<7L<5D,6WPD[BU+-$I"K)CA4!O?XYBG)RMP!6RH;`C^YWM_<,IN9@'Q/.&` M`7[J(Y`0P"EY9=)`YA(0*(%_@"TM!$C9HZ(."&X1108)5_E1L%-LWB[!5W:V M99M4N_;B+?O#WS>]/#EF\(K"]FV9:0S*^[]3@`G6.XCTK0TIBJ`GQU)-AN,> M^UX\(P"LQ&C!AL;^6N7LB*UKLBEZP!/2[3?MFFDIF:UQRMTI^:EWR4`QF]81 MF;1!3IQ%UD0).J1[!$H943]%'`@RL.9I+,DE8XI,%!?[6/D'/XH"1$F4VRB2 M.$8,:\$&4(]=(`6@[6R-ES*?TN)NILEZ!>P>HS M#[PM0D2-#!]1W?B[ZN(M^(B("J(S1H-V^O6C>]X7!P MU^K=]JXZ=U?*(]3HM7K'98Y\X3AWR\J!:)6A>$(2ML)(\"B=HCA$[B54TVS0 M6Q'R]^@V(3_'58B)O^=XY=G=Z/[J[`-(2&QFNOGRWQ>4GG=^-KK_'2[]-;RD M1UTTNW9.T.\E9/$1+__H)7"PCHI/%$JZ03#F;W:?>ZXOK)]"W/)UB!(YL,[O MTW$2+CP']MF]Z#0^?+1R2L=5?B]9!&P>"/)9DROQ1Z8YY/5)J2U7)M<:VRQ`!3#'S_( MH"OVFWCP5*T8V=AA@E741=5!FE1`!^KRV)IB%\I`Q/^?`F&Q8)>BP852=5'[ M-:&^.%G/+R;K$HE3(I/%K9T9A/O2#0O*G5 M'?6Q')%A!39SA2,:;X=[YEZ2K!GH;@A')7RW(M$,B#B_&9Z*M"N9LKPU6Y9\ MM(7?<^N#+`:6VPK*^%I5??.CSHVO:'/=X-OMXI.6TG]-@9459#0(WDSL`@WE M8K5EOUN:;)&FQ9%P(#6I>:]5_%*/W5'1[L^_DDSO#YH@T`N:"I(H11$N:'1Z MWM_OGS**8GU5-3W`H*E]/*JAQ.T%:\2`)74#03[^%1T("8!%-N(8.3/T[[D% M"?0%0RY`)=C](WK`+!_1`%Y?\E.N!\BZ)L7%53\I(7+$5L4OQ(!CZT$,OI49 M8]043;X(6W^1*'N16+Z(Y&AC$9E*1#);^:F85$`<0C0J%`:V[*VTNC79SR3S M@TQ\X2?VLHY9R@\[Q:'"0K;GU14JT8D"="N`F:21[*/((NPAE?>`RW$JKD?IC-[:#(Z8S6(;:("\="?5"JQH;WRW+J,M@"V.4#RTWOUO?%DB3RQFFB M=)1\/R*FD#>H6C\FH)$5\%TC;)')%W@X*O\HGG>7G@HI_PJO/Q!W1S/K&DT!_7L+&@ MZ17#ZRRKKLP/2GZ!`/'(6UHZ`HFW.9EL[3,D]Q7PQ_+[B7V2S4'O:A26PU-8 M?F'+E^@KC6%E^LH7;"(,4H!*5=1\68G^UVF<`)^.@',)O:#7Z'VH0@`#*2'H M40H"FMOH.I_Z?*4)$&`^]XF_<<5'1*\1U<>LH*M$\JU`;%'LM=176;Z=D[T= M"91T@2%5-#?G*#FP:Q3*%;62E&M$!,H>+;:;!"2!]:+E!7(4S,'+KE+OB@2\ M:37Q7IFQBUV7'SB<%%_`QIB_C,E-`<8KYC33&&!I8,.N9V&^IA<7A*]D!OA, ML3X1OU1T-FZ#'"!PR(G,F6%!/!%91;"U.8V1FH8HH+#:7(A(T4TV`R.9@*6@ MD%1&8M4)B-)^9!#44JF)(K`="_O;X7C4J+JH)F]"H*$P7'N\@FSF'WA$/AQY MP(&I6\O^Q;(NPWN#F8OOBLR\\+Y%,4W6D%^L7"'N0DGLJ$21EX="SB+3?UU0 MJF\1AS(9@LX,Z2ZR+5"LR*U#CY7G*!6W0/_S;)G,.Y;_AM.6/MS@BG&K5NAU>C MWJ@U:K>Z*FVWT1Q='5F0Y@H1DL>G%(S95;K#<[GSY]A*)5/R2?)3=+Z0/2_X MXYF\@T(U0,-C+UR4EU02:Q(Z:2'U%_W`P%.CI5WJ+B;;&,YQO"$F'&4!%I`8 MX8-@,JB]LP6E>Q;6C4J2L)J](!]^$*>8)9:I.+XWX1?8RP&( MD\02[$VT5RFSVAEU9GF@_C*P.@V^<-"6<55B6N%-X-Z__?7S]46WT51R*[<1 MX.X%P#"AZ15@*Q62V&"VEM@_?QS)@(7^!V%1DKS'+!W#(@%'TX?;CRM\34UQH3]2+R88"\ M\R)<"V#EA\RULTD5:'?!/?C>,SX/G1G`GR4A)?R-`1ZH`>&T+S[WF-`P/>]QE&V'4D?V]G&>,O$V\L$A,URRS94`0M^^>C-Z*3 M77Q=OG6;4O:13X,E+KVQV-'_'$NF<4F[W+KM:*7E-Z7$+&0N.:E2VUHY*VY2B9KM[V=3Z1CKZA>\F7]"Z M4M5QRI.68\_"9T$V7N5?4OFPBY133O@G3\D+#DY%BE`I!KU(MBG$'F3%EKS4 ML0.;`;S6Q-9M)9=,<##988O)\C/`)H$%L2\9:=^OSW\<=:Z:@TZ[,QC<-!K= M]G6[WVJH_,=VHU-]P\%*36D%*#$*0D')A!]>/WRQ"$BN`&D))ULBLOTIB$K) M\\R1OC&.>50+T.G$X$(JLLH_4M4J%4*6:E;!&j<^9=B)"DRTJ83?4;;2 M=M#WJCMKMF_[M<'@WN+X:MD>WK='UU>!NU&JT>[WJZTDK M96`JR&:IT-N%)<%G$?P,*ZM)TX^;0L?B8GM4X:=[RBY>:0Z6A_L0!=+$RD,7X+%@I!4FZ4HOXL\K83VQ1U&&!2MG.UR\\EVE M@R'.FSE1&I<:KTN5GM$\O@`M<9K,J/A6Y%4Q&7O)YM04`I29UT*6J5UGSM]( M.)#5IO)2Y`WG3.(P:W<@LJ2#4(C4"7L(HV)FTG6.!8%`"?DSY=9EJG#N?<$4 MJ'!,QTL2D8K]&"B_OB>&#\Z\2!ZPBLX6X%#H":/":>LO(`-K#CI"?`$-D94C MEZ5Z/BWDUM/3!NO"90LY M;!(10<03@1%>/(1R#%I(97X4,L;\'IG'LT)6.8Z7'`MJ!E;!2YN'OX$O8/0Y M:PRA2J1=+Q;I;&3'B,@\[L'&N"HL>\Q).+OR0A68OA[]LNX#67;O5BI5%%?@ M$NYU^AIG,$^*X^-EKE0Q!4:$^=!!G%5\/"417JN.OT*S7M'(A;P&#?XFE]9R M1.J+9Q>T>KW!:'!UT[AJ#7O]FT:OTQFH3GUWK?[M86OB7XHZ30%*EIHD>\3\ MM"K^^>6Y85M9$[R8^11]%^WH9-6\79@]0C\(B8VN`FSKFJV2*Z072N`"BJ4X M9E@P\/S"C'S+)*M45N&&Y.ISMERNC:KITJC[/#,[O:`G8V,/+TGSP*I\DS1! M;3`O!A!,(Q*SEY^#W+0Q%C&2'C>VBH676,PM$U%:N+55K3-/\5/#$B; MP)O+Z`9E-@68BPSZ3B`B+%(O29^=WW+8M++#:.OJ/%YEO6TWOY1@B@$*:R)KGB+C`@C*< M11KL/>4MR%'IZIE%#031.Y\G&)>4>)%R*IZ`3LE(;+5X2 M(T>4Z,BT2;@>S"Y,,2WT<%XQD1'K8]G--."%"<]><`$JD.C;BGE'0>B'TV76 M:"N0+<;76*JH[\[;79%=G5N($FT!NX)P[CEY,YAL#,^&IZYWD9*3?@JFW^M6 M5(W2L^XYF!;JRW%;&R[WUI)R1+4VYH45*EZRY&%!V3CA!U]:.DAH=/@==M=D.X69T]L&BXBN`J9"*Q:!^Y,5_H!:0A)&L,A\SD=-\ MA[F[A4'D*6R81'PA?\1=;@4=KN-G:<^Y('P!*%^OOS^KAZ_H[61C M?,DS\U\?`.Q<#]J-1K=_VVQ=M]O75ZUN[WITW6RV;VX:HZM^];FU%6OMP@HK M@.B(=8_#A#SY:)TW M/^1>"BS:21G5!W'4H_&QH@BY,'016#HPH?B3==XJW"HEND@V"AW)Z(MJ2MX* M3.DFL$2[L(0P\7U?^4UD'XI%5'`YCM,E%C[$<@HRK*\J>5!;HB9:UGFGL*C* M5Y;]0,A3S^(0+U]B,#2-UAL/BA0+?R-L25!D(C)S:PLGQ5/!B=40Q,9YDE[\ M!O>\E%VK00A9NK5%Y2MKCQMC'<^[_5_-O9_AQB7>?>_,N)OZ_+?)[7SAATO. M9>TZE&KNKD>-SF#G]135Y@K2!(]GIX,K[)(EM,7K9?FLUK9RQM=+6T8`:%E) M6ZM"2E*D:E*J8UP3,N>BLB^-8>OQAX\ZS"&'8L`OH:0%CA0+IA=(-1\;0"A% MRL'/QAP1+H <8!PF23C_5&*'+6!M15Y7_"RN+WTE MF!%^\^PV"PP8@PM8)O!QYKG`=/4:A=N[-Y8TSQ*PL^WVSYZ&E62P$A+-Q3>+ MDI(MU4+V+;#!J[!5J/T*VE4OP@=Z!9UH)?*YIUN,\\%`TWJ M%0=M"$$3(1P\HO^*>=''B>=&"KP3^=M[D`+KL)1/(8MC[1&UHJ6-EJQAP@8/ M=X^'Z^X+@X<&#PT_-'AXFGCX8G[X.J417O[3F#E_3&GLV(6T#9 M'<__V!PO>]J+_5:4WB&0#X$7U`98Q\M$#<89C#,89S#.8-QI8-SK-;^C4?!6 M(;;AK_OBR/5]&G5U`==WNH&@_YT)Q[2^=*_=T_7:=3E'O._5V;/&<;%7^-0% M=TZ2!PP'A@48%F!8P`FS@*;=:PP-%S!_U(=3(C[4_Y$7 MCOVE:'@DM7%_BZ^KM4M?URO"F_KIKM59;S&DVXM:&[RI6"C7B/QJ)ZU/D+2: MG;XA+4-:AK2JL!D[76WZHB$N0UR&N`IQ&4-:%=IHIV2*_9/:ER2O"?&^G-[V M6S58@4S3EM[\'&AJ@SS&25H?\75LY)3U,FKITY,,71FZ.G6ZTN@O-.1DR.G4 MR6W0QC@F]L_H3X>X6@-M764,:1G2,J15("U[V#75HH:X#'%5 M0%S=OKX0];&3U@F[M5]@B>VB`<+AD9>^#)#:8$'%`LK(H2.FAZ;=:IJ..X8B M#$7DN4;]INE#9RC"4$2F,]FMEFG1_&[;HT:&_FFV`C@>)T%SH*\UA\EC-_ZY MZOUS)T.:>RCD-"1J2-20Z&M<[/JR+@QI&M(TI&FD9XU)]'66ZMX<.E6"<'NY MQUYZ(1P<6;;L9E];QD==D,+X1.LCX0Z.(IIVQ\RL,A1Q6!VN:EP);+?T#7YY M5N,[A9)?0XN&%M\:[AOLL-G&*=#BFRRP&GE.=EJ:_S5,P%)[SBRSO,#Q4Q=^ M];+OM(V0+B-M&_#2#=.QS]]'\`?=@4+;,+IG8?LLWFMAJON<<=>V&[V*&.QK MX'D0>&?\TS4MGS<\TO#(2OTK?8VUT89'&AYI>&0=<-7P2(T\LF&W#9,T3-(P M2<,D#9/<-L70[@XK:OIM>.1V/^.S/NIC[_ M;7([7_CADO-['CUX#K]'A^`5^@.O"^[`D>^'#OWUV^0+=$I`&_D?H8W#.&Z M.(F_`KBNX)H__O)?__D??UY_RN9EJ8G5;Z*'U=UO7H]KK=Z;?[ MC?[=J-^]ZIW]9>5HB\?TU9OSV/J5/UI?PCG;SL,+M_M>P"]FPIW:;#6^_T2H MX@4@`I*/G0%0K$Y<^3KC%H*,!3]KW>SOE-^WYD,3G](P_= M_^&$7F(2`JT_@@QZND/OLP0A>*<#1,&CEY!52?UH`!45R0H_%Q\3A-&<^27I MV<1KLH6)+5H.]WUYS8]GC3/Z##S?49]?SQ#F+)IZ@=@D2Y-0?2$T2/KFT7.3 M&5P-@)#2""2-SQ8Q_ZC^^+0J7?)]%^-6N81J;XQ4OB#T19OY\:S3^?Y9X5>6 MS_+&9NNM-Q[*?>U=/W#7$'WS\QJU/L(#2;>MG9&8;[?FP__61,?@;?`:;`V! M_Y8F<0+"&_9HB7ZJ4A?=K%`5&OV(JT>H4+TX&FX0MN+NR?O`U]4E=HJ_9%0] MC7_[(JW?06^+_"6`YJ7;VP#\W0)SC0&\D]X-:>MT`NDA9VWY6=7CXS_I"^Y> MC``\;,JMVV\\6<0)#&*>*F+N50IEB%I+022IIY9[^\+G MS`M>(2-WNKMK^#9B3I(R_U!D^%<>S0T7U*]Y=_:@>3\#R[IQP=%T&O$I2^K) M:7X&4O:"V',.A9+_P?STQ0J-R?O?3OA%'P=+K*TAA>H'I%1;O;//V'>W8\-^ M*@?@2<2V]TRVVF!<.V%^*,S0`*X*=*R4_WW7N]P!^S.H>!RH:*!Z+.CXZ@>2)"PTB92V+B8N_OTX]1&LG9[?7O0-TW!C>_.S&0^:OA4JY\/+P?: MFF@9W#'P,?#9C=Z\F[A)O>!CG/G;H;DZ:E"4=,36`WRO3V/>7QOD?0K)\Y8] MU*=IOQN&.?)5!T3M^/G!>%V,N\H`KM:V0,/XZ@VV&<`=(>#JXHX_`7OCN,R* ME^8(K9<=GZ)/OM<$"T52].90!W_("K5B]OM2\']2R&,NAF`&<` M9QSDAZ#\'Y>.KUJOF*1TO.\C`O&P.?PX%.U>[QOW.-'BSL& M/@<&'^,>-^[Q-T'S+HPFW#,.\F>SSSMVIU>]@]PHVS6CO7IQ,@.XXP=/R('JP->W.L&,W->;8 M/#N#T;2CK`CCUBGY1)NO&:%;"^RK#9/[KCDP6?,&NZI*4KUL-6F&IQGQ8S"L M"F5D=_/&#]H7WNS:_5[7[K6;.X-773#D2-35P^58)I2W'9K_H"Y3-!J/?UMP M:D.5A-1\:L]F?54S)_1QBJ,P^%\PF,+PUAUAZ9,^@G>>0KU8\@%QWP,#W)X1 MMC:L5*];H490,_AXD/BHWQ%1(\@9G-R/4#\.Q\9Q9O_MP>-A2NB/AK+KQ5%- MOH,J%V1XH`>=[U!G_T>KV;0[#6UC+5Z3[E!C2;QWKFF8XWO`:]3Q6J!?;9@< MIE/WM+4:-=A5"^PZ$`$[N.SU33J$P;^C]RDV?&W=3GOTWN9RSB5RSF[G4X7_`@ M9HD7!O_"2Y5=\U%=`NRL??OS+?_WG?_SYJ>4^L^6;,\ESX@CG) M1?^F==?HW/5O.H/.W6VK>348##O]=K_1OQMUNZVKL[^LG&#Q-+YZ?B/R\`)`A^=@9`++I1(FO,V[A:;!@:?$X M\>:,DDG@VPGS(NL!(,BM<&)QYLPL,>HL)$!:4VRW:L$?>+'XX,+-5AIC=0E^ M>>4SYX\+.+#0!R#,0Y?[UJ.7S,3RH0]8CI<^TKMR]X(!ZK,IMUA^6A^?1-1G MH298@0.0X]%+8%]B!@T`=1'V^+GXF"",YLPO\8LF7I,M3`1C.=SWY34_GC7. MZ#/0OZ,^OQYKYBR:>H'8)$N34'TAV!%]\^BYR0RN!D!(U@1+F']4?WQ: M9>OYOHO>PHQ;]396>[W`WTA[^?&LW_W^63Y89NSRQF;SK3?N^K[=//!`_+KU M$F1%3.X^5S7YS,C`=T>XGM:QUMC5X&W@PMOHDV"P\':^*];Y%;B8]0O\-(NM M6V!NKO52-KO3;9;<]6_06`QUO(4Z6GN@CB<5ZF?J[/:-I3K#2`8/#1Z^`P]? MG#EGDNN?2*X/?;`9?;!"M?D@CC-5IM/?&8`.LDG6][7$GR,3%Z=(>`-]N1:G M37@'8BM4FR$EZ\=\;\*M M9;]MR,(85:^#[16@'8Z%RQ!)N%+TG%;W+W97"';>B=T!4>%BB M[#@)KW79,H1G+"P]L+KQ'CP@9-=:>MPWKC)J?Z4"N?/-[X"5;,B=?DM[8:K3; MW=OA]4V_/^A>->ZN[^YD>N--8]"ZWDUZ8P%%=I7NF)%3_U-L?;D?64R"T)J$ M$:4HKN'76YX8P/MJ6QKAO!'+Y.FUQ6:&'=6]]VD?:^;V6_:]R.+@>#FBP@' ME&+2;"G/U:2RUB:5M?_>5-;V6Q,]6X>2RFI28(]1.:Y91K'[YB4II;K"4Y@Y+<'YAT1\\L="J>'&\1%,H M:CSAG:,+1?T>/,CVN0!EJ1%:4A%L5^?V?0]COZ8)$70ZX:FELA&YM***^LO60N,#@LJ--@M;E(/'NG`P'&=;75GU2(\H[?F%=>RO)6,C%^X:7S0J+"&MV],9` M?C<([\)HPCV=$K[J'CO[%?1]N]D:[AI6IRWNC50W)OA1F>"=RXZV*31U.4AC M@N\GL%UA(>$Q6.9-N]4?VHU&A1UMCDPG/B":.WXQ77ML,\9WB=NT+@?:(FRU M/WMC?=?-N7[4IG=S,+`[&O4=8WO7DMR.7ZC7!4E.TO8&$=TV\6]C?+_)^-[C MF-&3S#MO#!MV5V-8_Q(_=K#;MR-O'?N< M6,QQ@$DD,?4UB0GF1`?60C2PL5@4L6#*\>_8\@*Z(7(9H*P8US82"P!3M>X3 M%K@LC^^NR#U6\.['?WZA`?\?*/7@(`<\0K%3'$NK"( M.I]&F[<`CIJ/P,M8W4;WHMNH[&UN_YUBJYD+2_XAJ$"V%(JM)+1^#8.+V_G" M#Y>C:A%K,]^'V&'8?<5^,$0PWX5ML`Y(Y?HI2VBJ.%(P) M^%'&@.6/#!LLQ9>6!4@=<_A2H:!\#]HS"SQ.8%-###?,,-R(^[2X&F-(`PQE MXQ8QTE"^>2"W>+&`K>$W-,T0]G3/.9P4W-4A&$S2".Z-+->+G32.)5"3G!K_ M%)>V40+W`F7#Y=/2<5W"O5[PE`47,"0BY"#)Z9RN`X"^II'47;]SW>W<]-JW MH^$-R*?;WG53RJI1[_;V9N>-I*J57>E\SJ(EM8O((5ADE0J&V@3&04FW2H$/ MZ.[%"/K/P"P`O07Y(//X/2;ZO95,X)2`7Z4J@1H!L2]$[#1@P+L3XE[X3,'' M`O)V$-N?>`$H#Q[SD5 M@7`A309=:ZY2:7`WP)#A60N<,'M^]M-H]!G4$.3$U&?4/B%PJ"QL1T&0 M`K"^\$48T;1B=;C_%T#I\P(6P(GA[[^P"%2D9D\X;H76\4:41YG)$*M!,1(P M0FTKC2)2*1PG@IV)PV/NO](XD:K?C"6V>I%PX052B0"QR(22;H/&SJT`@!K' M*(/@O!>"$9+"`X2"MV[9Z9CY1%_QC/-DE2I9VGX%)F5>&"B^V)\Z&N M?GP&MX$F9?EA'&MK$EF&UW;@)#.I;/I`NT?;$^X8J1!QS-$4? M5+=>9-/A(_)&-%"!'WJ1P@AU[5;+31K*@I;3,"TQ%?%Q8#-3Z)P#O@9PI.5 MV2OMY.S6,B\S3.MP,%L(^3#)!#W<`&J!2SZWA\Q-H0X:$!UT2*[&N:F3!LSW MA1:('AH0\9,T22.>J<>`&U[H/N-U."Y#:5<^V%L@5X>.ZJ\,E-!HF2-*LR/4 M7[ND?7&Z`7F3U;R``[SH-N!X'WB$7J^%[R76.5Y^AG>"1BM^$'[0>_P9#`Y` M"@^I/DW(388<$!@5D(STI9WG_JH/R&?(95?XG3@<$2P@AOQ4M)ND6JK!'LP- M0'3X*7=AQ"<^P`#^3:(P7DCXL06\GG0U2[3?!H/,$RD16VG&W+6!.-!\I"O` MXI1^P?P]E8X09(U`60K,-8)3==4E<_*DV]*12O(&293)DY,@77=JXKJT1"R= MK#G(4X`9Z.P(R?*Q!13VP\0#>`?@_%'F$:7G`D-B8S2*R780X)LBM`0:X<>G M`&4H7C_%7\.!D<$GT`3/[<$+TQA.*2(#-+=0GZ4)QP>MPYMXXF`!&Y`(U:&B M$8DJ`S'V1<$)AA[IE%S\ZGY'BG[7/@O[`X#"H M*8@F1YP4L8LD"$1<#T4<*88^ZN($9R!S,TLM''GYG8>6AX MD8+MSD28";@W^6M1I*.A*TU388J1_.3Y`4K#W&%11,PB"TN7'=:P!E_"\ZGI M]P240V`0<WVG<%0%/^H(P;HYSM@ID6Z!LY?4LTBV]DR2)T^#; M%1NN&$](A/F!^BD%+_:]UP/43DN`Y`J0*!>D.Y0EE$XIM$P05^D\%6F5(`PB M#E:D=/C<%#[B[6C=I7B=R%TDUR-8>OA:%_B*,FG3PNH8^E7%CMRU4!F9I#+X M)7-'*=6%M&(MM)T\AGHX%XA/+0O%_(%K2B5&[YP^,6P$ZH9L9X>P3\:"X-Y1)+4\%UCEAVS6:P:L'VG]>+ M`S#9OYQ`(VO9_I?'E#>#9_DXXR(!>W4@% M6*8L),%YI[`H.DJ07XS1%;G$.R-0P,)`I)'$,2AMKHQ29&$3D6C@;X0M68&J MJ`\OX/#:KDAHL5C^MFP*_)K`):,KJCYPP4!3W^9714-X;86U\^9DJF:;D.$: M+RX_@^3/UL3+[#&8>E]Z`"JE03`EJR,6(?N`KU03%:(JI03EF)@AF&C`F2B/ M6M`R%K)$S%'AT7GJ)YBZDGV?DU8831DP"9ES1/2$J1`I7(-4)VI8UAX:KE;M MC/F,^1/)B_*DB6+4)>:%;>&NXW3\+YGWI@@5-H$)WI$,XV;;%0E5XF^QK:7, MHT6`I0'RMZQ"6*1`6=9/J@S-7GM\S"FK4`(W=L(%R8K',/I#!H-!FF#^EO#J M,!2FH5N)-^=R7R+5.\9J:P\WD1ULJEAF:2,N!Q)R<94) M?`ZC6`2$F`@)P]^828P>/AY$(`Q$?CLL`W(@45WBZJE/3<'/JJ8D!?,*G=TVCT:31%[6YKH&]CDM^\ MI$(.%0E57"=J1<$N`-"G"V`I&#XN=&S(SF4+.R0C^#%<8W^23<[GJ&12BD>A M]##+]IH#@R'U:PT-!!&*U@O8`4'ZRT2="CK0L@*9B$\9E9\*WI1QI6)'!B9J M3WQ4D`K\H,`R[!6>H*Z($UA!5L6"Y@0Z6YQ%$5;>^43,U=W6&RAN4&B_L4F\ M4X$2X7F-\<.R?B-)@UFR""ZVH;?(^I/+PJSXLF0'%LP=F:D!S_EYHI@!"5$4 MT3)]FPQ#:G.#$)#IF;)HM_"3-$RIJ%L(\$6A=D%)[B]@1<;$!F0&>*8FL((R M@MU,9BR:BA=4E"SO$"4-^$FXXD6:ER-KAD7R/[KEE8$8R4<*&_1$2*YB#U'! MA+PIF)`G8+M4Q;:^/%Y5?2#T%`QN#W#A@IJ M%3N3RA>*A8`UDB+]B#RJ_,*,''/_0U`0MX)]V3DRL(+>:#%1.(HD59?9B^*QFG_K2R*Y&_P2NJ4A"W'E'F M2XO+SC3LJ#.&?2OI.F=_\&RU-74W75!DECMIL2HO6QOM0/>!=K6IZQ?`.>*8 MW(R>RKRJ#A7DW.8M.DQ)P#UZOH_&=!H+=Z?RG4%J'*RD; M:QKPI<>B0PUU=[H#@A'J5)1.@6G,05QBNIKH*TGUSG//^(NMX).%A6OY76_`)1' M*NI8/F5)];?L'W;9S@*DC)UV_<1 MB!ALS^ID'2:*G61B,+5\1Y8Q9/YG)`)Q4MR]8&`S88PX[\*BNJ7(]BEYCQ1, M%/9\*G5X]F%Y+<1;G@0$F,;EMBW%`MSRGGY[61<7>P.'2]44H2VL3KASI+HO MF,3F'5%),/7N*3?&5!"1[,?=#KX<8.A0C]-H*1\CJT>4?0-L5#:<\6*Q'EB] M`(7KK5N3/7/6MD;9XB_9FC>1H3A8H,!(40+DK5FQOA(TDXO"EJHHASR&VL?J M,U6%'4QMB[83D:88]O"RB9:^KTWOD^Q`&[@'U6QP2[D&)P>%)+7,!?!R/C#F M#DMC+IH5TVIELCI-^5FIDG)=ZC:+ZLII:'[5]N;:WL)7M8K+>G25:YSBT.?^ MHJ#6L@;Z;L=2ABB^MZ4J8,;6TI:I2?*E)L<&!1 M:9!.%`8AAE/F[^J#=G@@KS!K8)1.TS@I]""^RY+L-_KTKT)LNR3#<:/[J[,/ M8&#'F%BW\?+?%^0O1>?_[W#IK^$E/>JBV;7_S_:YJ6_!GW7_>6DF$"AM^9O= MYST7+ZR?0MSR=8AANL`ZOT_'2;CP'-AG]Z+3^/#1NO%B!\@_I8((Z_-8?G02L M&-2C9"P7_E-QA*JZP@+^@8RDI[P;2OF&<%3"EXJ'3D2< MWRQK*"53EK=FRV8UEO)WD>F$BU'>'LL2L6@6AI.L%VGE1TV]Z622S<;!$\<< MNJI02O\U#7A11H/@S<0NT%`N5EN''ENO:/?G7TFF]P=-$.@%305)M)ACDD77 M_RFC&M9756H(#'J$L1=40XG;"]:(`40:BX!\_"OFUR8`%CG);>3,/(YI3[D$ M^L)%*AJ.CQ-YO)^)$6@!']%VK@<4HOBTU45AJXG8JOB%&'!L85:<2A?EO>Y MI0K#PWW"$E29%8Z%^J!4C0WOIS)*<]@&KGI@N=9L?5\L22)OG"9*1REZ+R>4 M(*?J0M:/"?/;*&$J'K%TEA*J84R2\_ M/"M,N[HD?)7RE)1_Q"*L'T;]4*0U,F`E;I8RE11`RSU$OX_6.?M0K!'R24M& M#X.,\A)BB\3AO,@HH\#\='#13WC5^?A#>63*VI)"?US#QH*F5PQWLZPN*S\H M^04"!-XY63F"S"?RY(`+J3C30$3^6'X_L4^R.>A=C<)R>`K++T`(+]!7&L/* M])4OQ=XD:'\7^A9%0EXTVKBO?+.*4!V#QQ.BB]@8\Q? MQN2FR'K54+$I&=A8,A3F:U(/%R5\)3/`9XKUB?A5FM^F;9`#!`XYD3DL+(@G M(LL'MC:GP)ZHU2B5F80%,)()*`M!!)N4RDBL"D8I#4<.#[344`TQ@BT6]C?U MIR'514T)%@(-A>':XQ5D,_\`A@'"R`,.3./^]B^6=1G>&\QP9 MG$\%^R#3M[8)5\G`7B!:J2Q"ET!5?__YAS2^F#*V^'B?UW?D=MOG$/@\G,A7 M$&-7/EBB?_FO__R//V>WH&TJ!UF)W&E,O\W=N-E=PNGU+?G")S^>W=T@2OV] M_3]?;\XLSX4OX`4O.JV;7GMT.^P/1Z.;J]O.X+HS[/3;_4;_[GK8ONZ=_65% MU!8EQ5+_PO;-7]I)9*:*7SBRD195$TU8]!%)?I1-0D_YNHR#5 M"DN54O%D%(MHME3>6Q""(F>0I4F(.0H.N;#A@K$7J`8YZ#\6575//*JX)D#B MU]":1&)&-\92Q4X?>9[YN*7%]Q/`+;K[<'JX3'['*)0O$@?7GXC-Z;"='I8# MSLL7JR@'$X,M5?\$V)?O\11?M=#N:&UA_F^,&,AI0+O`G*.)\,0S%A(&282-%T M;9E\@S4(/'*PB2>I2,*+_KHEO<#!BFV!&JL=6Y+9RO#:O!V<-<6FB13]H;Y/ M>3&U-H`\40[_0O"(%:CJ.Z*6M1MO<[EV$)R08-B?5!ZIU!ED"",X4,<72/=S MUFSL/5V@#OHH=EH24NZ*]Z=817;G7'1P4SUS)(^UGY+!F:BF:'KA@%>>4#AN MKWCK>I.&#^J.!GS-)>,(!P6H;@1[.3)*UIKP%+@<,C)1^37U(*F%BE&"UTNA( MCOU:L$*.MA[G3>,2]M_4[OF35624GQI1"K6'#59PI@^E/^EATCHG"%/#86R* MJA+P[VG/.9)>7^@!$]X7IPMU&ZGSV`5=D'(2+CX]D1+;7R3"^T);@64VLI`W M0>"Z8%JL,%19MRH@8M4+$)9V2&0O?_9!7[&^SEFPVW#5NGOY(=Y9A=?$/G"B MA[^V/A2'V7VB&@E$7B8]6#2TFVU-+3+TH7;?;O>J#8]1L_P5[P5<X"\-31VBWG1H M!:R6'NN3.TULNUJ0XA3W*$&0\@$BF>-004"W:?=;FF3,%AR@FAV&[F$5RSFU M4\[]\>N(OW\,:`UZ^SG_,OD?FM-!M(%;^DZQF]KU_8X6]F*Q#/^+@]7*]?Y:6IF5[WVD,]61AJ@,T M,0H%#EL.(9H6FS=+' MZB7.'"(JRJ1MIK#^'.`C%L'8MK; M1L2IL7*H1'''$XM)ZW3C$,TT\-#$99A*C_T"8U'&H5;#KD79K%$PQV!1,6<9 MUN*`QN3SP5Y8J8\MPE=+!+9!D[I1:IH9PO44[EU0L!DK`^CEMIVAEZ%6N1:# M2AX`HT4=3J?54I#X&6M8L*1%]::[#EU:J3D<]`CPE!7-\Z9,V0SL,)++4J-/ M!;=Q%#*7*@DCKA*DX539V/?BE?*&=2S"G_'%;;K(7JDWH3=7_6"SKJU8`"+= M%SCUA=I3QB7,H'LL+)[0*L:TUC9RC.+-H3TC(3V5I M^6ZR&;I:D+G9T$044O*5"A=?5T"8=R#V60X-$H/RR`@J.&XW+S*;*G7+V3V9J%T@DM"ZOZ MB\*^F[IGWN9#MZ6R/PG1*@.=Z*,."Q@==SS:2A&%51;,1:OE`FWFCPV@HB)9 MX>?B8P*)_4O?3<9`97`R#&8022Y<(!D+)%S#^J/]9\!/F^H^PO]$[C M;H,?SYKM,RL*'^6'[.(?$C?_,]JX!&WFQ[-.Y_O2"H6E-ZV6W]ALO?7&0[FO MO>L'[AJB;WY>H]9'N`WC-R=,C,,$K,9/)2;3`H91Y"#%S^+ZTE>"Q/&;9[=9 M8&OHVYT`0_TX\UQ@97HUF>V#?4NC'DK`SK?;.GL:6))[25`T%]^P::KG6O_= MH/_>!,R-?*P`KJ=$Q^!M\!ILS:3XK9A<7@SL;U:HON0*E;B:E-NGLP`,PNI# MV'8-\75UB9WBK^@0]U(U;:=;^SWK1O?2[6T`_FZ!N<8`WDGOAK3?!Y\JR/E] M\-LI/OZ3ON#NQ0C`PZ;[4*,^4^81_8-/"2BWK,7/^F$9A&KCHGPVCC__M.)Q/)OO5*[5GC!5]'"RQ MMH84VMJT(YUPE8R%_/MK7.6-(*8ST@KC;F=CTH1N`%8!C'ID*.X+O=;)5AN, M:R?,#X49&L!5@8Z5\K_O>IM&8M83H@85]XV*!JK'@HXOMP_K@IJUA^J!!`FK MU"!_PJ1,[N[3CU,;R=KM]>U!?[VKWQMA49PX%.M?CZ\'*QW M]#L8V!C<,?`Y*OB\6&_>3=RD7O`QSOSMT/RRN0$)E;;KTYB?B^9I!79MA.1Y MRQ[JT[3?#<,<^:H#HG;\_&"\+L9=90!7:UN@87SU!ML,X(X0<'5QQY^`O7%< M9L5+;DDWD.J"%%4KTS6BK7IQ*@.XXP=9/Q8EPP!CZ'!Y^JW>-] MXQX_6MPQ\#DP^!CWN'&/OPF:=V$TX9YQD#^;?=ZQ.[WJ'>1&V:X9[=6+DQG` M'3_@JM7;FXW+YO`(H6;0S0#NQ`%GW.?&?:XCOSR;QV5M'<.EI>JRO?AFN6&* M@Z#>TXCV,'JP->W.L&,W->;8/`=+TXZR*HQ;I^03;;YFA&XML*\V3.Z[YL!D MS1OLJBI)];+5I!F>9L2/P;`JE)'O:@VWVM!ALVOW>UV[UV[N#%YUP9`C45T;8VK!2O6Z%&D'-X.-!XJ-^1T2-(&=P9_;<'CX$VZ0XTE M\=ZYIF&.[P&O4<=K@7ZU87*83MW3UFK48%IW#$ M2G+;[G7:=K>QEZS@&B.749-KS2@+/H0?$C2C-UV_LW,O@,GW`GXQXW0`S5;C M^_TCY5.;(PKR`CC/Y&-G`/BB<[<_!]9H$7D^.31L*YEQZSJ<`X8MK3ESN<4L M,:(L7"1>&%A3;).*Z2*%"_\46Q%W8'?^TF*+1>AA(U7K>N;QB77G!2QP/.9; MOTTFGL,CO'>11LZ,Q=Q:`\E;WJ#7L!L;^OB_92DKGK&(QU8X`3J;S^%]Y7RV MQ&*!Q67[*`O@Y7"+_SN%UY*@F#`O`H!%?_#$>F!^RG&-,HQ**\(?^*L`I\L2 M?FE97V=>++]Y9+$8"H>).C$^_.?`31T^!RA;U*K6"M,D]MSL.7!\;>OVWZF7 M+*W//@MH/5X^O$?/]V6>3^!:8PX[XNJMR,OUZ"4S.,L8LX+PS;0`M=7]7L_A MR#=-@1(B?XE52.JX!#`G7D2O%GC`!6,6+=4=.91M>G/X+EA[5[PPXG/F!?G* M-B[-+#CH*,%G6F,6PQDAEZ7K`Z!,^"/B7&C8MA6GXW_)!1UX!R](<<@?CQX0 M8]PTPK63&>!3XLWYI>%7K][MB*A3"T)E#MW"A)1MGMVWK%_FIL#P$-T`%0`C MM*S?MAN=OMUO5LO[)F%D3=(DC;CEQ7$*W!Q(%%=147!8Z4K/)?W M(YH,-$H%GE[?!6D;,7SB1X2HV+L0'2B20.AP/3@)E)O,8HL'K@8^4WX1^E'` M&EXBFC/_B7>KFKL2$6E9Z;M6\[*SWNSB39O"L]2VJ>9Z`^LW;6H!3'95:[*5 M[@/*DK^4VN(KZ*AR&CH,`GD&U=>S$?>,ZH/+]GJL=<^8/M1&?2]"](/2(,&> MCL)OWAPH$,P//?!N#NU!MZ=/"T*I&B9@"Z=!!))@&L#OK@#^!1A,'%N.S!<\ MB$E$4-%)$*.QY3-9>P)2XT(,/U_A*$@BPG9P/`JUJN,<87L:622L74&!ACA MA2ZIJ/HAV;YL;(FLO&4U0,T;HX(XXR MK+W(M3ZS*%E:]R3,KTB87Q>%^:T0YOM^A0K]%H709>5^#.4K]`(O\9@/>@HH M1:2RQ'F4(6-V9>&#?.:116B(9MR`?19_L5P/E*DD MC(3+N^PTM])84=N5SYP_+NZ=6>C#EN:ARWUA.D:<31(>E5V>@#)SSN(T6M_^ MDTMBR`/>CS-G9HV93R['>,:YW`Z+-WAQ2J^/NN3;:;YV$>O:X.C/0<9DB:^6 MCULY`;)CT*X/=37*Y2WN;EU1K^11DRQ4<;Z$V/$"V+$'VWY'1+(4@"2"4K1& M!PCT_%N@R#^/&&IY&7VAP$#LN!CL$Z^"=J"69TS"--)KW2&'%_Q7`!?AJLFO MTVPT]$$6\0(8TP6I5MO"J?)](;C7V,(L&]$?D#F*5N"++_+OFL%]' M%;[7;.O;EH2I<142.CZ,4&=5Z+I/235;2F0XQ&0GVS#"Y M)$[]!!GI7I*3*#=L$H7S%RI$\:<@5J6VD*^7Y0OK4D4*6 MD4Y]9(/\SA7-Y5.R'-!A0V9@->+\?WFD29O6)\K;/7W>."/*#U>46Q9(GK^F M?BYUO+C(GL?<87-.+%HY6\K/'^5(&.405R50#E(HI3>MJJ MZ!`$@[]C>K-\))CW'G\0&<\H53"4.T':1V\@0`P6!*2TQDNZ&K@.7@5/[]D( M!I$]B$FV%IYY&JCP\L:,O6)^])A;#C[#Y^Z;;-Q=RL7OVH/ZR:##$#`[$14G MPMHU;4Y\7(M#W1,U_2:HZ1_`LXCJ]KW9`\V4+4>0R(=:XE94=$*I-C+PY&Z- M![&5T(U<`84._BPB.>?$48BZ!JU6X].&:$_V:_/3!Y7VG<8R9,3B.)W+$$\0 M)B)AF@19Z/OA(S%P+%T!5GVKDH,>0A]0Q$<)!"\B,I!@8\"9DS#"(K_B%67Q MI_;2['\J"T*AYKDZ7L3`5"EXI6"4V7](WNW`EAB#V[T)AYW M"]"PYCR9A4H*E9]5A`LR[E*83R1,B!>G5'U\&DK8B#D)*0/P%AN3H>6S(B_^ MXV*"'!QKN2*T:2,\^"(X\=[?+^\OK:\1Q?B6UM+CODN[82KO"G43`#NG4(*T ME_,DKFV[P#/FDPEZ"+!2!GXF05YT/ZN=`C%Y+@I_\?`<+&M[%8\5$AM6"D)5 MU9`ML6!+U#9BI5.\6S\_;5:C\#WG).LA['4&)-6EU\6@<^3*V<):*F"!9#[J MD,M8\<&!?@8ABZU?^:'T)08U>W3E8!5,O$)MD:1*J+T2=,GWSZ+G)[",& MFU3-,MCI/EO$_*/Z8TUSR?==;".6E3'W-HZ!>T$C,MK+CV?][O?/%DB7*[[E MC>"!-'RK5X5[$9.[SXU3+#436)__]>[6EQN@]12[&KP-7`.E MJ4M_W#CT79G]!US,^D48:;>;C;0M;':GVRSU\7OI01OJ>"=UM/9`'4]VVGAF M`-^^L51G?TF#AP8/WX&'+VZI;Z;N;,?:?V0N!UU4?:0]M#O]G0$HQY+J(*0= MD=8S'>J`/TOTHK/ZG-*6/NQ3G:T-F74NAYJ' MPM3ES-_DH396S%[A4QNRZ%WVVX8LC%'U.MA^V1RG-(K>DXK>Y>YFY!VWHG=` M5'A8HNPX":]UV3*$9RPL/;"Z*26^&!TRXT.#5K.E7:<^;G*J'^4*@9CC@/J= MB.QKW+"5]_3&LI=B-_1R;SO^P#&[-4RGLX_6.?N@=NZ@T(.[QTLLXH(EL0XI M"+&"$!,$7-M:^-R=I&52VGM=XN+EH50&G@)7DO\^)DAI:2#%CPZN(F/!0@4@1A-:C/ M$R&9'+9`!4.LGCI)<>9+&/YAT>[P]C(UB?<'IDH41&^4CM*/;8W31`A+ ME""!V#I.Y)!UZEE!R^;:W(W/%#U6\*,&5G9UIG(XW5Q]5F2]"!*`D MZG0.J^$VP&W]-?/W`HDN,&C&<(02B'*L`HZQ=$LJV3\1)^E*!48* MF8`OHA-'U$RI1\#9B2KF]5%"81IGZP$IH09!CU.WXF&XW,=^74LY[@AWB3K$ MDBD_BT[-Y`>TE\IM&LZEV`UJ6"/C51*^PG%%MJE%M?@,Z8('H'"5.;$MG2^*3(&!PCA/U*]#4OL@> M]GNZJ:)D!4EVOCK.8U6]UK*'[P"&VIH2K':X0&XDB46I#'0HD@-X\SEW/:%I M4D=8+L=6(9/=VJ+"D-1.&[`H*]F:I&A?RZ-#@[=$6J3,X?:+5KX6K.I4WIAE M"[UEA%9%+Y"AOGY4AB(J+8DN*26(]PR;22$[TMJ#I::=5VKFW+W_GO+W=MO+09O'4JYNRF3/\8`>LT* M,&M58_EK2FY`8-LT9T5;"K1!NWR[;8-VJVCW3]4A9R0[Y(C!\C=HKMRAN?*+ M<`]@S[47YU1K2E;DAP*4;(G4Y M^_=RF@,QIJH$X4\BM+1/%E,;XMDMRD'L1E#72TROMK$4V=2V-F]K0U'FGU;9[P]TY&0ZR]$=;AYH:4=[Q"^O: M6TG&0B[>-[QL5MAHK&9';PSD=X/P+HPFW-,IX:ONP[U?0=^WFZWAKF%UVN+> M2'5C@A^5"=ZY[#2-"6Y,\)?"]JG`=H7-QH[!,F_:K?[0;C0J['I]9#KQ`='< M\8OIVF.;,;Y+W*9U.=`68:O]V1OKNV[.]:,VO9N#@=W1J.\8V[N6Y';\0KTN M2'*2MC>(Z+:)?QOC^TW&=VFVX>:Z2"W2J`W2R`U3K,Q3XN@D\\X;PX;=U1A6 M?S.036)ZO0C^^)6$VEM_QO)?42N&^H1!W<]>H[Y1\]Z^11SL++Z9!AQ;=W]8 M;>@J:!#3[`_T-;[!'A,A]CE,@X@[X32`WV5/6=GY#OM1\"`6S0/Y-_Q;=&G$ M%C_4'DWT57O@?KB@=HVR#8K'L"UF/:K:5B9K6Q?P*J%;4>^=QN6VX55O6>W@6B96@*MMN]GLUP);ISP`#/)% MKU5W[@5>G&!CF@=^N/BZ:034F^!*2'\BW:(T;4Y\Q,N?;D1/K2`NK@@YKXO( M>2N0<]_O4:%&4)4&SO?K#\)[ZRK'DGU9P5Y03QCO][B]?*<#(6>!(4^W2C/.O?$:(X8 MMAY_,'WSWM,W;SB\[#6&[7Y77_>\9N^=[?.ZG1UWI1L>2O<\\WX;[QL:[!M+=>8_&3PT>/@./-26%6[PT."AX8<& M#P\<#U_,#U^G-,++;TA.S-4OVQ)JWG:B_U6E-XAD`^!%]0&6,?+ M1`W&&8PS&&$T]C]UK:.OY6Y>3-%S`<`'#!5[# M!3HMPP/>ZT.HD1]K?\Z%+SQ.(L\1E6ZA\\=;?%W/SOG6">A7A#L3)*UFI\*^V(:T#&F=,&G9G:XV?=$0ER$N0UR%N(PA MK0IMM%,RQ?[)(IP0_IH0[\OI;;]5@Q7(M(K:W9YN2U4CODZ8G`2X!JUF2Y^> M9.C*T-6ITY5&?Z$A)T-.ITY.1DR9^)ANP&XKIGJVU=P^*/9X_":#H;:YLV\& M6EU0T+@LCT"8'@]IMCH[6"DJ:OX7C_=MNUF8_]"U-OK`WUU8N1G29QM0;:NLH8TC*D94BK0%KVL&NJ M10UQ&>*J@+BZ?7TAZF,GK1-V:[_`$MM%`X3#(R]]&2"UP8**!9210T=,#TV[ MU30==PQ%&(K(XV/5E71C2-*1I2--(SQJ3Z.LLU;TY M=*H$X?9RC[WT0C@XLFS9S;ZVC(^Z((7QB=9'PAT<133MCIE992CBL#I8'CIR[\ZF7?:1LA74;:-N"E&Z9CG[^/X`^Z`X6V873/PO99O-?"5/+-6<)C@&"`8/K")S^>W=VT&LWNW]O_\_7FS/)<^((YR<5-=S`SU?C^TTY=JE5$R&`<#A]QGHGCSI/;S/V]'R MV8XK]`3F-/R)B"Q2ZX0Z?CWF4*UOMIFT! M'UMOE_T6#+5+P9,"EOTIMD9!D`*POO!%&"460%0=[O\%4/J\@`5P8OC[+S1A MJ-FC_77AR!#_WX;RR+898K7O6P)&<,:`.Q'B+:!P!#N+90[?O](X$7K`"`&LK%(E2_:))O=(W"MXTA#GH`E/GH!+F56%"RZV)\X'N5_$9W`;IEB"Y(XS M"M,+K^W`2681YX+2@?UK@8'CV3LLGEEH;^[^D,W1 MOO9%@4'G>O(C"#_@DR[*4A2[P&:!-Z8QGZ2^Y0/I$FU/O&^H0L0Q3V+;>F!^ M*G4"'\X<>2-\ZP$_]"*%$>K:9X/XQ,L58T?D<4!70[/+2B)/YFM'VZ;8J:@_ MJ0E)2M(B3GT2)*@BN-YDPB,+7Q47`S8_B<(YX&<(3^8*"%)BJ5O+O,PPKXX^/DS!,4&W^&WRPOM%748C[FR7)XN,/ M/SP^/EY^&T?^91A-?V@U&NT?\.7VR7,#U``)"QS-:^X>UQ>'K/_^` M*WD?\?_P\?\#4$L#!!0````(``\P9D?(7QL6_PL``!QM```5`!P`;&IP8RTR M,#$U,#DS,%]C86PN>&UL550)``-.B#Q63H@\5G5X"P`!!"4.```$.0$``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`,U0XJ;2.V M5X4^&SM=;Q'7U>O2I6O5C_*O\SS0DDY+@'/%HO6M/I(#L(D'N9V4P;N[M6GM M)'5P=?H=A1Y'X\O<+'Q>M[[B?:?QJ*:?K;/^(1R8ZOCW:7&V5H<.(D=1Y,,) MEJW%NXQ`9B)=L3[@[+N=I2J35^X6T[;R.RIT5;31<\-P^5(JGM=( MG?3=Y2Z=+]W%;QRV#MK4:JO01]/;Q9#?6VS;HQ:GA;O%RJM6VGV<8"K;[KHL M*OAJS,E^P]9]G-;5]9.6O\#XU8[0WZ\>9[3@WVAZ:BQ.B?"%RVX7R#`$QV,? M(/@D`D27`GK4H&)D+.%6<^MN*S!M=K6*\AJQ@34X6)1--+M6D:MRF=!HT*H( M$D0!4C(!<1I(?NHB'P*3*-DZ?6YPX%7I)D5)Z_K+/;XW.UO)`*9E]EU_69#L?NP%/T"0ET>?'";Q:&9J?2K<9A.S;2= MN_4!S=8+FKN-XXHK!GVC^IGS(O;H+$AA%2`S&J+44W^,3F+N8LM"^O3)L--( M%N/@-097?CC]R[5809-U53/G4'J,'2B#$:@0>6!"*5#2,>8=CZS"W1@2_60, M&0"JU>2X[WTU3[*/)9Z8W!]0R6;_\FK+8!E)""H- M@#'CR%&+U(C=AE7\),/:+SIC3/.KSEYUD@CXH3[&"IDB)Q8)B- M03N30)#:@):IX6G@G*/:C17Q3\**8=$:AR4%15[UQ<>IN=P+)PMUTCC^[W$U M/1ZNEB4.>9*:&*)8DL=EDA2$,IPPC1331B52QD]_$>CD,_:,SQA,N$'9%0-_ MHU1F!=.TV,1`NBA(F/1@(](C#8XQA?9<;FT_SFD)W MXF&[S;OTK&?)6*^KFL5&\#@P#TX%`]*%")A%#L;[)$YB)4U8ZQ8,KO7ZM>Y^ MX8Q[LO;>.A)-3KM2DHQU*@)XCDF,/GBRYD\YTNEWZ(H!\!J#^U>;P=5'<]&< M'VRP][&T0A9%CG`)&D0:"U`B(A51:/`NEJF(A)5)]).P8:!1%K8X"GV-I!`:DROD$OI$DB'%-/.OP9U'?H!:\;+'BQ?^>$ M:;!CIQ5I@+V<>FV5T3=HBTO2\[JWMWF^7?>V'LRHZRYZ7;+<$"T,?>3:1[K: M(+WHEE@V<)5D]M+-#>M58K0X^&3LD-75OO7,ZTDCI M&,O/U#YBF1>>K'^)IK%3E[^W/O9>+B8+07I+/@HD5G.01GI`S6-@,DHLBTS* M^-I=@&'0>(]UH\+'LCC-"?O7%U]HX`[G5SE5\Z]79O(&7Y9@L;F03'.%',EO MCS@Y@"@#`\-E("^02?1*B"39\>!GG/V0X8:]&!'3,6(A4N#2F;J9A;>*OIJ7S*0?%(E.@-O3&X<4A^;Q,?DZ_2 MNIYS_T?C')$I_;THC[`\S1U6'\J#J7K3,[-8AFFVJ=1D,"-I!^.&[!D M1VG-#DH%%(EC.Y[TQV-C?K%:=03G(]*IC<8L"QQ>=K?+N1:*3`C M$#1CGD&@N!.LE@S0H`1"*`U.*"O4CF?/R?\'V?J&]W'(U_;Y!V;;DVV9@$PE MD3):)[3P)S$8%13XA"(,9":F>1<3-CMZU>DO3JZ>X'P<,MU)Y:$I<3^E8RMR M;2*0[#Q34H<8+*.0(T1&@K9*0Z*8=^1]S`PBU$9]Q+&@<;`3HF08C@(:*X!U3DZ7.DK(O]CON5[).YL/4[AB4CK/5_MBG<_U@ M.LKE+7/1GL9_+EXY0JK$!Z\=K6#6YD(RD:I(1R$`E](!$TQ#+*6!J+DC([2T MPIO.YWJ/$"1T'O&[M[^&A/013=;O^=S,74>3M41(9E22NHAY,''*`8,RD#)F M@&(EJ11+I$^?]$VRQS99_6`ZTGU3A^BKWPG#'T=4S?MFBGE[4+7*4JVKFZ5. ML306"@)+'*'*$C"&(+"!E-6$K%F?HO,$$P\Z#^_]VZF]`SDV>6YF8KX]Q]+E M%?H-R;.T;A:X364P''3B/,C$.9"BL?@V]5XG"NVN1NA14Q2&)$]?0`Z0T#_, MJ\?&2F^\V8O+'"$:W0_ALSFG;].%;U-!RY9F=5WF=E$W^T&?B_<%%9[7A`#U MZ>OAO,:2/)M5&9#]MI0QD898L0BTL0YX4(S6-=.\WT1IP91)$K,V]6N@^^W7 MD>E&"6U+2F<,*6R5'(&K6(#$B$/L%`)]XV07$V/4D[X4_*AC???B?"_XCO)J MK:)JWX)W?52YY[L[HC--(KLI#::7SZ-WB*TZ(-UAY^=])&]3)EA+,T0R!HQT!$S:%0Q`(8 MW;QH1GB&N.N>WTCVH\O@W7\_5J]0C4&+?^*5_7E59#UQ%A3 M,U,Z<"T"ATBF`B(325`L)CB=CG44:1?YI[UGURY)AQI]+PL=@!EQ:)N(Y\8]V=6[7P_6 MR3#F4:P(*.$4J:=]\VH$"H]2+FV2*NVMZ[Z+.N#@[S98RT>\%WA&>SL6^<'% M;>:OM_RK*V:2QZDR3I"VP8(/(898.`/,"YVR))&&[WCT/);A?T(Q1=]0K]F6 M>/']WX'1E_\!4$L#!!0````(``\P9D=;N[#SM"P``)L=`@`5`!P`;&IP8RTR M,#$U,#DS,%]D968N>&UL550)``-.B#Q63H@\5G5X"P`!!"4.```$.0$``.Q= M6W/;N))^WZK]#]Z<9\>X@YB:["E6(Q$QYR11"]%Q?'Y]0O2 MIF([DDCQ9CJS4ZF)(@%@]]<-]`T`?_WGM^7BY&NH%?`E>G,2K63I/ M5E]>O?CMXZG\J%^_?O'/__[/__CUOTY/_Z4^O#DQZ6RSC%?YB<[B*(_G)]=) M?GGRQSQ>_W5RD:7+DS_2[*_D:W1Z>M?KY/;3(EG]]3E:QR??ULDOZ]EEO(S> MI+,H+Y]\F>=7OYR=75]?O_SV.5N\3+,O9P@`?+;MM;=%\:_3JMEI\=4I1*<8 MOORVGK\X\?RMU@W&OVOY2_'K/-]VN-^8GMW^N&U:]'TP]#4NVT(AQ%GYZ[;I M.MG5T`\*S_[U]LW'$HW39+7.H]4L?N'A.CGY-4L7\8?XXJ3X^[]`@$Z7RR0OE'`M5W.=KG*OKUYOD[B6F`9= MAR'L791E7MF_Q@U1:S%4)\)7\WBUCHL'K=-%,B]FMHH6A3I^O(SCO`&]34<8 ME,SW4>8ANXSS9!8MNM.\<[AN#.19-,L_Q%_CU<9W6!2/]$_);QKK1=,1AB'S M79HWF67-^G<@L3)#?G)8/S?RF]>KBS1;EO:DCKPF?3N0]MI;T&7\*?I6#]2. MIAT>_/'2J^MENIA[@V[_=^,9JWO^_AZ]DG'LXM=\A%[)++]14;D@+*_\RE!J MA/U6?&Q/^C&C]LM.GL[^.K\JGN8U_4.\SK-DYN=A^;V\CK*YG'E(D\9K3X^/ M&(K1]>_18E,"+-?KS?+VNS[8:S)POTQMELLHNSF_V(5J!Y:.&;97ACY%GQ?U M*V)=ORXD5:Q_3+ZLD@MOTKT)F,W23>E;O?<.0!,/\KA1!B?WZ*6UTZB#L].O M%'J4QF^K:#-/\M)7_-%I_)C[_Y?.^OF%CM:7;I%>U_+08,,1&RZC))5=UH?#-,K MJ>7(I\MX^3G.VM*Y:XP^B;ST8V6SS>?X=`M)2U(/C+238*\DR2HIIMX;W^:N M94%3PV33[:#QMSSV4WS>>=B=QF8[>CFV'WV1SG:A4R)S$:T_E_!LUJ=?HNCJ MK%B2SN)%OJZ^*1>I4P#O,H3_N/LZ+')P\\TB+A;;JR2/%LF_;_WTT@?Q?,2O M_8*UI6T1?8X7?ME+9^&1(X14<0BME@0%$F/'B&!0*J>E%80*CA^RORARI&E6 M8?M$_)<^6&O>R]ZA411*1JTB1E!&,28<;/F&BM;Q_5VK9#8[23/O(;YZ`:M> M=Y/IJ+6_2%0793FUB\! M\9?BP_`*M?F\3N:)=](^1@7#MU'&M^3@%-K7)V14>220X%((J0&1`9,5*($4 M<"3E.;#`'JM,1PK[L2+UA%2I/D-KPG<*WT5+__%3%JW6T:S`PCPP_;M4HK9S MZ`RD%DBKN&7*<:$!#RJ.@5(RW.D+#:8C>WVP'1K278J/]6(HN/X.BC*^@CQ@ MZIGHQS%Z\6-86'P3_N8=NNPZ2XI877[)XM(TO7W@8-^3<%V7,+"*2<+<%@W`TEEQW!0H[A-JC"-)!$!IYKA=Y@61^EP/X$,]B'_G/SU?W8&DV M[>O'"1T41`628*:=P-IA27F%@U)`34Q3AO9&!\3NG@[]>O8P(&P7)#:NW'<. M1UN7WD<*5=]GJ?="BU3^YS_C6?XI/<_D5T]-X5"Z-+M+IZV^O(FC==PD`"S)SR2`5&!=@R?H<>)=3Q*83#0RM&.@%D)QM`'X5&36!]]%BAM=I99`/C M'&;$V""@L`+1FBOBU`'L,M.XJ'VIBLQ6BAP8(931DFUCD+$;L10<:RQ8=9Q:!%U$"$(*GZI MP>T*8^CY*]!8B+;2H(=\KG\@[WV<)>E\G[8TZQUR"Y#P"[;&G`@$`Z:)KO@( M5`">\=+2/EH<#L`QG!V9Q5&Q^3):V'6Q!ZH"[8!'LZ]+&`32$F:(A@YPA:4# M5&VY0T(\XX6C>S*A)]3&T(E'RNPV^2:+WWK1+#?+]]%-F8DTF_C!]Y7&?_`_ M1HM#L7\/HX?06.RGBS.,!P%3`3+&;H7@A=-*T_!/HFGC`]R'Q7JW*4!,+^ZV MM^>I+;/7Y8\-S=:A(4+!"006:8\F%4X":P-6<<25MJU4ACQSE1D8Q3[THGQZ M$80>Y<$\ZA52OY):;W$QED%@1&"LWOKPSIAV/BW]":7?#;@!JFS''>,<:W=F MM5V\23GKQ\8A\B$`V7)55AX:[H_4R`@5 M"&"4TL8P8IE'Z0X4@UOF$(;>']E2KOO4HR,H8WCZ]TFLS63_V#BD6#$$.%*! M!@Y)["0)*HX086JZQ9$>I)0.!,_/(/C)52@F(>\>O../WBV+U_I\%7N/Z*MW M$A._5KWW/>(LNSLZ>S@QW'B`4%G@`S].B?HB9-4%COUD*(:4XKYU@]RL.7.G\'2=OW*N6=P1LG8KM<^ M[)&?U^65)H?RM`\:AA*C()!8",P($<#_Y]0=)XA0$4QK.O?HKW?"83R)ZDU6 M7.[36+"/VH?4E"4$SPLS-F!&"L@JOKA"$Y-O6Z'LE&TW*$;QMZ+U9;%YU_]5 M[);^&BW*[;RYCK+L)EE]*6[S.!1Q-^H?(NFP\?-#%P[.3B@%'5=0R*TAI(ZKHTWBPH2AGG%K85,3\NR M]ZL//8/3RGWS'L55E,RU;UE MY&G5NOH18G]XC+-AL"3TCD"O:N?Y99P]0.+@!L':WB'31C#F_TA"E(:8:RVV MNFKYQ(I7_4[D_O$9W:=KZLN%DBCHD`8*6,04Q9I37/%A`E)[%\.X9:I^Y=P% MB3&W!;]?1+=7-7I;,MQ[3H<$LT9"K!"&G$4:,^#WBY>%)-V>>V!#6U/0?21O(\AM3=)]#E9>#CC MXN1KF99[FP@A$;6 MC^;9L_V=0DV@MS:>0S\1K&*`!GCK=%@UVD:&ACK0O^#V:T8WI$99X6]OVUR_ MCVZ*\GT#SWMGAQ![1"APP%LJ*JUF,`CH=A74;&+'9_H0T6-KT`!"&99,0XZ`80CK;6:0!^W2+(.M_\/(O1=HQA"]75XMTINX MNLG_*!6H[1M"#!$1'BU9<(R=,Q96_$JM22M5&,Q_'T`5^H;H:7R!HWR`T&FH M'"/*$$L)=D`%%MUQA"WF[:K@@WG^`PB],R9C2+E5#'#`-=((L@`:8)`*BDP# M#WA5#\*`F.FN^L-X?+TA-4I--5TNTU5)7A]B>5PN[8;(2&65>_MQZD2\HW484,$)1<@1`;BB/-!B"X[S7NRT M9O<`4NX.RBB._'Q>@APMWD?)_/7J[G:Y>RIZR*.O[1P6L"%*J`T0L(&SG,!J MAR?6@+8K@P_FSPV@!KUC-,[&B-S#%<]ME*V2U9>UCT\VRTWID!HOD%ERR.37 M=PZ99IA)8&'@)-``!09N%SR.5;MDSV`.WP!:T3M&3^,`'N7XA1A(283WD#4* MA)`&,EUE23'6+2OI@U58!Y!Z9TRFD/COD/#W]@]@4UR=9JAQRG@_9UN/O!Z@A.@!UZ*^4R.@U)EN-,*2Q@(K``@CMS-92&UP+5;=P?F MZLCCH`I!@@F``2%..::4Y;SBQF(XUD;D8X^#-A;"X>.@QW'_-SD.JHWF1C%) M'+8^[*"<5#DI[TZ`T2ZTZW(AP^TST.Z@-`K^D!DS[FAU!!RJMJK^>#NG;NVYC'03O( MN6=P1JZ"^$#H/"M7MGF9ZGT?9^7KBYL51O;U#A$41E(@-06V4&T(]%:QB2`3 M.P?>HV??/S@C*T1)XEIN\LLT2_X=[[H\JT&O$%(<<*@9XY@)%SC/L*AXA%9, M?VMD#PK0$90G$?SK]7ISG-!O>X2*8(HI"[BV7!J_RBEH*]Z8#5@P60X M@;<"Y$F$?;[)UWFTFB>K+\=(_%ZWT+-FC`.,*.+-IB'*(;)5:6+:S?,!*R+# MB;T]*N,7QEM8_68#A,#P@!AC'5`.V``:;K=+G+*RW2:)`6LEO>G#(/B,KQE' MF/_#'4/NL&.8:$2X8-@)AKX#B2%N%_NQ9Z<)'7%Y*@VH]0/V=PHU=2>C.'H*9G:`DVS/L^4`NF&?+*7NT6$@I# MUBX;$#Q3^;<'9HBR:%GW_1!_C5>;:J>V-U7YS5.^"_(^'?=>UMFD+EK7-;08 M"6,DH9;YV8Z8FJ;\4*%`=(` M.1P@*QU1"&)=82.Q&>N5PP=KKOT)^'&);03()ENH;<9R3>6V^2"AH!H$R`!G MH<.``Z8)VL(F6AZ.&;J4.ZR"_+"O;B`PQ]EU><^0U%4"?VP<"H$8@5@:IUEQ M#Z9%^CM'BM'IEH"'$-L!S>B$U\^@"9.K"4]3`7HH&ZHDS>/9Y8=X'?O^E^KE M[R\/5PKW=@@QTLQP"B23!C%N%*!!1:V/=R=V;J8+W.D`>+22WAZU_"-+L^':?E#L/'&+($37$^VU46FRPY997W#O! M)E89[-W_?!(4QUGZRZ#2>0COL9?$AUW(/7U""2EDEGH6J=%<<"Z%N../6"0G M=@OE8%%*7P"-F4KPZAOO2R14-!S[.)/.-H7N%S=_K?(DOWF]\O-C64Z-GA_U M>N4_QI^B;[TS4>:#=AY)&.P![Z*L>%'3U_@I\SLE62HJM^,OBPL9H]MYZ2?* MEW)%4S??F]R];$Y>1]F\20:H^^"AM^L66@D($H!CSC&34E%+C0D08+(V73UT MCJB6Q?4^'IOGC3H^(W3$"2XA_?OCZ@J>[-- MXP(]V0S4Q\WG=3)/HNSF8U3"TN2HP+X^(4+466H)5I;R`'*EX9U8N"02MKL2 M<[3\TF@J\5@I>\)SE".[>5D#6O6/8H@'02A,>;ZZ_?G>P7^0YN0*CG1K:[)WVX'U# M'^HX'\-R0YFF_D'0HFW((;I,E&HJ)O>:VHTSV'U5MA<8HIY$6T:I(=-7X M`/>;AK@H[#L7I=OU`J*+W5P0X$GEC'L+*5?Z(T0V-=\=G0`K<%/AT. MDC%FY^_QNJS]';;"]UJ%$@C(@`J8P)@*!IQVE69[(X3:&>'C+WQX9D:X/8(C M:D'M$OV@70@8TQASB`PH7JP-C&*TXD-R*Z9K@5M)8[=$.V'Q?&4[.>L[ODA[ ML+WGJ_@FCC*Y6B5?XVP=93?&1_SIQ?_XY:AF;TN#KB&B)&`0$B,T=P1S3I7= MFAL#V[VN;#`+W!+]=%!0VFU5\E%\`Q$^:A8RY*0J3HX0R@7`4'G_L:(,!J+= M8I#RR?1$?^2/++\H!4<3#X,KGZE-Z>8:HUP4>.%*+B MQ8T.8^'1<-CQ`)IM.*$(F'!9X__8N]+E-G(D_2[]`#NXCXV='S@G'-'3XI3 M.L'MS\U+HU/XQLU"+6@1J9=-9,*3:L3KYP(31%'HO9(^GJ.6((UK#`1W>?U* M.U/[.D.^;`^C/K:^G2V+:23$R5C7X8/!:2N]H0X02[BWR%/T0O-B(^M.VS6U M6P&IE^CFYUGQX+X4TTVZKGOW\#";%J=I?^2M8*1`E#%$@8\"D%H=@_'+NC8?OO144$I8+`;P!4>75D)@DX79KA(3Z\;H)6J#; M.9QP$4ZWR1.C,_?'Q0HMZ`!;Q_?=HCBN`AP^%2CRPCC(J2(`$*8DKC16D0J$ MC2RGHA6$R[;0R*?2QW^59U"I?BI8K!7C!EE/H;,8,\),-2\9U3=4"D7 MC3[$Z8>D;IRJ=EP]$P#AF#N(C2/.<\DD9[::/X$B+Q3>O+K]E:E#-:*1*.N%Q,!AV^1\F+<+A.FHY.!>J7E/V3 M\.\1SL?-XTDB'CP7$+!(*DN<<)YZ9!5R]?%B36;61'?U97,H4+:W_E[H./ER M'AU?/A<<0`1YFQQ`4F$$/=2D6H?A?&39+ZW0\8+U]T''G180/W="53IX+D#& MD*>8(^50U!SC&G"E,L(HG?(DB\\%*ARQ MT#/($',4`T=);2YJ;>UXE;A,[GA]]WL\H/Y@V7;0'9V.>L6(BFQ5``D5SDTCD%0K-J_)&W`J2<&HNY,8([Z7DT.$6UQM3G*$^^@%O7ZMN#=$"V.:GY M''TO0.L485P#!*&7D!LMZW4BAD=\2[`5ZIW'$1=A=;N\,3KU=GPL,8@:LNUP M%L]56_Q1S,NG;8FB+TFNGN&!/_UVL)AH("FED,!H-T!#,:O6;(T9F3;;$OV^ MU35:QJD/WOA;L2B6DWFLPCR=N$?BFD1 M9>%]^9)A_[8L5]^S?S-'"L9J%06J\5A)1#2A#M22V]K,P'-G]VT&X)!^@.U9 ML'QW$7?-3ZW3XP1.->3$(T"I$E8CP>KDNWB>Z[QCJ[.K.^,00:W#FBV7]A-* M)V?R+9MRM5Z=XI/S7PXP;@SOE.2(&80D`HK#VMK$F=*GL[M`0TJ?MK'L1>"D M&1]V=BW7Q?:GOS[-9^M=$?CDLOB0D(3'9$[#H:)>IQ$R!D"$".#.4@MDK==1 MGG>/M'FUDO%R5D_(]G*QY+E2\$[15YOUYW(Y^__4E?A-ECKR5D@X6F>8I1@I M;0V%SUJ?!BY/;VY^06W\W-,>B+V$J@]:333@E>,O!N3B5B"(2T(,!Q@HKVM= M3V"3=Z6U>7+]^-FE51S[YYCWD^7=2 M.6>`H*)H-5@(3Q!B0E*'<+6'L`4N3Q9E!+G'STJ=`-J/OO-&\Z27;LY4EO!9 M=SNJ!S4>+1A-G+'"$$`!@=X8`:IT?0Q-9E=2>(O.Z.[1'4IQVDV]H=*T>REX MKQTD/&4<&2?C6A6K(CJ8,I;9U^06'=.M@3@"P92BPQ;6Q MHQ<.]E7Q=_;PT;!,BY\)Q&&@M4)62HN!EY2I&D7C3:91<(M>]P%A[XUYCVU( M_<:&?+F\;0&@55SD-/YV\NEH^E07WPO0`,NT76#ZH^_LMA2?SU[&0_4+*AQ<1MKO->K6>+.[C:EM7&BZ>47!` M$N^,]]@APJ5CKB[]@+6DF3[!6XIA7!>%1JVF'";VJC\FLWFZX^;+Y;9N6QH;$?-2_?/:4'5]L]NGJWV!D>73#R=S\4>+H9 MOZW:(8AEQF'S;)U3@/,B`>@6@TV#`M]SIJ"9/,W6E0Z5%YEJ.%90FF-CHRWB M-(901<-;5#G;PMO,U`QTFR&I;K&]/G'YSR+9M\6]^J-81NMV^\O4%M1/9LMM MZE-O\O3D3`(C$G$B":?.&\H`]KS*$!8*R4R!>XL1L7%3IH]=4K4^^37NZ]F^ M>-$W@/R2(M2KM+*T]M7',@J$E[]/MR%^*=?_7:P_%-/RTR(I4#OK=P?3D;W1 MR_=#RA-CW"')XTE(+&5U5Q@A&,N]ZWV+8;TQTN.J]\%.-,0#<_^C]-RQD$Z_ M$PE$>N.]<9%;,"36:"&J^]=229K9^.^68I1709C!,ZA?;F_WI5A.9ZOCSI+& M@P5A/:"4$D6)Q8AS+^K2.#(2,2\W`]UD?+)K<*]!?Z_65JMGV\WX;K&.@*QF MTZZ5]G,^'XC2$@)-J)"[V1CEN,B1%;+<-\C960Y%G,7[ MS7+Z.4[ZA#U5"!B"V3'"LJI,2V/C<8@YE2\N;"@!U@>1$_[*1U M%6/\^'FVC*M=KK]&G6#V-(N+?K/HR/DC!!<1<29B1:0F&A@+ZS)14C*59P;A M6PJ1=8MH%H=L.VN556>MPQ3? M4ORI%V"[89LWPT!-7@\ZJH*3'ZZQ1!')X". MVO[?74AYMUBMEYOTP]7=^G.Q_/AYLMC;@K63;J?:=>$$:#J'8!52AD7\%;;2 M.X$X0<\:02Y#WV*$8JPT&=`%N_5>7%##XO#]X""/5HP76I-(),2U]*3V!1J6 M:2;>8DR@"SRO.MKU/-+NI==;;)!($DY!:X7Q7W.\PUL1@#9;3VE`!!P$E?0D=G;MT`J)WU;IL!'3NCN_A>L*G!%-%`0,Z) M!=N*;CMLL4>4]M7@>#*?ORW8!N.GUZ?Z""BPE6`)QOOU?T[G9?SD7W^*>FOQ M_,-RL8X2Q+`Q[4[[BI2,*SZZM&3V?EK M$#8XVMNW&9ZC,->OH%&JT]9[C7FT]I"ED'+-38VJ(GZ\7<8RN:./CJEYH/Y@ MV7;0[9]5&_7VO2I.'=!.?\[9.MG]ZLUW`L>.>:61LHA(1+'TMM:'M$#7UL&H M4Q*_9?A>"&H?3--.AU_+XA^`G&#.2&0D,4+7RK.]NM9%?3)+&X#VP2C[:.-) M!CEX+EBHE8;&$&^UY`0:*GFU#LHU0YJ6'-).O#AC+1BO M7=8*]1JU^LW#ZG9Y8W0&T/A88A`5M>/NS\HIK;RGSFD%H4;(6E8C24UO=G$; MW7W/IE]&]^=F./7!&_UT?V80IX*+@%GAG96(6XRJ=7OH\QJ^#-3].9<_ND#J MEI(,G2:$."ZL(Y`JB+C4-:Z4PDYZ M0PMY-@Q2#SAQ3`NL.-*(@IW1%VU^1[@9.J,AWSMR?A;#A=\(D%'@M,3&:4,1 M%T`1N\?00(C[DL)',Q?Z9)4WDQ7Z!?K&$A0(B]86DC+J-L`2+4E4C*O%.\_S M],'>$A1Z(_W1I(1F&/Z($[I;(8*.A+_4P@0'S4E3'0E&*SA9+S.KTSNZ"74 MFP7J#Y9M!]W1^>2NF%.O-;XL/424&6@0!X+RU/4"5.N2#(W,N!Z6M&?%EYL! M.@I1=OE-K0_E?.[+97JI"TLN:R*!1`7*6T`=0\AX`:UTI%;EL3EI]8V,M3NT M7<9,EQO9(2.ZXXJ\Q1Y9R+#$0$NFM:`5_BGV<"/[HF/F'.PZ;#/R7??VZ;Y6 M?L,I!&0-)`!(ARGF3+KXQSP?[R*SA.V/S3-&ZEWWWOG'ECR#[IW#*00@/8#* M:9!J#2NK*"&H0M\8FU=F<7S%9VYE[UQ$O>O>.Y$H#\5LZ.WSS2R"E9)YRS!P M/AJF6ECM:OD%`^!U;Z*:2"<;,HS&?=!DI@'SJ$X`3:50 MU$G)";:U(BYT9J/>\:F"5^%?Z)!P?Y9-./*=%R+!O&.`,&BPUAQJ*VPM.CW. M;"0\NNTV-,^/<.\V)/UU;]@1]+MJ>X[!.T"YI%AP38C`$!#C:N:C)K.^_H^M M.]36[9;^U[U_#ZWF<>[?AG,,4>O3J?Z^MH92C[EQ_#E"ZC3_TSENKGS_=DO_ MZ]Z_>YM]LRQ6X]R\3288%+;(*ZYU*F>O`-1>53DT%F&;=_'WFAU&5[YS.R1^ M#W<[MEFNK5^4J*Y%_#K[M)@]S*81!S6=EIO%MJ!_.9]-9P-]])=4:"!=Y1KR M82SK\[<7R(8`2V<9,QRI1C-%JGELL*`181&;5AU9Q M&NW-A@])BI^XU5`_$QS&Q!"JD"`I:8/&]<-JT<32O!.XMQL-;5'T=>ID)CR] MY-6FN9W.IGU^*CBA'4HMZ@3U2"I,$;/5&B"#([X:D$&'[U'R(ARNDZ:CRYWO MEY3]D_#O$<['S>-)(AX\%P@VWBF*'#'`.<:5$*I:AQ0PSW/16=`@BP)E>^OO MA8Z3+^?1\>5S@7CI@:&<.H69H8HP(JIU")!Y^[0S#W(K=+Q@_7W0\4W-X+=5 M\;"9_SQ[.*9;G_%V8!0(8H2'!F"A&?3$ULAY)_*273K;NQTJV.V#U;ZM?Y8] MW)$Q_MMBLKE/:3:FC.,LMFZ7Q2I^ZWY;_Z(JU[*Z>S"3U6<_+_\U4)F$NG#, M.64/OGDX<"@]HE'!IE99+9#@6!F%&$DU[90YJ9-TO*J3]O3!@P%HKY7!<3L8 MK165P&NV7PU4P/9U/>=X08$+B/!-CZ(+5C]:6]@DO^HR*:AQZZ=;16F)O9,59(B[S.3'KBWI3*J7O6#4 MAY[PS=3/N@]]Y*W@@7<><`"-(IP8"#0#U1JAIFB\YG;[9#S%)Q?#=ILL,CKK M?=2V;.U M,]]`1P1O&:4L:A\L;<>&,!4]A8<3>K=8EZ9\?"P79_#`)6,&@`QS#$6-"SN" MF*/&U1PN6*;7J+.\I=8YHT?L^E`3?BG6R7Y_ORS_F$5C/9Z0JY3$=!?5\4GR M,NSK0L9EJM]3#=7I^HCVT'RP8!B%WO&(H:8&,^H!K8]>8DE?O?O.S:5ISW3M M'*N>N&=7OO?GLUL(P@;ATG%`:!3*A M>U0Q0B0O!MF98M,C\XT`[>&27!LGG<:5^2CZB;.6.>A-E/RN4OVPX;:W6/9Y M?#0L<<_*Y&R(:!^\DGK<3Q;38J\Z1C5OW^4HI8SN:Y&O[I9F/ID=#3LT&B

XML 23 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2015	Oct. 31, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	LA JOLLA PHARMACEUTICAL CO
Entity Central Index Key	0000920465
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		18,241,509

XML 24 R18.htm IDEA: XBRL DOCUMENT

Shareholders’ Equity (Stock Option and Restricted Stock Award Activity) (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding beginning balance, Shares underlying stock options and restricted stock awards		618,900	54,000
Granted, Shares underlying stock options and restricted stock awards		942,285	567,876
Restricted stock awards vested, Shares underlying stock options and restricted stock awards			(2,976)
Exercised, Shares underlying stock options and restricted stock awards	(35,035)	(42,535)	0
Forfeited, Shares underlying stock options and restricted stock awards		(24,465)
Outstanding ending balance, Shares underlying stock options and restricted stock awards	1,494,185	1,494,185	618,900
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding beginning balance, Weighted - average exercise price		$ 9.54	$ 6.00
Granted, Weighted - average exercise price		23.83	9.88
Restricted stock awards vested, Weighted - average exercise price			0.00
Exercised, Weighted - average exercise price		9.74
Forfeited, Weighted - average exercise price		10.19
Outstanding ending balance, Weighted - average exercise price	$ 18.54	$ 18.54	$ 9.54
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]
Vested and expected to vest ending balance, Shares underlying stock options	1,494,185	1,494,185
Vested and expected to vest ending balance, Weighted - average exercise price	$ 18.54	$ 18.54
Vested and expected to vest ending balance, Weighted - average remaining contractual term (yrs)		9 years 2 months 17 days
Vested and expected to vest ending balance, Aggregate intrinsic value	$ 15,765,631	$ 15,765,631
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding ending balance, Weighted - average remaining contractual term (yrs)		9 years 2 months 17 days
Outstanding ending balance, Aggregate intrinsic value	$ 15,765,631	$ 15,765,631
Exercisable ending balance, Shares underlying stock options	211,408	211,408
Exercisable ending balance, Weighted - average exercise price	$ 10.60	$ 10.60
Exercisable ending balance, Weighted - average remaining contractual term (yrs)		8 years 8 months 3 days
Exercisable ending balance, Aggregate intrinsic value	$ 3,643,505	$ 3,643,505

XML 25 R4.htm IDEA: XBRL DOCUMENT

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue
Contract revenue - related party	$ 647	$ 0		$ 0
Total revenue	647	0	$ 647	0
Expenses:
Research and development	7,781	2,625	19,637	6,218
General and administrative	3,353	2,436	11,122	8,259
Total expenses	11,134	5,061	30,759	14,477
Loss from operations	(10,487)	(5,061)	(30,112)	(14,477)
Other income, net	13	9	33	13
Net loss and comprehensive loss	$ (10,474)	$ (5,052)	$ (30,079)	$ (14,464)
Basic and diluted net loss per share (usd per share)	$ (0.70)	$ (0.37)	$ (1.99)	$ (1.58)
Shares used in computing basic and diluted net loss per share	14,899	13,646	15,129	9,131

XML 26 R12.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation and Use of Estimates The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission ("SEC") Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2014, included in the Company's Annual Report on Form 10-K filed with the SEC on March 16, 2015. The unaudited condensed consolidated financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the condensed consolidated balance sheet of the Company at September 30, 2015, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2015, and the condensed consolidated statement of cash flows for the nine months ended September 30, 2015. Estimates were made relating to useful lives of fixed assets, valuation allowances, impairment of assets, share-based compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ materially from those estimates. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the full year or any future interim periods.
Use of Estimates	Basis of Presentation and Use of Estimates The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission ("SEC") Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2014, included in the Company's Annual Report on Form 10-K filed with the SEC on March 16, 2015. The unaudited condensed consolidated financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the condensed consolidated balance sheet of the Company at September 30, 2015, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2015, and the condensed consolidated statement of cash flows for the nine months ended September 30, 2015. Estimates were made relating to useful lives of fixed assets, valuation allowances, impairment of assets, share-based compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ materially from those estimates. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the full year or any future interim periods.
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of La Jolla Pharmaceutical Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity from the date of purchase of less than three months to be cash equivalents. The carrying value of the Company's money market funds is included in cash equivalents and approximates the fair value.
Restricted Cash	Restricted Cash Under the terms of the Company's credit card arrangements, there is a requirement to maintain a collateral cash account pledged as security for such credit cards. Under the terms of the leases of certain of the Company's facilities, there is a requirement to maintain a certificate of deposit as security during the terms of such leases.
Property and Equipment	Property and Equipment Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from two to seven years.
Revenue Recognition	Revenue Recognition In accordance with GAAP, the Company recognizes revenue when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the seller’s price to the buyer is fixed or determinable; and (4) collectibility is reasonably assured. The Company currently recognizes revenue from payments received under a services agreement with a related party. Under the terms of this services agreement, the Company receives payments from this related party for research and development services that the Company provides at a negotiated, arms-length rate.
Clinical Trial Expenses	Clinical Trial Expenses Payments in connection with the Company's clinical trials are often made under contracts with multiple contract research organizations that conduct and manage clinical trials on the Company's behalf. The financial terms of these contracts are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Generally, these contracts set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. Payments under these contracts depend on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. As of September 30, 2015 and December 31, 2014, the prepaid clinical expenses of $360,000 and $1,528,000 on the condensed consolidated balance sheets represent the initial upfront payments to clinical research organizations for two clinical trials that commenced in 2015. The Company amortizes prepaid clinical trial costs to expense based on estimates regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Expenses related to clinical trials are accrued based on estimates regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the contracted amounts are modified, the accruals are modified accordingly on a prospective basis. Revisions in the scope of a contract are charged to expense in the period in which the facts that give rise to the revision occur.
Research and Development Expenses	Research and Development Expenses Research and development expenses include salaries and benefits, facilities and other overhead expenses, research-related manufacturing expenses, contract services and clinical and preclinical-related services performed by clinical research organizations, research institutions and other outside service providers. Research and development expenses are charged to operations as incurred when these expenditures relate to the Company's research and development efforts and have no alternative future uses. In accordance with certain research and development agreements, the Company is obligated to make certain upfront payments upon execution of the agreement. Advance payments, including nonrefundable amounts, for materials or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed. Acquisition or milestone payments that the Company makes in connection with in-licensed technology are expensed as incurred when there is uncertainty in receiving future economic benefits from the licensed technology. The Company considers the future economic benefits from the licensed technology to be uncertain until such licensed technology is incorporated into products that are approved for marketing by the U.S. Food and Drug Administration (the "FDA") or when other significant risk factors are abated. For accounting purposes, management has viewed future economic benefits for all of the Company's licensed technology to be uncertain.
Share-Based Compensation	Share-Based Compensation The Company accounts for share-based payment arrangements in accordance with Accounting Standards Codification ("ASC") 718, Compensation - Stock Compensation and ASC 505-50, Equity - Equity Based Payments to Non-Employees, which requires the recognition of compensation expense, using a fair-value based method, for all costs related to share-based payments, including stock options and restricted stock awards. These standards require companies to estimate the fair value of share-based payment awards on the date of the grant using an option-pricing model. See Note 4 for further discussion of the Company's share-based compensation plans.
Net Loss Per Share	Net Loss Per Share Basic net loss per share is calculated based on the weighted-average number of common shares outstanding. Diluted net loss per share is calculated using the weighted-average number of common shares outstanding plus common stock equivalents outstanding. Outstanding convertible preferred stock, stock options and unvested restricted stock awards are considered common stock equivalents and are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Common stock equivalents are not included in the computation of diluted net loss per share if the inclusion of these securities is anti-dilutive.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2014, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This update is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable) and to provide related footnote disclosures. The ASU provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. The ASU is effective for annual periods ending after December 15, 2016, which for the Company is the annual period ending on December 31, 2016, and interim periods within annual periods beginning after December 15, 2016, which for the Company is the annual period ending December 31, 2017. Early adoption is permitted. The Company does not intend to early adopt this standard. The adoption of this standard will not have a material impact on the Company's financial position or results of operations. In June 2014, the FASB issued ASU No. 2014-12, Compensation - Stock Compensation (Topic 781): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period. This update requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. This update is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2015, which for the Company is the annual period ending on December 31, 2016. Early adoption is permitted. The Company does not intend to early adopt this standard. Entities may apply the amendments in this update either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of this standard will not have a material impact on the Company's financial position or results of operations. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). This update outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. This guidance was originally effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016, which for the Company is the annual period ending on December 31, 2017. Early adoption was not originally permitted. In July 2015, the FASB approved the deferral of the effective date of the new standard by one year, but to permit companies to adopt one year earlier if they choose. The Company does not intend to early adopt this standard. The standard may be adopted using a full retrospective or a modified retrospective (cumulative effect) method. The adoption of this update will not have a material impact on its financial position or results of operations.

XML 27 R11.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies In January 2015, the Company entered into a 25-month lease agreement for 4,047 square feet of lab space. The lease term is from March 2015 through March 2017, and the Company's total lease payments through the end of the lease will be approximately $93,000. The lease contains options to extend the lease for two additional six-month periods. In February 2015, the Company entered into a 32-month sublease agreement as a sublessee for 18,599 square feet of office space to be used as the Company's corporate headquarters. The lease term is through October 2017, and the Company's total lease payments through the end of the lease will be approximately $1,466,000. The Company also leases a total of 3,713 square feet of office space with a lease term through March 2018, and total lease payments through the end of the lease are approximately $300,000.

XML 28 R19.htm IDEA: XBRL DOCUMENT

Shareholders’ Equity (Stock Options, Valuation Assumptions) (Details)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Equity [Abstract]
Volatility	147.00%	188.00%
Expected life (years)	4 years 10 months 28 days	6 years 8 months 23 days
Risk-free interest rate	1.40%	2.20%
Dividend yield	0.00%	0.00%

XML 29 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Narrative) (Details) $ in Thousands, shares in Millions		3 Months Ended		9 Months Ended
	Jan. 14, 2014	Sep. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2015 USD ($) shares	Sep. 30, 2014 USD ($) shares	Dec. 31, 2014 USD ($)
Property, Plant and Equipment [Line Items]
Reverse stock split ratio	0.02
Restricted cash		$ 237		$ 237		$ 37
Property and equipment, net		1,751		1,751		279
Depreciation expense		114	$ 5	209	$ 10
Prepaid clinical expenses		360		$ 360		$ 1,528
Potentially dilutive common shares related to the outstanding preferred stock, stock options, restricted stock units and warrants \| shares				9.1	8.1
Comprehensive loss		$ (10,474)	$ (5,052)	$ (30,079)	$ (14,464)
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets				2 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets				7 years

XML 30 R13.htm IDEA: XBRL DOCUMENT

Shareholders’ Equity (Tables)

9 Months Ended

Sep. 30, 2015

Equity [Abstract]

Summary of Stock Option Activity and Related Data

The Company’s stock option and 2013 Equity Plan restricted stock award activity for the nine months ended September 30, 2015 and the year ended December 31, 2014 was comprised of the following:



	Outstanding Stock Options and 2013 Equity Plan Restricted Stock Awards
	Shares Underlying Stock Options and Restricted Stock Awards		Weighted-Average Exercise Price per Share	Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at December 31, 2013	54,000		$6.00
Granted	567,876		$9.88
Restricted stock awards vested	(2,976	)	$0.00
Outstanding at December 31, 2014	618,900		$9.54
Granted	942,285		$23.83
Exercised	(42,535	)	$9.74
Forfeited	(24,465	)	$10.19
Outstanding at September 30, 2015	1,494,185		$18.54	9.21 years	$	15,765,631
Vested and expected to vest at September 30, 2015	1,494,185		$18.54	9.21 years	$	15,765,631
Exercisable at September 30, 2015	211,408		$10.60	8.67 years	$	3,643,505

Stock Options, Valuation Assumptions

The Company estimated the fair value of each stock option grant on the grant date using the Black-Scholes model with the following weighted-average assumptions:



	Nine Months Ended September 30,
	2015		2014
Volatility	147	%	188	%
Expected life (years)	4.91 years		6.73 years
Risk-free interest rate	1.4	%	2.2	%
Dividend yield	—	%	—	%

Summary of restricted stock activity

The Company’s RSA activity for the nine months ended September 30, 2015 and the year ended December 31, 2014 was comprised of the following:



	Number of Shares		Weighted-Average Grant Date Fair Market Value
Unvested at December 31, 2013	1,746,853		$	11.80
Granted	2,976		$	8.40
Vested	(423,693	)	$	9.18
Forfeited	(47,129	)	$	4.41
Unvested at December 31, 2014	1,279,007		$	12.86
Vested	(188,414	)	$	12.30
Unvested at September 30, 2015	1,090,593		$	12.95

Summary of Share-based Compensation Expense

Total share-based compensation expense related to all share-based awards for the three and nine months ended September 30, 2015 and 2014 was comprised of the following (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Research and development:
Stock options	$	636	$	98	$	1,609	$	142
Restricted stock	240		147		1,452		652
Warrants	15		—		40		—
Research and development share-based compensation expense	891		245		3,101		794
General and administrative:
Stock options	1,443		286		2,950		575
Restricted stock	545		1,212		3,719		5,226
Warrants	182		—		573		—
General and administrative share-based compensation expense	2,170		1,498		7,242		5,801
Total share-based compensation expense included in expenses	$	3,061	$	1,743	$	10,343	$	6,595

XML 31 R14.htm IDEA: XBRL DOCUMENT

Business (Details) - USD ($) $ in Thousands	1 Months Ended		9 Months Ended		45 Months Ended
Business (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Jul. 31, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net cash used for operating activities			$ 16,702	$ 7,475	$ 36,500
Schedule of Capitalization, Equity [Line Items]
Cash and cash equivalents	$ 135,055		$ 135,055	$ 54,131	$ 135,055	$ 48,555	$ 8,629
Underwriting Agreement [Member]
Schedule of Capitalization, Equity [Line Items]
Proceeds from the underwriting agreement, including additional shares sold, net of cost	$ 104,600	$ 53,100

XML 32 R16.htm IDEA: XBRL DOCUMENT

Contract Revenue - Related Party (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Related Party Transaction [Line Items]
Contract revenue - related party	$ 647	$ 0		$ 0
Biotech Research B.V. [Member]
Related Party Transaction [Line Items]
Term of written notice for termination of agreement	60 days
Contract revenue - related party	$ 647		$ 647

XML 33 R21.htm IDEA: XBRL DOCUMENT

Shareholders’ Equity (Share-based Compensation Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 3,061	$ 1,743	$ 10,343	$ 6,595
Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	891	245	3,101	794
General and administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	2,170	1,498	7,242	5,801
Stock Option [Member] \| Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	636	98	1,609	142
Stock Option [Member] \| General and administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	1,443	286	2,950	575
Restricted Stock [Member] \| Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	240	147	1,452	652
Restricted Stock [Member] \| General and administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	545	1,212	3,719	5,226
Warrant [Member] \| Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	15	0	40	0
Warrant [Member] \| General and administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 182	$ 0	$ 573	$ 0

XML 34 R5.htm IDEA: XBRL DOCUMENT

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating activities
Net loss	$ (30,079)	$ (14,464)
Adjustments to reconcile net loss to net cash used for operating activities:
Share-based compensation expense	9,330	6,595
Third party share-based compensation expense	1,013	0
Depreciation expense	209	10
Changes in operating assets and liabilities:
Restricted Cash	(200)	0
Prepaid clinical expenses	1,168	0
Prepaid expenses and other current assets	(347)	(110)
Other assets	(57)	0
Accounts payable	1,837	(151)
Accrued expenses	219	713
Accrued payroll and related expenses	205	(68)
Net cash used for operating activities	(16,702)	(7,475)
Investing activities
Purchase of property and equipment	(1,681)	(86)
Net cash used for investing activities	(1,681)	(86)
Financing activities
Net proceeds from the issuance of common stock	104,596	53,063
Net proceeds from the exercise of stock options for common stock	287	0
Net cash provided by financing activities	104,883	53,063
Net increase in cash and cash equivalents	86,500	45,502
Cash and cash equivalents at beginning of period	48,555	8,629
Cash, cash equivalents at end of period	135,055	54,131
Series C-1 Convertible Preferred Stock [Member]
Non-cash investing and financing activity:
Conversion of stock	11	0
Series F Convertible Preferred Stock [Member]
Non-cash investing and financing activity:
Conversion of stock	61	452
Series C-1 and D-1 Convertible Preferred Stock [Member]
Non-cash investing and financing activity:
Conversion of stock	$ 0	$ 3,099

XML 35 R10.htm IDEA: XBRL DOCUMENT

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred income tax assets and liabilities are recognized for temporary differences between financial statement and income tax basis, using enacted tax rates in effect for the years such differences are expected to reverse. The Company recognizes deferred tax assets to the extent that it believes such assets are more likely than not to be realized. Due to uncertainties surrounding the Company's ability to generate future taxable income, the Company believes that it is more likely than not that deferred tax assets will not be realized, and consequently a full valuation allowance has been established. The Company continues to maintain a full valuation allowance against its deferred tax assets as of September 30, 2015. The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has a 50% or less likelihood of being sustained. There have been no material changes in the Company's unrecognized tax benefits since December 31, 2014; and, as such, disclosures included in the Company's 2014 Annual Report on Form 10-K continue to be relevant for the nine months ended September 30, 2015.

Shareholders’ Equity (Summary of Restricted Stock Awards) (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Vested, in shares		(2,976)
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance, in shares	1,279,007	1,746,853
Granted, in shares		2,976
Vested, in shares	(188,414)	(423,693)
Forfeited, in shares		(47,129)
Ending balance in shares	1,090,593	1,279,007
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance, in usd per share	$ 12.86	$ 11.80
Granted, in usd per share		8.40
Vested, in usd per share	12.30	9.18
Forfeited, in usd per share		4.41
Ending balance, in usd per share	$ 12.95	$ 12.86

Shareholders’ Equity (Narrative) (Details) $ / shares in Units, $ in Thousands			1 Months Ended							3 Months Ended		9 Months Ended			12 Months Ended
	Jan. 25, 2014 USD ($) shares	Jan. 14, 2014	Sep. 30, 2015 USD ($) $ / shares shares	Aug. 31, 2015 USD ($) shares	Apr. 30, 2015 shares	Feb. 28, 2015 shares	Dec. 31, 2014 party $ / shares shares	Jul. 31, 2014 USD ($) $ / shares shares	Sep. 30, 2013	Sep. 30, 2015 USD ($) $ / shares shares	Sep. 30, 2014 USD ($) $ / shares	Sep. 30, 2015 USD ($) $ / shares shares	Sep. 30, 2014 USD ($) $ / shares	Sep. 30, 2013 shares	Dec. 31, 2014 $ / shares shares	Jul. 31, 2015 shares	Aug. 31, 2014 shares	Jan. 02, 2014 shares	Dec. 31, 2013 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reverse stock split ratio		0.02
Common stock, shares authorized			100,000,000				100,000,000	12,000,000,000		100,000,000		100,000,000			100,000,000		100,000,000
Preferred stock, shares authorized			8,000,000							8,000,000		8,000,000
Preferred stock, par value (usd per share) \| $ / shares			$ 0.0001							$ 0.0001		$ 0.0001
Weighted-average grant date fair values of stock options granted \| $ / shares										$ 21.49	$ 8.38	$ 21.13	$ 9.49
Unamortized share-based compensation expense \| $			$ 19,856							$ 19,856		$ 19,856
Recognized weighted average period												2 years 11 months 25 days
Stock options exercised										35,035		42,535			0
Intrinsic value of stock options exercised \| $										$ 641		$ 752
Warrants granted to purchase common stock							51,000
Warrants issued, number of third party recipients \| party							2
Third party share-based compensation expense \| $										197		613
Share-based compensation expense \| $										3,061	$ 1,743	10,343	$ 6,595
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense \| $										891	245	3,101	794
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense \| $										$ 2,170	1,498	$ 7,242	5,801
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued				4,000
Number of shares of unvested stock awards			1,090,593				1,279,007			1,090,593		1,090,593			1,279,007				1,746,853
Stock issued during period, value \| $				$ 92
Restricted Stock [Member] \| Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recognized weighted average period												4 months
Share-based compensation expense \| $										$ 240	147	$ 1,452	652
Unamortized share-based compensation expense \| $			$ 178							178		$ 178
Restricted Stock [Member] \| General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recognized weighted average period												17 months
Share-based compensation expense \| $										545	$ 1,212	$ 3,719	$ 5,226
Unamortized share-based compensation expense \| $			$ 3,117							$ 3,117		$ 3,117
Grant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant vesting period							4 years
Consultant [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued	2,976
Stock issued during period, value \| $	$ 25
Chief Executive Officer [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of unvested stock awards																1,042,680
One-year Anniversary Date of Grant [Member] \| Grant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant vesting rights percentage							25.00%
One-year Anniversary Date of Grant [Member] \| Grant Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant vesting rights percentage							100.00%
2013 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity plan, term									10 years
Period of share-based payment awards									4 years
Automatic annual increase based on outstanding shares of Common Stock as of the last day of the previous year end, percent									10.00%
Shares available for grant			1,613,525							1,613,525		1,613,525						440,441
Shares of common stock authorized for issuance			3,100,000							3,100,000		3,100,000					1,100,000
Shares of common stock for future issuance			3,047,710							3,047,710		3,047,710
2013 Equity Plan [Member] \| Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of share-based payment awards						3 years
Stock options granted						60,000
Share-based compensation expense \| $										$ 0		$ 362
2013 Equity Plan [Member] \| Consultant [Member] \| Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted				40,000
Share-based compensation expense \| $										$ 38		$ 38
2013 Equity Plan [Member] \| Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of share-based payment awards									3 years
2013 Equity Plan [Member] \| Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted					60,000
2013 Equity Plan [Member] \| One-year Anniversary Date of Grant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage									25.00%
2013 Equity Plan [Member] \| One-year Anniversary Date of Grant [Member] \| Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage									33.00%
2013 Equity Plan [Member] \| One-year Anniversary Date of Grant [Member] \| Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage					25.00%
2013 Equity Plan [Member] \| Upon Grant [Member] \| Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage						25.00%
Common Stock [Member] \| Director [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued														79,622
Common Stock [Member] \| Chief Executive Officer [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued														1,327,048
Common Stock [Member] \| Employees [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued														336,185
Series C-1 Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, shares authorized			11,000				11,000			11,000		11,000			11,000
Preferred stock, par value (usd per share) \| $ / shares			$ 0.0001				$ 0.0001			$ 0.0001		$ 0.0001			$ 0.0001
Shares issued upon conversion, per share			1,724							1,724		1,724
Preferred stock, shares issued			3,906				3,917			3,906		3,906			3,917
Shares reserved for future issuance			6,735,378							6,735,378		6,735,378
Liquidation preference per share \| $ / shares			$ 1,000							$ 1,000		$ 1,000
Liquidation preference \| $			$ 3,906							$ 3,906		$ 3,906
Series C-1 Convertible Preferred Stock [Member] \| Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued												19,134			5,341,670
Series F Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, shares authorized			10,000				10,000			10,000		10,000			10,000
Preferred stock, par value (usd per share) \| $ / shares			$ 0.0001				$ 0.0001			$ 0.0001		$ 0.0001			$ 0.0001
Shares issued upon conversion, per share			286							286		286
Preferred stock, shares issued			2,737				2,798			2,737		2,737			2,798
Shares reserved for future issuance			782,032							782,032		782,032
Liquidation preference \| $			$ 2,737							$ 2,737		$ 2,737
Series F Preferred Stock [Member] \| Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued												17,360			129,105
Underwriting Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock to be issued and sold in underwriting agreement			2,932,500					5,395,000
Proceeds from the underwriting agreement, including additional shares sold, gross \| $			$ 111,400					$ 56,600
Proceeds from the underwriting agreement, including additional shares sold, net of cost \| $			104,600					53,100
Issuance costs \| $			$ 6,800					$ 3,500
IPO [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Price per share of shares sold (usd per share) \| $ / shares			$ 38					$ 10.50		$ 38		$ 38